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Cancer is the leading burden of disease in Australia. Overall cancer survival has improved in the last 
30 years; however, there are population groups within Australia whom experience poorer cancer 
survival. These population groups are Indigenous Australians, people living in remote areas, and 
socioeconomically disadvantaged persons.  
Previous national healthcare expenditure reports, although dated, show the cost of cancer is high. 
There is a growing body of research estimating the cost of cancer in Australia by cancer type, or 
element of care; but there are limited studies regarding the national cost of cancer, or the distribution 
of these costs by population groups. It is important to understand the cost of cancer in order to 
efficiently allocate resources in a tight fiscal environment. 
The objective of this PhD was to estimate the cost of cancer in Australia, with a particular focus on 
the distribution of these costs by Indigenous status, remoteness, and socioeconomic disadvantage. 
The aims were: 1) to quantify the direct costs to the public healthcare system and patient co-
payments for the first 12-months following diagnosis, and to determine the distribution of these costs 
by Indigenous status, remoteness, and socioeconomic status; 2) to quantify the annual indirect costs 
due to changes in labour force participation of people with cancer; and 3) using female breast cancer 
as a case study, to quantify the direct costs to the public healthcare system and individual for the first 
three years post-diagnosis, and the distribution of these costs by Indigenous status, remoteness, and 
socioeconomic disadvantage.  
Methodology 
Two datasets were utilised in this PhD. The first was a model based on linked administrative data, 
‘CancerCostMod’ (addresses aims 1 and 3), and the second was the 2015 Survey of Disability, Ageing 
and Carers (SDAC) (addresses aim 2).  
CancerCostMod 
The base population for CancerCostMod is a census of all patients with a new cancer diagnoses 
reported to the Queensland Cancer Registry between 01JUL2011 and 30JUN2012 (n=25,553). Each 
individual record was then linked to the individual’s Queensland Health Admitted Patient Data 
Collection, Emergency Department Information System, Medicare Benefits Schedule (MBS), and 
Pharmaceutical Benefits Scheme (PBS) records, to facilitate extraction of three full years of data 
following diagnoses. The base population was then weighted to represent the Australian population 
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of cancer patients with a new cancer diagnosis using a programmed SAS macro (GREGWT) (weighted 
n=123,900).  
Costs were assigned to each hospital inpatient separation and emergency department presentation 
based upon costs reported by the Independent Hospital Pricing Authority. Costs for MBS services and 
PBS datasets were included in the dataset. All costs are reported in Australian dollars, and were 
adjusted to the 2016-17 financial year.  
For aim 1, the total cost of cancer in the first 12-months following a cancer diagnosis was calculated 
by five cost categories: admitted and non-admitted hospital episodes, ED presentation, MBS rebate, 
PBS rebate, and patient co-payments. For aim 3, costs were aggregated in six-month periods from 
date of diagnosis to 36-months following diagnosis of breast cancer for the same cost categories, 
except patient co-payments were further split into MBS co-payments and PBS co-payments.  
2015 SDAC 
The SDAC is a national survey conducted every three years by the ABS. For this study, the dataset was 
limited to people of working age (25-64 years). The participants were assigned to one of three health 
groups: no long-term health condition (LTHC), those who identified cancer as a LTHC, and those with 
any other LTHC. 
Results 
Aim 1: Direct costs of cancer in Australia during the first 12-months post-diagnosis 
The total cost to the public healthcare system was $4.8 billion and the total patient co-payments was 
$127 million during the first 12-months post-diagnosis. After adjusting for sex, age at diagnosis and 
broad cancer type, significant differences in costs were observed in relation to Indigenous status, 
remoteness and socio-economic status within the first year post-diagnosis. The costs of admitted and 
non-admitted hospital episodes were higher for people living outside of metropolitan areas, and 
lower for people from the least disadvantaged quintiles (Q4-5). Costs related to ED presentation were 
higher in Indigenous Australians. MBS rebate costs were lower among Indigenous Australians, and 
people living in remote areas, but higher in people living outside of the most disadvantaged quintile. 
PBS rebate costs were lower for Indigenous Australians, but higher for people living in remote areas, 
and people living outside the most disadvantaged areas. Patient co-payments were lower for 




Aim 2: Annual indirect cost of cancer in Australia 
The 2015 SDAC included 34,393 participants of working age (weighted N=12,387,800). Approximately 
half (46%) of participants with cancer were not in the labour force, resulting in an approximately $1.7 
billion reduction in gross domestic product. Of people in the labour force, people with no long-term 
health conditions were 3.0 times more likely to be employed full-time compared to people with 
cancer. Amongst people with cancer, people without a tertiary qualification were 3.7 times more 
likely to be out of the labour force compared to people with a tertiary qualification. 
Aim 3: Breast cancer case study 
In Queensland, 3,080 women were diagnosed with breast cancer between July 2011 and June 2012, 
representing approximately 15,335 Australian women once weighted. The costs of admitted and non-
admitted hospital episodes were higher for Indigenous women than non-Indigenous women, and 
women from the most disadvantaged quintile compared to those living in the least disadvantaged 
quintile. There was no consistent trend in the cost differences for hospital episodes by remoteness. 
For cost of ED presentations and MBS rebates paid, there were some differences, but no consistent 
trends in relation to remoteness, Indigenous status and socio-economic status. For PBS rebates paid, 
costs were lower for Indigenous women than non-Indigenous women during months 7-to-12 and 13-
to-18, higher in women living in regional verse metropolitan areas during the first 12-months, and 
lower for women living outside the least disadvantaged quintile (Q5) during the first 12-months. 
The patient co-payments for MBS services were lower for Indigenous verse non-Indigenous women 
during the first 12-months, and for women living in the most disadvantaged quintiles. Patient co-
payments paid for PBS prescriptions were consistently lower for Indigenous women compared to 
non-Indigenous women, and for women living outside of the least disadvantaged quintile. There was 
no difference in the MBS or PBS patient co-payments paid by remoteness. 
Conclusion 
This is the first Australian study to describe the distribution of costs to the public healthcare system 
and individual by Indigenous status, remoteness, and socioeconomic disadvantage. The findings 
presented in this thesis demonstrate differences in both public healthcare system costs, and patient 
co-payment costs for these three population groups. The findings are robust because linked data 
from several large, population-based administrative databases were used, thereby minimising 
selection bias and measurement bias. These results are of particular importance for policy makers to 
ensure equitable allocation of healthcare resources throughout Australia. Future studies should aim 
to identify if there are any differences in service use and access for these population groups which 
are driving these differences in costs.  
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Chapter One: Introduction 
Background 
Cancer was the leading contributor to the burden of disease in Australia in 2011, accounting for 19% 
of the total burden.1 The majority (94%) of the burden from cancer was due to premature death.1 In 
2019, it is anticipated that an estimated 144,713 new cases will be diagnosed in Australia,2 with 
prostate cancer and breast cancer the most commonly diagnosed cancers for males and females 
respectively.2 The number of new cases of cancer is rising due to increasing cancer rates and an ageing 
population.2, 3 Fortunately, survival following a cancer diagnosis is improving in Australia.2, 4 The 
overall five-year relative survival rate has improved from 50% in 1986-1990 to 69% in 2011-2015.2 
Cancer of the testes, thyroid, and prostate had the highest five-year relative survival rates, and 
cancers of the pancreas, other digestive organs, and mesothelioma had the lowest five-year relative 
survival rates in Australia.2 However, despite improvements in the national survival rates, it is well 
documented that some population groups experience poorer survival. Specifically, Aboriginal and 
Torres Strait Islanders (hereafter, respectfully referred to as Indigenous Australians), 
socioeconomically disadvantaged persons, and people living in remote and very remote areas.2  
Reflective of this high burden of disease within Australia, the costs associated with cancer are also 
considerable with expenditure on cancer and other neoplasms accounting for $4,858 million to the 
healthcare system in 2008-09.5 This is equivalent to 7% of total health system expenditure on chronic 
disease during this time.5 Due to the increased incidence rates of cancer, as well as emerging cancer 
therapies and new technologies, the cost of cancer is expected to increase in the future.6-8 In a tight 
fiscal environment, it is important to understand the economic burden of cancer for policy makers to 
efficiently allocate resources for prevention and treatment. The economic burden of cancer can be 
divided into direct and indirect costs. The direct costs are further divided into direct medical and 
direct non-medical costs, and are any costs that relate directly to the medical condition. Direct 
medical costs include the cost of diagnosis, treatment, and care, and direct non-medical costs include 
the costs of accessing this medical treatment, such as transport, relocation, etc.9 Indirect costs consist 
of the lost productivity due to morbidity or premature mortality, and can include paid work, or unpaid 
work (such as household activities, childcare, caring for others, or volunteer work).9-11 Although the 
direct cost of treating cancer is high,5 the indirect cost of cancer may exceed the direct costs of 
cancer.6, 12-16 Therefore, it is important to consider both the direct and indirect costs of cancer, which 
may be used to develop cost projections, and to assist policy makers in budgetary and service design 




Within Australia the direct costs of healthcare may be incurred by the state and federal governments, 
individuals, private health insurers and accident and injury compensation companies. These costs are 
distributed in line with the structure of the Australian healthcare system. Briefly, Australia has a 
universal healthcare system, Medicare, which provides free medical treatment in a public hospital, 
and free or subsidised medical treatment outside of hospitals. Medicare is funded by the Australian 
government. Private health insurance is optional for individuals and families. Some medical 
treatment outside of hospitals are provided under the Medicare Benefits Schedule (MBS), where 
Medicare pays a proportion of the fee to the medical provider (known as a Medicare rebate) and 
individuals may incur an out-of-pocket (OOP) co-payment. These services include General 
Practitioner (GPs), specialist services, some imaging and pathology, optometry, and some allied 
health services.17 The Pharmaceutical Benefits Scheme (PBS) provides approved medications at a 
subsidised rate with a valid prescription.17 National healthcare expenditure reports commonly 
provide the costs for hospitalisations, out-of-hospital services, and PBS services separately.5, 18 Many 
studies also use these three categories, and may also identify the costs incurred by the individual. 
In this introductory thesis chapter, the costs of cancer (direct and indirect) in Australia will be 
described, followed by the rationale and aims of the thesis, and thesis structure. The cancer survival 
inequalities in Australia experienced by different sub-populations are described in Chapter Two. 
Direct costs of cancer 
The Australian Institute of Health and Welfare (AIHW) estimated that the direct cost of cancer to the 
healthcare system was $4.5 billion (excluding population screening) in 2008-09. This was an increase 
from $2.9 billion in 2000-01. In 2008-09, approximately 79% of the total costs was spent on hospital-
admitted patient services, 9% on out-of-hospital expenditure (including general practitioner, imaging, 
pathology and other medical services), and 12% on prescription pharmaceuticals. The cancers with 
the highest expenditures were prostate cancer in males and breast cancer in females.5 However, this 
report is now a decade old, and does not identify the distribution of this expenditure across 
population groups with known poorer outcomes.  
More recently, the AIHW and Cancer Australia published a report ‘Cancer in Aboriginal and Torres 
Strait Islander peoples of Australia: An overview’.18 This report estimated that the total Australian 
expenditure for hospitalisations where cancer was the principal diagnosis in 2010-11 was $4,021.1 
million.18 The average per person hospital expenditure for Indigenous Australians was 0.5 times lower 
than non-Indigenous Australians.18 This report included only admitted patient services for both public 
and private hospitals, and may potentially be an underestimate of the total cost of hospitalisations. 
In Australia, oncology services may also include non-admitted patient services in which the patient 
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may receive care in the hospital as a day patient, and thus never be included in the admitted patient 
data collection.  
Other previous Australian studies have identified the direct costs of cancer to the healthcare system 
for specific cancer types such as prostate cancer,19-21 lung cancer,22 and oesophageal cancer,23 
melanoma;24 or limited to an element of care, such as the cost of chemotherapy,25 or end of life 
care.26 There is growing utilisation of linked administrative data to estimate the cost of cancer to the 
healthcare system. There have been two recent papers published, which identify the OOP costs, and 
Medicare rebates using linked individual-level data. Both studies included participants from a large 
Queensland study (QSkin Sun and Health Study), linked to the Queensland Cancer Registry (QCR), 
MBS and PBS claims data.27, 28 Both of these studies included the cost to the healthcare system (for 
rebates paid by Medicare) and the patient co-payments paid (the patient co-payments will be 
discussed in more detail shortly). The first study included 452 participants from the QSkin Study who 
were diagnosed with one of the five most commonly diagnosed cancers in Queensland (breast, 
prostate, melanoma, colorectal, and lung cancer). The median Medicare rebate was $6,280 during 
the first two-years following diagnosis for the five cancers combined. During the first two-years from 
diagnosis, lung cancer accounted for the highest provider fees, followed by breast cancer.27 The 
second study included 419 individuals diagnosed with one of the five major cancers (from the QSkin 
Study), and matched separately to 419 high GP users (individuals without cancer, but with chronic 
medical conditions), and 421 participants from the general population.28 Compared to high GP users, 
and the general population, people with one of the five commonly diagnosed cancers had significantly 
higher median provider fees.28 In addition to these studies, Goldsbury et al.29 utilised linked 
administrative data from MBS, PBS, Hospital Admitted Patient Data Collection, and Emergency 
Department Data Collection to estimate the excess cost1 of all cancer. The cohort for this study was 
Australians aged 45 years and older with cancer, matched to non-cancer controls. The authors 
estimated that the excess cost of cancer for people diagnosed between 2009-2013 was $6.3 billion 
in 2013.29 To date, no Australian study has identified the distribution of cancer cost among those 
experiencing poorer health outcomes. The use of individual-level administrative data may be used to 
estimate the distribution of cost by patient characteristics.  
In addition to the costs to the healthcare system, the cost of cancer can also be evaluated from the 
individual’s perspective. The cost to the individual includes the direct and indirect costs.9 Direct 
medical costs may include the OOP cost to the patient that directly relates to their health care, such 
1 The excess costs of a disease is estimated by calculating the difference in costs between people with 




as medical services, medications, medical aids, and pathology, while direct non-medical costs may 
include transport, accommodation, parking, and childcare.9 The indirect costs to the patient may 
include costs of lost productive time, such as lost wages, lost time completing household activities, 
or forgone time with friends, family and completing other activities.9 
In Australia, the OOP fees accounted for 20% of health expenditure, which was equal to the 
Organisation for Economic Cooperation and Development’s (OECD) average (20%) in 2015. However, 
this is still higher than other developed countries including France (7%), the United Kingdom (15%), 
New Zealand (13%), and Canada (15%).30 A recent study showed that 21% of Australians with cancer 
don’t access healthcare due to the cost.31 There is growing concern that people diagnosed with cancer 
have high OOP costs, and are facing financial hardship.27, 32-36 The term ‘financial toxicity’ was coined 
to describe the high costs of accessing medical care for people diagnosed with cancer.37 Zafar and 
colleagues described financial toxicity as a type of adverse effect of cancer treatment.37 
A number of Australian studies have identified the high OOP costs for cancer patients.27, 32, 36, 38-40 
However, only two studies have compared the OOP costs by geography. The first compared the OOP 
costs by distance travelled from home to the Townsville Hospital Cancer Centre in North Queensland, 
Australia. This study found that people living more than 100km away from the treatment centre had 
greater OOP costs compared to those living 100km away or closer.36 The second study (conducted in 
Western Australia) reported that people living in a region with a Comprehensive Cancer Centre had 
lower OOP costs than those living outside of this region.38 This study did not include analysis by 
geographical remoteness, or distance travelled, which makes it difficult to generalise to the Australian 
population. To the author’s best knowledge, only two studies have evaluated the patient OOP costs 
by Indigenous status,41, 42 and no studies have evaluated the patient OOP costs by socioeconomic 
status.  
The majority of the studies evaluating OOP costs have relied on self-reported data through surveys.32, 
36, 38, 40 The use of self-reported data does have some inherent weaknesses. These include the accuracy 
of patient recall, and the recruitment of patients to the study which may potentially exclude those 
who have passed away, or those who are not well enough to participate in the study. The use of 
administrative data may overcome the limitation regarding accuracy of patient recall associated with 
self-reported data.43 However, a limitation of using administrative data to capture OOP costs is that 
it currently only includes patient co-payments. It does not include other OOP costs, such as private 
medications or medical services, medical aids, travel, accommodation, and parking. To date, four 
Australian studies have used linked administrative data to estimate the patient co-payments by 
people with cancer. The two studies which evaluated the OOP cost by Indigenous status utilised the 
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linked administrative data and the candidate was part of the research team. Callander et al.41 found 
that Indigenous Australians diagnosed with cancer had lower OOP expenditure compared to their 
non-Indigenous counterparts during the first three years post-diagnosis. However, Indigenous 
Australians also had fewer Medicare services compared to non-Indigenous Australians.41 The second 
study found that Indigenous Australians had significantly lower patient co-payments in the first 6 
months (61% less), and during months 7-to-12 (63% less) compared to non-Indigenous Australians. 
Indigenous Australians also had significantly fewer hospitalisations compared to non-Indigenous 
Australians.42 Two Queensland studies were from the QSkin Study. The first study described the 
patient co-payments for 452 QSkin Study participant. Of the five major cancers, breast cancer 
conferred the highest median co-payments ($4,192; IQR: $1,165 - $7,459), followed by prostate 
cancer ($3,175; IQR: $971 - $3,619).27 The second study using QSkin participants, matched to high GP 
users, and the general population found that the OOP costs were significantly higher for people with 
cancer, compared to people in the high-GP user group, and the general population group.28 
Indirect costs of cancer 
In addition to the direct costs of healthcare, there are significant indirect costs.6, 12-15 Approximately 
40% of Australians diagnosed with cancer in 2017 were of working age (25 to 64 years).44 It is not 
surprising that a cancer diagnosis leads to temporary or permanent changes in labour force 
participation.45 Using the 2003 Survey of Disability, Ageing and Carers (SDAC), Schofield et al.46 
reported that 49% of 45 to 64 year olds with cancer were not in the labour force.46 Another Australian 
study found that of those employed prior to their diagnosis, 67% of participants reported a change in 
their employment, and 64% reported that their household income had reduced following a cancer 
diagnosis.47 Although these changes in labour force participation have an effect on the national 
economic growth, there is also a significant impact to the individual and their families through lost 
income. The definition of financial toxicity has grown, and now encompasses the high cost of 
accessing care, and the impact that reduced income has on the individual and/or household.48, 49 
Globally, there is increasing evidence of the substantial cost of lost productivity due to premature 
mortality.16, 50-53 This is an emerging field of research in Australia. Carter and colleagues54 estimated 
that 88,000 working years were lost due to premature deaths from cancer in 2003, accounting for 
approximately $4.2 billion in lost income.54 Another report estimated that the total lifetime 
productivity cost for Australian adolescents and young adults diagnosed with cancer in 2016 was 
$508.4 million.55 Other Australian studies have evaluated the indirect cost of individual cancers,40, 56 




Gaps in the literature 
The cost of cancer to the healthcare system is expected to rise. A recent Lancet Oncology Commission 
found that health system expenditure in many countries has increased due to the rising costs of 
treatment (i.e. chemotherapy and radiotherapy), and an increased use and cost of imaging (such as 
PET and MRI scans).6 In Australia, the national expenditure on cancer is expected to rise to $10.1 
billion by 2033.7 The PBS expenditure on anticancer drugs rose from $64.8 million in 1999-2000 to 
$466.3 million in 2011-12.57 This was a 19.1% increase per year, compared to 9.0% increase for all 
other drugs combined.57 Between 2000 and 2012, 23 new anticancer medications were listed on the 
PBS.57 In Australia, all medications, or any revisions to medications currently on the PBS2 must 
undergo a review by the Pharmaceutical Benefits Advisory Committee (PBAC) before it is listed on 
the PBS. The review process considers the medical condition which it is listed for, the clinical 
effectiveness, safety, and cost-effectiveness.58 There are several factors which have led to the rise in 
PBS expenditure, including the increase in the number of PBS listings, and the high cost paid for these 
medications.57 Pharmaceuticals are expected to continue to rise due to advances in targeted cancer 
therapy.6, 8, 57  
Although the cost of cancer is increasing,5-8 there are only a finite amount of resources to fund the 
healthcare system within Australia, necessitating choices to be made about what to fund. 
Furthermore, there is a paucity of studies in Australia identifying the distribution of costs by 
population groups experiencing poorer health outcomes, specifically Indigenous Australians 
compared to non-Indigenous Australians, people living in different areas of remoteness, and 
socioeconomically disadvantaged people. The direct and indirect costs of cancer need to be 
understood, in order to predict future expenditure, and to ensure equitable allocation of future 
resources. There are examples in Australia and internationally where costs have an important place 
alongside clinical effectiveness, and safety in approvals for funding recommendations for 
pharmaceuticals or medical services.58-60 In Australia, the PBAC Guidelines require that applications 
for submission include either a full cost-effectiveness analysis or a cost minimisation economic 
evaluation.58 The PBAC Guidelines include descriptions of what to include in the economic evaluation. 
For example, to determine the cost of medical services, the MBS scheduled fee for the item should 
be used, or for hospital services, the average cost weight should be applied to the Australian refined 
diagnostic related group (AR-DRG).58 The Medical Services Advisory Committee (MSAC) also require 
applications to evaluate the cost-effectiveness of medical services.60 Similarly, the United Kingdom’s 
                                                             
2 Changes may include revision of the current dose or eligible patients, changes to formulation, 
changes to the current listing etc  
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National Institute for Health and Care Excellence (NICE) guidelines evaluate evidence for both the 
effectiveness and cost-effectiveness to make decisions.61 
Administrative data may be used to identify costs of cancer. Administrative data is routinely collected 
by a number of Government agencies throughout a person’s cancer journey. Data linkage allows 
researchers to consolidate these various sources of data to develop a single dataset. The 2012-13 
Productivity Commission’s Annual Report recommended greater use of administrative data in 
research to evaluate policy efficacy.62 The AIHW’s Australia’s Health, 2018 report identified that a 
number of knowledge gaps may be filled by making use of existing data, and linking data from various 
agencies.63 
Thesis rationale 
Improving cancer outcomes for all Australians remains a national health priority.64 The 2015 National 
Aboriginal and Torres Strait Islander Cancer Framework identified seven priorities to improve quality 
cancer care for Indigenous Australians and thus, improving cancer outcomes.65 One of the priorities 
was to “strengthen the capacity of cancer related services and systems to deliver good quality, 
integrated services that meet the needs of Aboriginal and Torres Strait Islander peoples”65(p19). 
Additionally, the most recent national healthcare expenditure reports are now potentially out of date. 
The current Cancer Australia’s Strategic Plan calls for action to ensure that ‘all Australians receive 
accessible, best practice diagnosis and cancer care’.66 (p15) However, it is well known that some 
population groups have poorer outcomes. The AIHW Cancer in Australia reports regularly identify 
their key population groups as Indigenous Australians, state and territory populations, people living 
in different remoteness areas, and people living in different socioeconomic disadvantaged areas.2, 44 
Many factors have been identified in the literature in contributing to these poorer outcomes 
(discussed further in Chapter 2); however, to date, there are limited studies which have explored the 
distribution of cancer expenditure (as measured by costs) for these population groups. It is possible 
that the distribution of costs to the healthcare system and individual may contribute to the existing 
literature describing the inequalities in cancer outcomes by indicating poorer access to health 
services. In order to determine if there are any inequities in the distribution of the costs, and thus the 
investment in health care of patients, it is important to quantify the costs by population group. There 
are several benefits to using individual level administrative data. The first is that it captures all health 
service use for each individual and therefore may be used to identify the distribution of cost by 
patient characteristics. The second advantage is that it overcomes potential limitations of self-





The purpose of this thesis is to quantify the cost of cancer in Australia, thus providing more recent 
estimates of the total cost of cancer from a healthcare and individual perspective. This thesis will also 
be the first to describe the distribution of the costs of cancer by Indigenous status, remoteness, and 
socioeconomic disadvantage. If there are differences in the distribution of costs, this will be further 
investigated in post-doctoral work. In order to estimate the cost of cancer in Australia, linked 
administrative data are used in this thesis, thus meeting recommendations from the Productivity 
Commission and the AIHW. In this PhD, costs are calculated from different perspectives, in order to 
provide an estimate of the cost of cancer to the public healthcare system, society, and the individual 
patient. 
The specific aims of this thesis are:  
1. To quantify the direct costs to the Australian public healthcare system and patient co-
payments for the first 12-months following diagnosis, and to determine the distribution of 
these costs by Indigenous status, remoteness, and socioeconomic status; 
2. To quantify the annual indirect costs in Australia due to changes in labour force participation 
of people with cancer; and  
3. Using female breast cancer as a case study, to quantify the direct costs to the Australian 
public healthcare system and individual for the first three years post-diagnosis, and to 
determine the distribution of these costs by Indigenous status, remoteness, and 
socioeconomic disadvantage.  
Populations groups of interest  
In this thesis, three population groups were identified as experiencing poorer survival, which is 
further detailed in the Literature Review (Chapter 2): Indigenous Australians, socioeconomically 
disadvantaged persons, and people living in remote and very remote areas. The terminology used in 
this thesis for each of these population groups is outlined below. Although other population groups 
experience differences in cancer outcomes, the three population groups outlined above were chosen 
for several reasons: 1) they are the key population groups identified in national cancer reports; 2) 
these population groups are identifiable using administrative data; and 3) these population groups 
should have suitable sample sizes for analysis.  
Indigenous Australians included Australian Aboriginal and/or Torres Strait Islander persons, and was 
compared to non-Indigenous Australians. A common limitation in Australia is the incomplete 
recording of Indigenous status in health and vital registration data collections.67, 68 The Australian 
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Cancer Database considers five jurisdictions to have sufficient completeness for reporting purposes, 
New South Wales, Victoria, Queensland, Western Australia and the Northern Territory.44 This is 
important to note, as the Australian cancer statistics may underestimate the incidence of cancer for 
Indigenous Australians. 
In Australia, there are several ways to define geographical remoteness. The Australian Institute of 
Health and Welfare (AIHW) and the Australian Bureau of Statistics (ABS) commonly use the 
Accessibility/Remoteness Index of Australia (ARIA), Australian Standard Geographical Classification 
(ASGC) or Australian Standard Geographical Standard (ASGS). ARIA is a measure of remoteness based 
on road distance measurements to the nearest Service Centre category.69 ARIA consists of five 
categories: highly accessible, accessible, moderately accessible, remote, and very remote.70 The ASGS 
replaced the ASGC in 2011. The ASGS has five categories of remoteness: metropolitan, inner regional, 
outer regional, remote, and very remote.71 Existing literature use a number of definitions for 
geographical remoteness, including collapsing the above ARIA or ASGS categories into two or three 
categories, for example: major cities or metropolitan areas, and areas outside of major cities or 
metropolitan areas.  
For the main dataset used within this thesis, CancerCostMod, ASGS was chosen as the measure of 
remoteness as it was possible to map the postcode to the ASGS. In the development of 
CancerCostMod, the, postcode of residence was mapped to ASGS to provide an area of remoteness. 
The categories were collapsed from the five ASGS categories to three categories: metropolitan, (inner 
and outer) regional, and remote (and very remote) due to sample size and comparability with 
previous works, including the AIHW reports. 
The ABS developed Socio-Economic Index for Areas (SEIFA), which is a measure of relative advantage 
and disadvantage.72 SEIFA contains four indices:  
- Index of Relative Socio-Economic Disadvantage (IRSD) summarises the economic and social 
conditions of people and households in an area. A low score indicates relative disadvantage, 
and a high score indicates a lack of disadvantage;72 
- Index of Relative Socio-Economic Advantage and Disadvantage (IRSAD) summarises the 
economic and social conditions of people and households in an area but includes both 
relative advantage and disadvantage. A low score indicates the most disadvantaged, and a 
high score indicates the most advantaged;72 
- Index of Education and Occupation (IEO) is a measure of the level of education and 
occupation, where a low score indicates relatively lower education and occupation, and a 




- Index of Economic Resources (IER) uses variables relating to income and wealth, but excludes 
education and occupation. A low score indicates the most disadvantaged, and a high score 
indicates the most advantaged. 72  
During the development of the PhD proposal, it was noted that IRSD was commonly used in previous 
Australian studies and reports,2, 73-76 therefore, IRSD was chosen as the measure of socioeconomic 
disadvantage to enable comparison to other Australian studies, and governmental reports.2 In the 
development of CancerCostMod, the postcode of residence was mapped to IRSD. IRSD deciles were 
collapsed into quintiles, where Q1: most disadvantaged and Q5: least disadvantaged. This was due to 
sample size and to ensure comparability with previous works. 
Thesis structure 
This thesis contains four parts, and eight chapters. A brief outline of each of the parts and chapters is 
presented below. A number of chapters comprise peer-reviewed articles which have been published, 
or are currently under review. A full list of publications contained within this thesis is described 
previously (page viii) and in Figure 1 below (page 14). 
Part 1: Introduction and literature review (Chapters One and Two) 
Part 1 comprises two chapters. Chapter One provides a background on the cost of cancer in Australia, 
and concludes with the rationale, structure and aims of the thesis. Chapter Two is a literature review 
about the health inequalities, and specifically inequalities in cancer survival, observed by Indigenous 
status, remoteness, and socioeconomic disadvantage.  
Part 2: The cost of cancer in Australia (Chapters Three and Four) 
Part 2 of the thesis comprises Chapters Three and Four, and addresses aims 1 and 2. In Part 2, the 
focus is on all cancer types and the 12 months following diagnoses. In Chapter Three, the 
development of the microsimulation model, CancerCostMod, which is the primary dataset used in 
this thesis, is described. This is the first publication of the thesis. Also in this chapter, the costs to the 
public healthcare system in the first 12 months following diagnosis for all cancer types are quantified. 
This PhD is nested in a larger project, “Quantifying Queensland cancer patients’ health service use 
and costs”. The original project aimed to identify the patient OOP costs and distribution of these costs 
by population groups using linked administrative data. The project was expanded to include the aims 
of this thesis.  
The fourth chapter consists of the second publication of the thesis, which is an examination of the 
labour force participation rates of people with cancer to measure the annual indirect costs of all 
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cancer types in Australia. This chapter only addresses a small part of the indirect costs of cancer, 
specifically the cost of lost productivity due to morbidity using the 2015 SDAC. This nationally 
representative survey was chosen as it had the potential to identify labour force participation rates 
for people with cancer, which could then be used to measure the annual indirect costs due to 
morbidity. Conducting a full study on the indirect costs of cancer, including lost productivity costs due 
to morbidity and mortality were beyond the scope of this PhD. 
Part 3: A case study of the cost of female breast cancer in Australia (Chapters Five, Six, and Seven) 
The third part of the thesis comprises three chapters (each chapter is a separate manuscript, these 
are currently under review or published), and addresses aim 3. The focus is on female breast cancer 
as a case study, and costs in the 36-months following diagnoses are examined in greater depth. Breast 
cancer is the most commonly diagnosed cancer for women worldwide,77 and in Australia.2 
Accordingly, it was chosen as the case study for the remainder of this thesis. Although males can 
develop breast cancer, the proportion is much lower, and thus all analyses in this part of thesis are 
limited to female breast cancer only. The public healthcare system expenditure for hospital 
presentations are examined in Chapter Five, and for MBS and PBS Government rebates in Chapter 
Six. Chapter Seven is an investigation of the patient co-payments for MBS services and PBS 
prescriptions. 
Part 4: Discussion and conclusion (Chapter Eight) 
The final part of the thesis presents a synthesis of the main findings of the thesis in the context of 
relevant literature and the strengths and limitations of the overall programme of research. 
Recommendations for policy, practice and research are provided.  
List of publications 
Five of the chapters within this thesis comprise published works, or works under review. For each of 
the papers contained within this thesis, I am the primary author. Details of the publications are 
summarised in the diagram below of the thesis structure. For chapters which comprise of or contain 
a published article, the original article has been inserted into the chapter as published, thereby 
retaining the formatting and referencing of the journal. These chapters contain a brief introduction 
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Chapter Two: Exploring the cancer survival inequalities 
in Australia 
Introduction  
According to the Australian Institute of Health and Welfare (AIHW), one in two Australians will be 
diagnosed with cancer in their lifetime.1 In 2019, this was anticipated to translate to approximately 
144,713 new cases of cancer,1 with breast cancer, prostate cancer, colorectal cancer, melanoma of 
the skin, and lung cancer the most commonly diagnosed.1 In 2011, cancer accounted for 19% of the 
total burden of disease, ranking it ahead of cardiovascular diseases (15%).2 The majority (94%) of the 
burden of cancer is due to premature mortality.2 Three in ten deaths in Australia were due to cancer 
in 2016;1 most commonly from lung cancer, colorectal cancer, prostate cancer, breast cancer, and 
pancreatic cancer.1 
Cancer survival in Australia has improved over the last 30 years.1, 3 The five-year survival rate for all 
cancers combined improved from 47% during the period 1982-1987 to 69% between 2011-2015.1 
Despite these improvements, Aboriginal and Torres Strait Islander Australians, hereafter, respectfully 
referred to as Indigenous Australians (approximately 3% of the population4), people living in remote 
areas, and socioeconomically disadvantaged persons experience poorer cancer survival.1, 5-20 To add 
to the complexity, these three population groups often overlap. For example, a greater proportion of 
Indigenous Australians reside in remote and very remote areas compared to non-Indigenous 
Australians (an estimated 18.4% vs 1.4% respectively in 2016).21 In addition, a greater proportion of 
Indigenous Australians, and people living in rural and remote areas experience disadvantage with 
respect to education, employment, and access to goods and services.22, 23 
The aim of this review is to describe the differences in cancer outcomes for Indigenous Australians, 
people living in remote areas, and socioeconomically disadvantaged people in Australia. The general 
inequalities in health status will be explored, followed by a description of the differences in risk 
factors and cancer screening participation; incidence and mortality; and access to healthcare and 
treatment for these different population groups, thus highlighting the need to assess the distribution 
of costs by these characteristics when describing expenditure on cancer. 
Methods 
Indigenous Australians, socioeconomically disadvantaged persons, and people living in remote and 
very remote areas are three population groups identified in this thesis as experiencing poorer 
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survival. The research question for this review was broad, and sought to describe the health 
inequalities, and the inequalities in cancer incidence, mortality, and survival by Indigenous status, 
remoteness, and socioeconomic disadvantage. A narrative literature review was chosen. 
A search of Medline (Ovid), Cinahl, and Scopus databases was completed. The search strategy was 
based on keywords and subject headings. Search terms included 1) neoplasm or cancer; 2) diagnosis, 
incidence, survival, mortality; 3) inequality or inequity, social determinants of health, socioeconomic 
or disadvantage, rural or remote or geography, Indigenous or Aboriginal; and 4) Australia, Australian 
Capital Territory, New South Wales, Northern Territory, Queensland, South Australia, Tasmania, 
Western Australia. These categories were then combined using ‘AND’. Reference lists of the included 
articles were also screened to identify any other eligible studies. All study designs were included in 
the review, but only articles that compared inequalities between the population group of interest 
and its comparator (ie Indigenous vs non-Indigenous Australian, or urban vs non-urban). A grey 
literature search of Australian and international organisations was conducted to find reports that 
include disparities between population groups, and national cancer reports. For example, the AIHW, 
Cancer Australia, Cancer Council, and World Health Organization (WHO). 
Health inequalities 
The differences in health status between population groups are labelled health inequalities. If these 
differences in health status are unfair and potentially avoidable, they are defined as health inequities. 
Health inequities can be described by the social determinants of health, which are ‘the conditions in 
which people are born, grow, live, work and age’.24 The social determinants of health include social 
gradient, stress, early life, social exclusion, work, employment, social support, addiction, food, and 
transport.24, 25 The social gradient describes the social and economic factors which includes income, 
family assets, education, employment status and position, housing, and other circumstances.24, 25 
People who are lower on the social gradient (i.e. more disadvantaged) experience poorer health and 
reduced life expectancies compared to those who are higher on the social gradient.24-30 
The Australian burden of disease studies by the Australian Institute of Health and Welfare measure 
the burden of disease using disability-adjusted life years, which combines premature mortality and 
morbidity.2, 31, 32 These studies can be used to monitor population health and can be used to compare 
diseases and population groups.31 In Australia in 2011, a total of 4.5 million years were lost due to 
premature mortality and morbidity.31 However, the proportion of this burden was not equal across 
all population groups. The age-standardised rate of burden in very remote areas was 1.7 times the 
rate for major cities.31 Using the Index of Socioeconomic Disadvantage (IRSD), the most recent 




a greater proportion of the total burden than people from the highest socioeconomic quintile (23.6% 
compared to 15.7%).31 In 2011, the burden of disease was 2.3 times greater for Indigenous Australians 
than non-Indigenous Australians.32  
It has been estimated that one third (31%) of the total burden of disease in Australia is due to 
modifiable risk factors, and is therefore preventable.31 These modifiable risk factors that contribute 
to the burden included tobacco use (9.0%), high body mass index (5.5%), alcohol use (5.1%), physical 
inactivity (5.0%), and high blood pressure (4.9%).31 Amongst Indigenous Australians, modifiable risk 
factors account for an even greater proportion (37%) of the total burden.32 Tobacco use is the highest 
modifiable risk factor for Indigenous Australians, contributing to 12% of their total burden.32 
Approximately half (51%) of the gap in disease burden between Indigenous Australians and non-
Indigenous Australians is attributable to modifiable risk factors.32 
Studies have found that there is an association between socioeconomic disadvantage and poor health 
behaviours such as tobacco use, alcohol consumption, diet and exercise.26, 33-35 The Whitehall II Study 
found that tobacco use was highest in the lowest employment grade and decreased with increasing 
employment grade.26 Poor health behaviours have been also associated with lower education 
attainment.33, 36 People living in the most disadvantaged quintile were more likely to smoke daily 
compared to those living in the least disadvantaged quintile (21.4% vs 8.0).37 According to the 2014-
15 National Health Survey (NHS), smoking rates were highest in outer regional and remote areas of 
Australia (20.9%) and lowest in major cities (13.0%). Although the smoking prevalence has declined 
over the last 20 years for both Indigenous and non-Indigenous Australians, Indigenous Australians are 
still more likely to be smokers compared with their non-Indigenous counterparts (45% compared to 
16% in 2014-15).38 Indigenous Australians living in remote areas are more likely to be smokers (56%) 
compared to those living in non-remote areas (42%).38 
The 2014-15 NHS also reported that women living in socioeconomically disadvantaged areas were 
more likely to be overweight and obese (61.1%) compared to those living in the least disadvantaged 
areas (47.8%); however, there was no differences observed in males. Adults living in inner regional 
(69.2%) or outer regional/remote areas (69.2%) were more likely to be overweight compared to 
adults living in major cities (61.1%).37 In 2012-13, Indigenous Australians were 1.5 times more likely 
to be obese than non-Australians. The rates of overweight and obese Indigenous Australians were 
highest in non-remote areas (67%) compared to remote areas (61%).39 
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Risk factors and cancer screening participation 
Risk factors 
The 2011 Australian Burden of Disease Study reported that 17 risk factors accounted for 44% of the 
burden of cancer. The largest contributing risk factor was tobacco use, which accounted for 22% of 
the total burden of cancer. In total, tobacco use was attributable to 11 types of cancer.2 Whiteman 
et al.40 estimated that 32% of all cancers diagnosed in Australia in 2010 were attributable to 13 
modifiable risk factors. The leading risk factors contributing to the population attributable fraction 
were tobacco smoke, solar radiation, inadequate diet, and being overweight or obese.40 Other risk 
factors for cancer include but are not limited to: alcohol consumption, certain infections (such as 
Hepatitis B virus and human papillomavirus (HPV)), reproductive and hormonal factors, family 
history, genetics, dietary factors, being overweight, physical inactivity, and ultraviolet radiation 
exposure.41 The increased risk factors reported between the population group of interest and its 
comparator (ie Indigenous vs non-Indigenous Australian, or metropolitan vs non-metropolitan, or 
most disadvantaged vs least disadvantaged) may in part describe the increased incidence of cancers 
for which exposure to these risk factors are known to be causally related. 
Participation in cancer screening 
Australia has three national cancer screening programs, which provide population-based screening 
targeting a specific population to reduce morbidity and mortality through early detection.1 These 
three programs are: BreastScreen Australia, National Cervical Screening Program (NCSP), and 
National Bowel Cancer Screening Program (NBCSP). There are some reported differences in 
participation rates in these programs between the three population groups of interest in this thesis. 
However, national participation rates for the NCSP and NBCSP are not available for Indigenous 
Australians, as Indigenous status is not routinely collected on pathology forms.42, 43 
Breast Cancer Screening  
BreastScreen Australia provides free mammograms for women aged 40 years and older every two 
years. The target age range is women aged 50 to 74 years. In 2014-15, the national average 
participation rate for the target age group was 54%. Indigenous women had lower participation rates 
than non-Indigenous women (37% verse 53%). Women living in outer regional areas had the highest 
participation rate (57.2%), and the lowest participation rate was in very remote areas (46.6%). 
Participation was similar for women from all socioeconomic groups.44 
Cervical Cancer Screening 
The NCSP was introduced in 1991, and until 2017, the NCSP recommended a Papanicolaou smear 




the National HPV Vaccination Program.45 Persistent HPV infections are a known precursor for 
developing cervical cancer.46 In 2007, Australia introduced the National HPV Vaccination Program for 
adolescent girls and young women. In 2013, the program was extended to include boys as well.47 The 
new guidelines recommend a Cervical Screening Test every five years.45 Although more research is 
required to determine the effect that the HPV vaccine has had on cervical cancer incidence and 
mortality, recent studies have reported a reduction in the prevalence of HPV-types that are included 
in the vaccination.48, 49 
Prior to the changes to the NCSP, differences in screening participation rates were reported by 
Indigenous status, remoteness and socioeconomic disadvantage. In 2015-16, the age-standardised 
national screening participation rate was 56% for women aged 20-69 years.45 Women living in very 
remote areas had the lowest participation rates (46.3%), and women living in major cities and inner 
regional areas had the highest participation rates (56.4% and 56.6% respectively).45 Participation 
rates were highest for women from the highest socioeconomic group (62.1%) compared to women 
from the lowest socioeconomic group (50.4%).45  
A recent Queensland study using linked administrative data found that the two-year participation 
rates in the NCSP in 2010-11 was approximately 20% less for Indigenous women than non-Indigenous 
women.50 In this study, the highest participation rates for both Indigenous and non-Indigenous 
women were in outer regional, and the lowest in very remote areas; and rates improved with 
increasing advantage; however, participation rates were lower in Indigenous women than non-
Indigenous women in all areas of remoteness and advantage.50 Similar findings were reported in the 
Northern Territory, with participation rates for Indigenous women approximately 18-19% lower than 
national Australian participation rates during 1999-2000, and 2003-2004.51 In contrast, the AIHW 
(using the 2012-13 Australian Aboriginal and Torres Strait Islander Health Survey (AATSIHS)) did not 
report any geographical variance in participation rates.52 The lower participation rates for NCSP are 
thought to be factors for increased cervical cancer mortality rates for Indigenous women.9, 50, 51  
Bowel Cancer Screening 
The target population for the NBCSP are aged 50-74 years. The national participation rate was 41% 
in 2015-16.53 Differences in participation rates were reported for socioeconomic advantage, with the 
highest rates reported in the most advantaged areas (43%) and lowest rates in the least advantaged 
areas (39%).53 The rates were also highest in inner regional areas (44%), and lowest in very remote 
areas (28%).53 The 2018 NBCSP report estimated that the 2015-16 participation rates for Indigenous 
Australians was 19.5% compared to an estimated 42.7% participation rate for non-Indigenous 
Australians.53 The Aboriginal and Torres Strait Islander Health Performance Framework 2014 Report 
Page 24
 
(using the 2012-13 AATSIHS) found that 18% of eligible Indigenous males and 11% of eligible 
Indigenous females reported participating in bowel cancer screening.54 The 2017 Aboriginal and 
Torres Strait Islander Health Performance Framework Report did not contain any more recent data.23 
Incidence and mortality 
The most recently published national statistics reports that for the period 2010-14, the age-
standardised incidence rate for all cancers combined was highest for people in the two lowest IRSD 
areas, and lowest for people living in the two highest socioeconomic areas.1 During this same time 
period, the highest age-standardised incidence rates for all cancers combined occurred in people 
living in inner regional areas (513 cases per 100,000 persons), and rates were lowest among people 
living in very remote areas (445 cases per 100,000 persons).1  
People living in the lowest socioeconomic areas had higher age-standardised mortality rates for all 
cancers combined compared to those living in the highest socioeconomic areas during the period 
2012-16 (187 vs 136 per 100,000 persons).1 The highest age-standardised mortality rate for all 
cancers combined (195 per 100,000) occurred in people living in very remote areas, and people living 
in major cities had the lowest rates (157 per 100,000).1  
Differences in incidence and mortality by geographical location have been consistently reported in 
the literature. Cancer atlases, which identify geographical variation in incidence and survival for 
multiple cancers, have been published in Queensland (2011)14 and South Australia (2012).15 The 
Queensland Atlas presented cancer incidence and cancer survival between 1996 and 2007. 14 In 
general, compared to the average survival, people who lived in more rural or disadvantaged areas 
had lower survival.14 A Queensland study recently compared survival of individuals diagnosed with 
one of the major five cancers between 1997-2004 and 2005-12, and found that although cancer 
survival has improved, there are still differences in survival by geographical location.19Recently, an 
interactive online ‘Australian Cancer Atlas’ was launched by Cancer Council Queensland, with the 
support of Queensland University of Technology, and FrontierSI.16 The Australian Cancer Atlas 
provides a summary of cancer diagnoses (2010-14) and excess deaths (2006-14) for all cancers 
combined, and a number of individual cancer types.16 Other studies have also found differences in 
survival by area by geographical location for specific cancer types.17, 18 For example, in men diagnosed 
with prostate cancer, although the five-year survival rate improved in Australia between 1982 to 
2004, the survival gap widened between urban and rural areas.17 The risk of dying from rectal cancer 




A recent study reported that the gap in survival from cancer has increased by level of socioeconomic 
disadvantage in New South Wales (NSW) between 1980 and 2008, and that this difference remains 
after adjusting for stage of disease.5 Another NSW study found that 13.4% of cancer deaths were 
attributable to socioeconomic inequality.6 Tervonen et al.13 analysed all new cancer cases in NSW 
diagnosed between 1980 and 2009. The authors reported that compared to people living in the least 
disadvantaged areas, those living in more disadvantaged areas had higher odds of being diagnosed 
with a distant staged disease. This association was stronger for the most recent period, 2000-09. This 
study also found that compared to people living in major cities, people living in either inner or outer 
regional areas were less likely to be diagnosed with a distant staged disease.13  
In March 2019, the AIHW released a new Cancer in Australia 2019 report. However, due to available 
data sources, the age-standardised rates of cancer were not reported.1 Thus, the following 
information is from the Cancer in Australia, 2017 report.20 The current national statistics regarding 
the incidence of cancer in Indigenous Australians published by the Australian Institute of Health and 
Welfare contains information from five (of eight) jurisdictions in Australia.20 This was because these 
jurisdictions are deemed to have ‘sufficient completeness’ on Indigenous status.20 The age-
standardised incidence rate for all cancers combined was 484 per 100,000 for Indigenous Australians 
compared to 439 per 100,000 for non-Indigenous Australians between 2008 and 2012, and the age-
standardised mortality rate for all cancers combined was also higher in Indigenous Australians than 
non-Indigenous Australians between 2010-14.20 
In Queensland, the incidence of cancer in Indigenous Australians between 1997-2006 was 21% lower 
than in the total Queensland population; however, the mortality rate was 36% higher.7 A national 
study found that cancer survival was lower for Indigenous Australians compared to non-Indigenous 
Australians at one year (63.8% vs 83.4%) and five years (46.7% vs 70.0%) following diagnosis. Cancer 
mortality rates were 65% higher for Indigenous persons in very remote areas compared to 
metropolitan areas, but only 23% higher for non-Indigenous people.8 A recent Queensland study 
found that although the five-year survival was lower in Indigenous Australians compared to non-
Indigenous Australians, the first year after diagnoses accounted for 50% of the excess mortality. In 
this study, survival did not vary by geographical location or socioeconomic disadvantage.10 A separate 
study found that after the first year of diagnosis, the survival ratios were relatively constant for most 
cancers; however, the survival inequality continued to widen for liver cancer, breast cancer and head 
and neck cancers.12  
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Access to healthcare services 
Although Australia’s universal healthcare system aims to provide equal access to medical services,55 
there are several barriers to accessing healthcare services. These barriers include but are not limited 
to physical access, access to culturally appropriate services, and patient costs.22 Before these barriers 
are discussed, it is important to introduce Australia’s universal healthcare system, Medicare. 
Medicare provides free treatment at public hospitals, and free or subsidised medical care outside of 
public hospitals. The Medicare Benefits Schedule (MBS) contains a list of services which receive a 
rebate from the Commonwealth Government through Medicare. If there is a gap between the total 
charged by the provider and the rebate, the patient will be charged a co-payment.55 In some cases, 
the service provider may choose to ‘bulk-bill’ the patient, or accept the rebate as the full fee for the 
service. Access to subsidised approved prescription pharmaceuticals are provided under the 
Pharmaceutical Benefits Scheme (PBS). In contrast to the MBS co-payments, for approved 
prescriptions, patients will be charged any amount up to the total patient co-payment (in 2018, the 
general co-payment was $39.50, and $6.40 with a valid concession card).56 In other words, the patient 
will only pay a maximum of the patient co-payment, and if the cost of the prescription pharmaceutical 
is greater than the co-payment, the Commonwealth Government will pay the remainder of the cost 
of the medication.55, 56 
The sheer size of Australia’s landmass provides challenges in physically accessing healthcare services. 
Access to healthcare services reduces with increasing remoteness.22, 57 In 2015, there were 442 full-
time equivalent (FTE) medical practitioners per 100,000 population in major cities, and 263 FTE per 
100,000 population in remote/very remote areas.58 The availability of cancer services also varies 
according to remoteness.59 In 2006, the Clinical Oncological Society of Australia (COSA) published 
results of rural and regional oncology services in Australia. They found that in 2003-04, of the 1,304 
Australian public and private hospitals surveyed, only 157 regional hospitals administered 
chemotherapy, 11 had access to radiation units of which less than half were fully staffed, and only 
five had surgical oncology services. The accessibility of specialist medical practitioners or cancer 
support staff were also much lower in rural and regional areas.59 Therefore, many patients who live 
outside metropolitan areas will be required to travel from their homes to access treatment, and stay 
away from their homes for the duration of their treatment.59 Travel and accommodation incurs a 
substantial economic burden for people with cancer,60-66 which may be a barrier to accessing care. An 
additional barrier for rural patients is spending time away from family and friends, and on-going 




Telehealth is an emerging model of care, which is being used to provide healthcare services, including 
oncology services to areas lacking physical access to specialists. The Townsville Cancer Centre 
introduced tele-oncology in 2007 to provide medical oncological services to regional North 
Queensland.67, 68 This model of care enables patients to receive chemotherapy treatment at rural 
hospitals (for example Mt Isa, approximately 900km from Townsville), with the consultant medical 
oncologist being located in Townsville, and a senior doctor, chemotherapy-competent nurses, and 
allied health workers being located at the rural hospital.68 However, telehealth may not be 
appropriate or available for all patients. For example, patients requiring radiotherapy or haematology 
treatment are still required to travel. 
Indigenous Australians face additional barriers to accessing healthcare. The Aboriginal and Torres 
Strait Islander Health Performance Framework 2017 report23 identified several barriers including 
transport and distance to the health provider, waiting too long, availability of culturally appropriate 
services, and cost.23 The number of Indigenous Australians working in the health workforce is low.23 
Increasing the number of Indigenous Australians working in the health workforce has been identified 
as essential to achieve equitable outcomes.69 There are also different cultural beliefs surrounding 
health, healthcare, and cancer, which may influence health seeking behaviours.70-72 
Although Australia has a universal healthcare system, individual OOP costs are a potential barrier in 
accessing healthcare. The out-of-pocket costs of health care in Australia have received attention from 
the Australian Government in recent years. In 2018, the Ministerial Advisory Committee on OOP costs 
was established to provide advice on reforms in OOP costs for health care.73 The 2017-18 ABS Patient 
Experiences Survey reported that only 4% of people who needed to see a GP delayed or did not go 
due to cost.74This could reflect the fact that during 2016-17, 86% of non-referred GP services were 
bulk-billed (all-time high).75 However, as this is a household survey, there is potentially selection bias. 
A higher proportion of people delayed or skipped seeing a medical specialist, dentist, or delayed or 
did not get their prescribed medication due to cost.74 According to a recent AIHW report on OOP 
costs for out-of-hospital Medicare services, almost half of all patients incurred an OOP cost in 2016-
17.76 The amount varied by Primary Health Network area, state, and type of service. For example, the 
highest OOP costs were for specialist and obstetric services.76 
The term financial toxicity has been coined to describe the high OOP expenditure associated with 
cancer treatment,77 and is a growing concern in Australia and internationally.60, 62, 63, 78 A recent study 
of Australians with chronic health conditions found that 21% of Australians with cancer reported that 
they had skipped treatment due to the costs.79 Another study found that 63% of participants reported 
a level of financial burden due to obtaining medications prescribed in relation to their cancer.80 These 
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OOP costs may be a greater financial barrier to accessing care for those with greater socioeconomic 
disadvantage. To date, some studies have identified that people living further away from a treatment 
centre incur higher OOP costs for travel and accommodation.60-66 However, to date, no study has 
identified the distribution of OOP costs by Indigenous status, or socioeconomic status. 
Variation in cancer treatment 
Following a cancer diagnosis, there have been a number of differences reported in the treatment 
received by patients based upon their Indigenous status, geographical location, and socioeconomic 
disadvantage. Clinical factors, such as cancer type, stage of disease at diagnosis, and co-morbidities 
may impact the recommended treatment options. As discussed previously, variation in the stage of 
disease at diagnosis has been reported in different population groups. Indigenous Australians with 
cancer are also more likely to have more co-morbidities than their non-Indigenous counterparts.13, 81-
83  
In a recent systematic review of variations in outcomes for Indigenous women with breast cancer in 
Australia, Dasgputa et al. (2017)84 identified five studies in which clinical management by Indigenous 
status was examined.82, 85-88 Differences between Indigenous and non-Indigenous women were 
reported in two82, 88 out of the five studies.84 For women diagnosed with breast cancer in New South 
Wales between 2001 and 2007, after adjusting for age, year of diagnosis, and stage, Indigenous 
women were less likely to receive surgical treatment than non-Indigenous women (odds ratio 0.50, 
confidence interval: 0.33-0.78, p=0.003).82 Of those who received surgery, Indigenous women were 
more likely to have a mastectomy than non-Indigenous women.82 The second study was a national 
study of 50-69 year old women who had participated in BreastScreen during the period of 1996-
2005.88 This study reported, that of women screened, Indigenous women were more likely to undergo 
mastectomy surgery rather than local excision.88 Differences in uptake of treatment by Indigenous 
status has also been reported for other cancer types.81, 83, 89 A Queensland matched cohort study of 
adults diagnosed with cancer between 1998 and 2004 found that Indigenous Australians were less 
likely to receive any treatment compared to non-Indigenous Australians.83 Similar findings of reduced 
treatment have also been reported for Indigenous Australians diagnosed with lung cancer.89  
Reduced physical access to healthcare services is a factor when considering variation in treatment. 
Several studies have reported lower rates of surgical intervention between people living in rural 
areas.17, 86, 90-94 Men diagnosed with prostate cancer in regional or rural areas had lower rates of 
radical prostatectomy compared to men living in urban areas.17 Lower rates of breast conserving 
surgery and higher rates of mastectomy have been reported for women living outside of urban 




There is also evidence of reduced uptake of radiotherapy for people living further away from 
radiotherapy centres.66, 91, 95 Spatial differences have also been reported in women’s intention to 
choose adjuvant therapy (radiotherapy, chemotherapy, and hormone therapy), with women living 
close to a treatment centre more likely to intend to use adjuvant therapy.95 For some rural women 
diagnosed with breast cancer, having to travel in order to receive radiotherapy was a reason in 
choosing not to have radiotherapy, and instead choosing a mastectomy.66 Hegney et al.64 explored 
the experiences of 17 people diagnosed with cancer who had to travel 150km to receive radiotherapy. 
The authors identified five major themes in the study: the burden of travel, accommodation, financial 
burden, being away from family and friends, and the burden placed on their family and friends. 
Conclusion 
Inequalities in health status still exist in Australia, despite improvements in health.22 It is well 
documented that Indigenous Australians, people living in remote areas, and socioeconomically 
disadvantaged persons experience inequalities in health status, and more specifically,22 for cancer 
outcomes compared to the overall Australian population.1 This review explored a number of factors 
which contribute to this difference in cancer survival. These factors include increased exposure to risk 
factors, differences in screening participation, variation in incidence and mortality, differences in 
stage of disease at diagnosis, barriers to accessing healthcare services, and more specifically, variation 
in cancer treatment. 
As highlighted in Chapter One, the cost of cancer is substantial. In 2008-09, the cost of cancer to the 
Australian healthcare system was $4.5 billion. The majority of this was spent on hospital services 
(79%), followed by prescription pharmaceuticals (12%), and out-of-hospital expenditure (9%).96 The 
cost of cancer is expected to rise.96-99 However, little is known about the distribution of these costs 
by Indigenous status, remoteness, or socio-economic disadvantage. The current literature identifies 
inequalities in cancer survival. Many factors have been identified which contributes to these 
differences in cancer survival, including variation in access to, and treatment of cancer by these 
characteristics, therefore it is reasonable to expect that the cost of cancer differs between these 
population groups. This thesis seeks to provide a more recent estimation of the cost of cancer in 
Australia, and the distribution of these costs by population group. Understanding the economic 
burden to the public healthcare system, society, and the patient will be the first step to help policy 
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PART 2: THE COST OF CANCER IN AUSTRALIA  
This part of the thesis addresses the first two aims of the thesis and contains two published papers. 
In Chapter Three, the methodology used to develop the model, CancerCostMod is described, and the 
cost of cancer in Australia for the first 12-months following a cancer diagnosis for all cancer types is 
presented. The distribution of these costs by population group are also modelled. In Chapter Four, 
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Chapter Three: Developing CancerCostMod, a linked 
administrative model 
Introduction 
This chapter comprises the first publication for the thesis, which describes the methodology used to 
develop the model, CancerCostMod. The cost of cancer in Australia for the first year following a 
cancer diagnosis for all cancer types are also presented in this chapter, thus addressing the first aim 
of the thesis. In brief, CancerCostMod used administrative data which is routinely collected 
throughout a person’s cancer journey, from diagnosis to three years following diagnosis. 
Administrative data is becoming more widely used to assess patient outcomes, health care service 
use, and disparities. 
The development of CancerCostMod includes a census of all individuals diagnosed with cancer 
between July 2011 and June 2012. The data were then linked to administrative health records 
between July 2011 and June 2015. The original dates of data extraction for CancerCostMod were 
chosen due to completeness of data available at the time of commencement, and to allow for all 
participants to have at least three years of follow up data. 
This aim of this paper was to 1) describe the development of our dataset, CancerCostMod; 2) to 
describe the total costs of cancer in Australia during the first 12-months post-diagnosis; and 3) to 
describe the distribution of the cost of cancer in Australia during the first 12-months post-diagnosis 
by population group. 
This chapter is inserted as published in the Health Economics Review: 
Bates N, Callander E, Lindsay D, Watt K. CancerCostMod: a model of the healthcare 
expenditure, patient resource use, and patient co-payment costs for Australian cancer 





CancerCostMod: a model of the healthcare
expenditure, patient resource use, and
patient co-payment costs for Australian
cancer patients
Nicole Bates1,2* , Emily Callander2, Daniel Lindsay1 and Kerrianne Watt1
Abstract
Although cancer survival in general has improved in Australia over the past 30 years, Indigenous Australians,
socioeconomically disadvantaged persons, and people living in remote areas still experience poorer health
outcomes. This paper aims to describe the development of CancerCostMod, and to present the healthcare
expenditure and patient co-payments for the first 12-months post-diagnosis. The base population is a census
of all cancer diagnoses (excluding non-melanoma skin cancer) in Queensland, Australia between 1 July 2011
and 30 June 2012 (N = 25,553). Each individual record was linked to their Queensland Health Admitted Patient
Data Collection, Emergency Department Information System, Medicare Benefits Schedule, and Pharmaceutical
Benefits Scheme records from 1 July 2011 to 30 June 2015. Indigenous status was recorded for 87% of
participants in our base population. Multiple imputation was used to assign Indigenous status to records
where Indigenous status was missing. This base population was then weighted, using a programmed SAS
macro (GREGWT) to be representative of the Australian population. We adopted a national healthcare
perspective to estimate the cost of cancer for hospital episodes, ED presentations, primary healthcare, and
prescription pharmaceuticals. We also adopted an individual perspective, to estimate the primary healthcare
and prescription pharmaceutical patient co-payments. Once weighted, our sample represents approximately
123,900 Australians (1.7% Indigenous Australians). The total healthcare system cost of all cancers during the
first 12-months post diagnosis was $4.3 billion, and patient co-payments costs were $127 million. After
adjusting for sex, age at diagnosis, Indigenous status, rurality, socioeconomic status, and broad cancer type,
significant differences in costs were observed for population groups of interest within the first year post-
diagnosis. This paper provides a more recent national estimate of the cost of cancer, and addresses current
research gaps by highlighting the distribution of healthcare and individual costs by Indigenous status, rurality,
and socioeconomic status.
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In Australia, the overall cancer mortality rate decreased by
23% between 1982 and 2017 [1]. However, three popula-
tion groups experience poorer cancer outcomes compared
to the general Australian population: Australian Aborigi-
nal and/or Torres Strait Islander people (hereafter respect-
fully referred to as Indigenous people), socioeconomically
disadvantaged persons, and people living in remote areas
[1]. To add to the complexity of this issue, these popula-
tion groups often overlap. Indigenous people more often
live in remote and very remote areas [2], and a greater
proportion of people living in rural and remote areas ex-
perience socioeconomic disadvantage [3]. A recent study
found that the socioeconomic disparities in cancer sur-
vival appear to have worsened over the past 30 years. The
gap remained after accounting for diagnosis stage, and
cancer site [4].
A number of factors have been identified in contributing
to these survival inequalities, including but not limited to
differences in risk factors [1, 5], being diagnosed at a later
stage [5, 6], differences in access to oncology services [7,
8], a greater number of comorbidities [6], and differences
in treatment [6, 9–11]. High patient out-of-pocket ex-
penditure (OOPE) may also impact a person’s decision to
access care, with one study finding 21% of people with
cancer skipping healthcare due to the cost [12], and an-
other study found that 11% of patients found that pre-
scriptions relating to their oncology treatment caused
financial burden [13]. A recent study reported that the
median total cost to the patient for provider fees during
the first 2 years was over $20,000 for people diagnosed
with lung or breast cancer [14]. Studies using self-reported
costs, have found that OOPE is higher for those who have
to travel to receive treatment, due to travel and accommo-
dation costs [15, 16].
The healthcare system expenditure for cancer is also
high [17–19]. A commissioned report estimated that
the lifetime costs of cancer for a patient diagnosed in
New South Wales (NSW), Australia, in 2005 was $3.9
billion [17]. These costs are expected to rise with new
technologies, new pharmacotherapies, and population
changes [20]. This predicted increase in costs has
already been seen with the annual Pharmaceutical Ben-
efits Scheme (PBS) expenditure on anticancer drugs in-
creasing by approximately $400 million between 1999
and 2000 and 2010–11. This was an average increase of
19% compared to 9% for all other drugs combined [21].
The Australian Institute of Health and Welfare (AIHW)
reported that cancer cost approximately $4.5 billion in
2008–09 (excluding screening). The majority of these
costs were due to hospital admitted patient services
(79%), followed by prescription pharmaceuticals (12%),
and out-of-hospital costs, such as general practitioner,
specialists, pathology, and imaging (9%) [18]. However,
these reports are now a decade old, and do not look at
the distribution of costs by population group. To the
author’s best knowledge, only one report has compared
the cost of hospital expenditure by Indigenous status.
The AIHW and Cancer Australia reported that in
2010–11, the per person hospital expenditure for all
cancers combined for Indigenous Australians was half
of that for non-Indigenous Australians [19].
CancerCostMod is Australia’s first model of health ser-
vice use, healthcare expenditure, and patient co-payments
for people diagnosed with cancer in Australia. This model
has several objectives:
1. To quantify the current health system use, and
healthcare expenditure for people with cancer, and
to determine any inequalities by Indigenous status,
socioeconomic status, and remoteness;
2. To quantify the patient co-payment for people
with cancer, and to determine any inequalities by
Indigenous status, socioeconomic status, and
remoteness;
3. To estimate the costs to government and
individuals of “optimal service use” - if all patients
received the maximum access of care.
This paper aims to 1) describe the development of our
model, CancerCostMod; 2) to describe the total costs of
cancer in Australia during the first 12-months post-diag-
nosis; and 3) to describe the distribution of the cost of
cancer in Australia during the first 12-months post-diag-
nosis by population group.
Methods
Base population – Linked administrative data
The protocol describing the data linkages that were under-
taken to create this dataset has been described previously
[22]. Briefly, the base population for this model was a cen-
sus of all patients diagnosed with cancer in Queensland
between 1 July 2011 and 30 June 2012, as recorded by the
Queensland Cancer Registry (QCR) (N = 25,553 patients).
Each individual’s QCR record was linked to their Queens-
land Health Admitted Patient Data Collection (QHAPDC)
records (243,034 separations for 21,944 patients), and
Queensland Health Emergency Department Information
Systems (EDIS) (46,455 presentations from 12,825 pa-
tients) from 1 July 2011 to 30 June 2015. This linkage was
conducted by the Queensland Health Statistical Services
Branch using deterministic and probabilistic methods.
Each participant’s record was then linked to their individ-
ual Medicare Benefits Schedule (MBS) (6,058,380 services)
and Pharmaceutical Benefits Scheme (PBS) (2,619,712
prescriptions) records from 1 July 2011 to 30 June 2015
by the Data Linkage Unit at the AIHW using probabilistic
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linkage. Overall, 99.4% of cohort members were matched
to the Medicare enrolments register.
The QCR dataset contained date of diagnosis, Inter-
national Classification of Diseases for Oncology (ICD-O)
morphological code, ICD-O topographical code, differen-
tiation code, behaviour status, as well as date and cause of
death if applicable. The stage at diagnosis is not routinely
collected by the QCR. Other variables included sociode-
mographic information, such as date of birth, sex, Indi-
genous status, and postcode at diagnosis.
The QHAPDC records contained information on all
separations from a private or public hospital in Queens-
land. Facility number, patient residential postcode, admis-
sion and separation date, length of stay, hospital insurance
status, and the Australian Refined Diagnostic-Related
Group (AR-DRG) was recorded for each separation. The
AR-DRG is a classification system, where episodes of care
are coded using the ICD-10-Australian Modification
(ICD-10-AM) and Australian Classification of Health In-
terventions, which is used to code procedures and inter-
ventions [23]. The EDIS dataset contained all emergency
department (ED) presentations, including information
such as date of presentation, facility number, patient post-
code at time of presentation, triage category (Australasian
Triage Scale for treatment prioritisation), discharge des-
tination, and ICD-10-AM code.
MBS data include individual patient identifier, patient
postcode, date of service, provider postcode, MBS item
code, fee charged, benefit paid (by MBS), patient
co-payment costs, and hospital flag. MBS claims data
exclude Department of Veteran’s Affairs beneficiaries.
PBS data includes individual patient identifier, patient
postcode, date of supply, PBS item, patient category
(concession or general), patient co-payment costs,
benefit amount, pharmacy postcode. PBS data excludes
private prescriptions, over-the-counter medications,
under co-payment prescriptions, Repatriation Pharma-
ceutical Benefits Scheme prescriptions, and any medi-
cations dispensed under special arrangements.
Development of CancerCostMod
Cancer classification
Using the ICD-O 3rd Edition [24] and the Cancer
Council Queensland methods website [25], the type of
cancer was grouped into 18 broad cancer categories:
head and neck; digestive organs; colorectal cancer; fe-
male genital organs; breast cancer; prostate cancer;
male genital organs excluding prostate; urinary tract;
eye, brain and other parts of the central nervous sys-
tem (CNS); mesothelioma, Kaposi sarcoma and soft
tissue; thyroid and other endocrine organs; other thor-
acic and respiratory organs; bone; tracheal, bronchus
and lung cancer; other skin; melanoma; blood and
lymphatic system; other or ill-defined cancers.
Socioeconomic status and rurality
The patient’s postcode at diagnosis was mapped to the
Australian Bureau of Statistics (ABS) Index of Relative
Socio-Economic Disadvantage (IRSD), and Australian
Statistical Geography Standard (ASGS) [26]. IRSD is a
summary of the economic and social conditions of an
area, and is a measure of relative disadvantage only,
where decile 1 was the most disadvantaged, and decile
10 was the least disadvantaged. ASGS has five categor-
ies ‘metropolitan’, ‘inner regional’ ‘outer regional’, and
‘remote’ and ‘very remote’. There were 151 records with
‘unknown or not stated’ postcodes at diagnosis, which
could not be mapped to IRSD or rurality. We have
categorised these records as ‘unknown or not recorded’
for IRSD and rurality. For our analyses, we collapsed
rurality into three categories (‘metropolitan’, ‘regional’,
and ‘remote’) and IRSD into quintiles (Q1: most disad-
vantaged and Q5: least disadvantaged).
Indigenous status
A common data limitation in Australia is that Indigenous
status may be incompletely recorded in health and vital
registration data collections [27]. The Australian Cancer
Database considers five (of eight) jurisdictions to have
sufficient completeness for reporting purposes, NSW,
Victoria, Queensland, Western Australia and the North-
ern Territory [1]. A 2011–12 audit found that Indigenous
status in Queensland Health hospital admission records
had 87% weighted completeness (CI 84–91%) [27].
Indigenous status was recorded for 87% of partici-
pants in our original cohort from the QCR dataset.
We used a number of methods to assign Indigenous
identification to the 13% of records for which there
was missing data or ‘unknown’ Indigenous status re-
corded (n = 3316). Initially, records with missing or
unknown Indigenous identification on the QCR data-
set were assigned to be ‘Indigenous’ if they resided in
a local government area (LGA) that had greater than
or equal to 75% of the population identified as Indi-
genous, as reported by the ABS’ estimated resident In-
digenous Australian and non-Indigenous Australian
populations in each Queensland LGA for 2011 [28].
Seventy-five percent was chosen as a conservative
cut-off, reflecting the definition by the ABS of a
‘Discrete Indigenous Community’ as one that has
greater than half of the population identifying as Abo-
riginal and/or Torres Strait Islander [29].
We then used multiple imputation (MI) to impute the
remaining missing values for Indigenous status (n = 3297).
We used the MI procedure in SAS 9.4 (SAS Institute Inc.,
Cary, NC, USA), which has three distinct phases [30]. We
used logistic regression to develop the imputation model
for multiple imputation, as the variable of interest was di-
chotomous (Indigenous or not-Indigenous). Covariates
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used were similar to those used by Morell et al. [31],
and included sex, 5-year age group, 12-month survival,
country of birth (Australia, not Australia, or not stated/
unknown), broad cancer group (18 categories), rurality
(5 categories), and IRSD deciles. We used PROC MI
with a monotone logistic statement, with 20 imputa-
tions, followed by PROC LOGISTIC, and finally PROC
MIANALYZE to produce inferential results.
Weighting to the Australian population
In order to provide results that are representative to the
Australian population, we used the programmed SAS macro
GREGWT to weight our dataset to the Australian popula-
tion. GREGWT is a generalised regression reweighting algo-
rithm which was developed by the ABS and is commonly
used to weight their household surveys against known
benchmarks [32]. The mathematical techniques underlying
GREGWT have been described elsewhere [33, 34]. In the
current study, data were benchmarked against the 2012
Australian Cancer Database [35]. This database provides
Australia-wide cancer incidence rates stratified by cancer
type, age group and gender. Cancer incidence rates for 2012
were extracted from this database and used as the bench-
mark for the calculation of weights in the current study.
Defining costs
We developed CancerCostMod to allow analyses of costs
from different perspectives. We adopted a national health-
care perspective, to estimate the direct cost of cancer to
the healthcare system for hospital, primary healthcare and
prescription pharmaceuticals. We also adopted an individ-
ual perspective, to estimate the patient co-payments for
primary healthcare and prescription pharmaceuticals.
All costs were calculated monthly for each individual from
the date of diagnosis (t = 0) for 36 months. If an individual
had no health services for the month, the cost was recorded
as $0. All costs are reported in Australian dollars (AUD),
and were adjusted to the 2016–17 financial year using the
Reserve Bank of Australia inflation calculator [36].
Hospital costs
Within Australia, public hospitals are run by the State and
Territory governments, and are jointly funded by the state
and national governments through either activity-based
funding (ABF) or block funding [37]. The ABF model pays
hospitals for the number and mix of services provided, and
accounts for patients that may be more complicated. The
Independent Hospital Pricing Authority (IHPA) was estab-
lished as part of the National Reform Act 2011, and is re-
sponsible for the implementation of the ABF for public
hospitals. The IHPA produces an annual National Hospital
Cost Data Collection (NHCDC), which includes the volun-
tary submission of cost data for each AR-DRG from public
and private hospitals. This information is then used to
develop the National Efficient Price, which determines the
federal contribution to the ABF system, and the National
Efficient Cost, which determines the federal contribution
to block funding. Each State and Territory is then respon-
sible for distributing the federal and state funding to their
public hospitals. The annual NHCDC reports are available
online [38–41]. Private hospitals are owned and operated
by private institutions but must still comply with national
standards. Private hospitals receive funding from patient
charges, private insurance, and Medicare rebates [42].
The cost attributed to each AR-DRG for public hospital
separations was assigned using the actual cost as reported
by the NHCDC Report (available online) [38–41] for the
relevant year. To reflect possible variations in the costs of
delivering healthcare to some individuals, we included the
adjustment for certain patient demographics produced by
the IHPA (pediatric, patient remoteness and/or Indigen-
ous person, and private patient service and accommoda-
tion) [43–45]. As there were no adjustments published for
the 2011–12 financial year, we used the adjustment for the
2012–13 period. The cost attributed to each AR-DRG for
private hospital separations was assigned for the relevant
year using the average charge per separation reported by
the Private Hospital Data Bureau Annual Reports (avail-
able online) [46].
In Australia, some patients may receive treatment as a
non-admitted (out-) patient at a hospital location, but are
not formally ‘admitted’, and are therefore not captured in
the QHAPDC dataset. In order to capture these non-ad-
mitted hospital services, we included MBS items which re-
lated to services or procedures performed in a hospital
setting. This method has been used in previous Australian
studies [47, 48]. We identified these MBS items by con-
ducting a keyword search of the MBS item descriptions to
identify hospital items: ‘hospital’ (excluding codes which
specified it was in a place ‘other than a hospital’), ‘theatre’,
‘emergency department’, and ‘prior to discharge’. Item
codes relating to chemotherapy and radiotherapy were
also identified through consultation with staff from the
Townsville Hospital and Health Service, Townsville Can-
cer Centre. The rebate paid by Medicare for MBS codes
for these ‘hospital’ items were included in the hospital
costs. Hereafter, admitted and non-admitted hospital epi-
sodes will be referred to as ‘hospital episodes’.
The ED classification system, Urgency Disposition
Groups, and Urgency Related Group (URG), was origin-
ally developed in Western Australia [49] to group patient
presentations into categories. The IHPA implemented this
system nationally in 2012, and it has since undergone sev-
eral revisions commissioned by the IHPA [50]. Each ED
presentation was coded to a URG using the triage cat-
egory, discharge destination and the primary reason for at-
tending the ED (ICD-10-AM). The cost attributed to each
URG for each ED presentations was assigned using the
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average cost per presentation as reported by the NHCDC
Report (available online) [38–41] for the relevant year.
MBS and PBS costs
Briefly, Australia’s universal healthcare system (Medicare),
provides free and subsidized medical services under MBS
and PBS. For services covered by MBS, if there is a gap be-
tween the rebate paid by Medicare and the amount
charged by the service provider, the individual will incur
an out-of-pocket co-payment. In some cases, the service
provider may ‘bulk-bill’ a patient, or charge the amount
equal to the Medicare rebate, resulting in no individual
co-payment. For prescription pharmaceuticals, the indi-
vidual will be charged up to the set patient co-payment
for concession (low income card holders) and general pa-
tients. Australia has several safety net arrangements for in-
dividuals and family groups with high OOPE (two
Medicare Safety Nets, and one PBS Safety Net). Once an
individual or family group reaches a given amount on
co-payments for a calendar year, they will receive a higher
government subsidy, resulting in reduced patient co-pay-
ments [51]. Furthermore, Indigenous Australians living
with, or at risk of chronic disease may also be eligible to
receive prescription pharmaceuticals at reduced cost
through the Closing the Gap (CTG) PBS Co-payment
Programme [52]. However, hospital prescriptions are ex-
cluded from this programme [52].
The MBS and PBS data includes date of service/dis-
pensing, MBS/PBS item number, patient postcode,
provider/pharmacy postcode, and total fee charged,
rebate paid, and patient co-payment.
Statistical analysis
Initially, descriptive analysis was undertaken to describe
the social and demographic characteristics of the sample,
and weighted sample. Then the total cost for the first
12-months post-diagnosis for the five types of healthcare
expenditure: hospital episodes, ED presentations, MBS
items, PBS items, and patient co-payments are presented
for the broad type of cancer, and the population groups of
interest. We also present the average total healthcare cost
per person (to the Australian healthcare system), and the
average patient co-payment per person during the first
12-months following a diagnosis. We chose to include the
standard deviation, as in many cases, the standard devi-
ation was greater than the mean, indicating a wide disper-
sion of the costs.
Finally, the total cost of cancer for the first 12-months
following diagnosis for each of the five types of healthcare
were modelled with a generalized linear model using a
gamma distribution, with a log link function. This in-
cluded the number of months the patient survived as an
offset to the model. The analysis was limited to include
adults (≥ 18 years at diagnosis), and only to those who had
costs for the healthcare type used in the model. Independ-
ent variables included in the analysis were sex, age at
diagnosis, Indigenous status (reference group = non-Indi-
genous Australians), rurality (three categories; reference
group =metropolitan), IRSD quintiles (reference group =
Q1 (most disadvantaged)) and broad cancer type (18 cat-
egories; reference group = tracheal, bronchus and lung
cancer).
All analyses were undertaken using SAS V9.4 (SAS
Institute Inc., Cary, NC, USA). Weighted estimates are
presented, unless otherwise stated.
Human Research Ethics approval was obtained from the
Townsville Health and Hospital Service Human Research
Ethics Committee (HREC) (HREC/16/QTHS/11), AIHW
(EO2017/1/343) and James Cook University HREC
(H6678). Permission to waive consent was approved from
Queensland Health under the Public Health Act 2005. No
identifiable information was provided to the authors.
Results
CancerCostMod cancer incidence
In total, 25,553 individuals were diagnosed with a new can-
cer in Queensland between July 2011 and June 2012. Once
weighted, this represents 123,900 Australians. Table 1 re-
ports the demographic characteristics of our model for all
cancers, and for the five most commonly diagnosed can-
cers in Australia. Our original QCR dataset had complete
Indigenous status for 87% of our records, which matches
an audit of Queensland Health hospital admission records
in 2011–12 [27]. After imputation, we estimated that 2129
of our model were Indigenous Australians.
Table 2 reports the age-standardised incidence rates for
our weighted model, compared to the national age-stan-
dardised incidence rates for new cases diagnosed in 2012.
The CancerCostMod age-standardised incidence rate for
the five most commonly diagnosed cancers in Australia
are similar to the national age-standardised incidence rate
for new cases in 2012.
Cost of cancer during the first 12-months post-diagnosis
by broad cancer type
The total initial cost associated with newly diagnosed
cancer for the healthcare system was $4.3 billion, and
total patient co-payment was $127.7 million. Hospital
episodes accounted for 77% of the healthcare expend-
iture, followed by PBS (14%) and MBS 6%. Table 3
shows the total cost of cancer for the first 12-months
following diagnosis for all cancers combined, and for
each broad cancer type (excluding ‘bone’ and ‘other
thoracic and respiratory organs’ cancers due to sample
size). The most expensive cancers to the healthcare
system were cancers of the blood and lymphatic
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system, followed by colorectal cancer and breast can-
cer. Colorectal cancer was the most expensive cancer
in regards to hospital episodes, and cancers of the
blood and lymphatic system had the highest MBS and
PBS rebate costs. During the first 12-months, cancers
of the eye, brain and other parts of the central ner-
vous system (CNS) accounted for the highest average
cost per person to the Australian healthcare system,
followed by cancers of the blood and lymphatic sys-
tem. The most expensive cancers in regards to patient
co-payments were cancers of the blood and lymphatic
system, followed by breast cancer and colorectal can-
cer. The average patient co-payment costs per person
were highest for cancers of the blood and lymphatic
system, followed by cancers of the eye, brain and
other parts of the central nervous system (CNS).
Table 1 Demographic characteristics of CancerCostMod for all cancers combined, and most commonly diagnosed cancersa




Actual n 25,600 3100 4200 2900 2100 3300
Weighted N (%) 123,900 15,400 (12.5) 20,700 (16.7) 14,800 (11.9) 11,100 (9.0) 12,300 (9.9)
Died within 12-months post-diagnosis (%) 25,100 (20.2) 700 (4.2) 1000 (4.6) 2400 (16.3) 6400 (57.7) 400 (3.1)
Age group
≤ 17 (%) 1000 (0.8) – – – – –
18 to 44 (%) 9300 (7.5) 1800 (12.0) 100 (0.6) 700 (4.7) 200 (1.6) 1800 (14.6)
45 to 64 (%) 42,700 (34.5) 7600 (49.1) 7800 (37.7) 4100 (27.7) 2900 (26.3) 4500 (36.4)
≥ 65 (%) 70,900 (57.2) 6000 (38.9) 12,800 (61.8) 10,000 (27.6) 8000 (72.1) 6000 (48.7)
Sex
Male (%) 69,300 (55.9) 100 (0.7) 20,700 (100) 8100 (54.9) 6500 (58.4) 7200 (58.4)
Female (%) 54,600 (44.1) 15,300 (99.3) n/a 6700 (45.1) 4600 (41.6) 5100 (41.6)
Indigenous status
Non-Indigenous Australian (%) 121,800 (98.3) 15,200 (98.4) 20,500 (99.0) 14,600 (99.1) 10,800 (97.3) 12,100 (98.8)
Indigenous Australian (%) 2100 (1.7) 300 (1.6) 200 (1.0) 100 (0.9) 300 (2.7) 100 (1.2)
Ruralityb
Metropolitan (%) 58,500 (47.5) 7800 (50.5) 9100 (44.1) 6700 (45.9) 5000 (45.2) 6100 (49.7)
Regional (%) 54,500 (44.2) 6400 (41.7) 9600 (46.5) 6600 (45.1) 5100 (45.8) 5300 (43.7)
Remote (%) 10,200 (8.3) 1200 (7.8) 1900 (9.4) 1300 (9.1) 1000 (9.0) 800 (6.7)
IRSDc Quintilesb
Q1 (Most disadvantaged) (%) 11,300 (9.2) 1100 (7.2) 2100 (10.2) 1400 (9.8) 1300 (11.6) 1000 (8.2)
Q2 (%) 5700 (4.7) 800 (5.0) 900 (4.3) 700 (4.6) 600 (5.3) 500 (4.3)
Q3 (%) 19,900 (16.2) 2500 (16.3) 3400 (16.5) 2500 (16.7) 1900 (17.5) 1800 (14.7)
Q4 (%) 56,000 (45.5) 6700 (43.7) 9300 (45.2) 6700 (45.7) 4900 (44.5) 5900 (47.9)
Q5 (Least disadvantaged) (%) 30,200 (24.5) 4300 (27.8) 4900 (23.8) 3400 (23.1) 2300 (21.1) 3000 (24.9)
a Weighted results reported (except in the first row), and rounded to the nearest 100. Weighted values less than 100 are not reported
b Excluding individuals with missing postcodes
c Index of Relative Socio-Economic Disadvantage
Table 2 Australian and CancerCostMod Cancer Incidence






All cancers 121,693 482.85 123,915 492.75
Breast cancer (female only) 15,337 120.42 15,335 120.56
Prostate cancer (male only) 20,687 168.25 20,687 168.37
Colorectal cancer 14,793 58.46 14,774 58.54
Tracheal, bronchus and lung cancer 11,114 43.78 11,104 43.52
Melanoma of the skin 12,250 49.51 12,250 49.42
(a) Incidence rates are standardised to the Australian population as at 30 June 2001 and are expressed per 100,000 population
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Cost of cancer during the first 12-months post-diagnosis
by population group
We then aimed to describe the cost of cancer for the
first 12-months post-diagnosis by Indigenous status,
rurality, and socioeconomic disadvantage, as shown in
Table 4. The average total healthcare cost per person
was greater for Indigenous people diagnosed with
cancer in the first 12-months, compared to non-Indi-
genous people diagnosed with cancer. However, the
average patient co-payment was greater for
non-Indigenous people diagnosed with cancer, com-
pared to Indigenous people diagnosed with cancer.
Table 4 also shows that the average total healthcare
cost per person was greater for people from the most
disadvantaged quintile (Q1), and the lowest for people
in the least disadvantaged quintile (Q5). Conversely,
the average patient co-payment was greatest for people in
the least disadvantaged quintile (Q5), and lowest for
people in the most disadvantaged quintile (Q1).
Finally, we conducted five generalized linear models
to predict costs, limiting our analyses to adults only
(≥ 18 years), adjusting for sex, Indigenous status, rur-
ality, IRSD quintile, age at diagnosis, and broad can-
cer type (co-efficients not shown). Table 5 shows the
abbreviated output for the five types of cost: hospital
episodes, ED presentations, MBS rebates (excluding
hospital items), PBS rebates, and patient co-payments.
Indigenous Australians had significantly higher costs
for hospital episodes (22% higher) and ED presenta-
tions (23% higher), but significantly lower costs for
MBS rebates (8% lower), PBS rebates (18% lower), and
patient co-payments (61% lower) compared to
Table 3 Total cost of cancer during the first 12-months post-diagnosis by cancer typea
















All cancers combined 123,900 3,302,933,000 88,103,100 263,243,600 631,804,300 4,286,083,900 34,600 (41300) 127,673,700 1000 (2000)
Prostate cancer 20,700 279,788,000 6,416,200 36,828, 600 38,650,600 361,683,300 17,500 (17,300) 16,324,000 800 (1200)
Breast cancer 15,400 266,860,700 6,744,700 36,690, 600 170,956,200 481,252,200 31,200 (29,700) 21,040, 900 1400 (1500)
Colorectal cancer 14,800 581,675,500 11,849,400 30,563,000 71,878,900 695,966,800 47,100 (38,200) 16,979,500 1100 (1800)
Blood and lymphatic
system
13,300 564,265,300 13,286,600 40,503,100 176,947,100 795,002000 59,800 (70,800) 24,655,400 1900 (4100)
Melanoma of the
skin
12,300 53,047,300 1,575,700 23,174,800 12,506,700 90,304,500 7400 (12600) 4,945,100 400 (500)
Tracheal, bronchus
and lung cancer
11,100 396,063,600 15,618,400 24,164,600 45,331,000 481,177,600 43,300 (34,700) 10,168,700 900 (1700)
Digestive organs 10,100 394,784,900 12,668,100 20,303,100 31,119,600 458,875,800 45,500 (36,800) 11,273,000 1100 (2000)
Cancers of the
urinary tract
6200 181,697,200 5,022300 10,703,000 17,623,000 215,045,500 34,700 (31800) 4,816,000 800 (1100)
Gynaecological
cancers
5200 138,156,900 3,121,600 10,475,000 16,774,700 168,528,200 32,300 (31500) 5,171,800 1000 (1600)
Head and neck 4000 118,588,400 2,478,200 10,264,700 9,019,700 140,351,100 34,900 (45,500) 2,374,400 600 (1200)
Other or ill-defined
cancers
2700 67,701,500 2,316,900 4,295,300 6,051400 80,365,200 29,600 (29,700) 2,239,700 800 (1700)
Thyroid and other
endocrine glands
2600 48,531,700 799,400 4,195,500 3,631,300 57,157,900 22,000 (34,400) 1,180,600 500 (600)




1600 62,604,600 1,882,200 3,245,200 9,187,200 76,919,200 47,100 (46100) 2,080,100 1300 (2200)
Male genital organs,
exc prostate
900 17,921,400 678,900 2,190,200 2,267,400 23,057, 900 25,000 (30,400) 643,200 700 (1200)
Other skin cancer 800 11,920,400 283,300 1,749,400 1,456,800 15,409,900 18,600 (28100) 541,900 700 (1100)
a Weighted results reported, and rounded to the nearest 100
b Excluding broad cancer types with less than 500 individuals (‘bone’, and ‘other thoracic and respiratory organs’)
c Admitted and non-admitted hospital episodes
d MBS rebate, excluding items included as non-admitted hospital episodes
e MBS and PBS patient co-payment
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non-Indigenous Australians. The costs for hospital
episodes had significantly higher costs in the first
12-months post-diagnosis with increasing remoteness,
6% for people living in inner and outer regional areas,
and 15% higher for people living in remote and very
remote areas compared to those living in metropol-
itan areas. People living in remote and very remote
areas had 10% lower costs for MBS rebates and 10%
higher PBS rebate costs. Compared to those living in
the most disadvantaged areas (IRSD Q1), those in
quintiles 3–4 had decreasing costs associated with
hospital episodes. There were no differences in the
costs of ED presentations for IRSD quintiles. The
costs incurred for MBS and PBS rebates and also pa-
tient co-payments increased as the IRSD quintile in-
creased (moved towards the least disadvantaged).
Discussion
The use of administrative health data is growing in
Australia and is supported by a number of Australian
Government agencies [53]. There are many advantages
of using administrative data for research, including being
non-intrusive to the target population, no (or low) cost
for data collection (but there may be a cost-recovery
charge), and the ability to capture a large population.
Administrative data has advantages over sample data,
which relies on self-reported information from patients,
and also excludes patients who have passed away. There
are a growing number of international studies which
have used linked administrative data to describe the
patterns and cost of cancer. For example, recent
international studies have used administrative data to
describe the excess cost of cancer in New Zealand
[54], Canada [55], and England [56]. Our model, Can-
cerCostMod does not seek to describe the excess cost
of cancer compared to the general population, but ra-
ther, describe the distribution of costs for population
groups experiencing poorer health outcomes. This
paper aimed to 1) describe the development of our
model, CancerCostMod; 2) to describe the total costs
of cancer in Australia during the first 12-months
post-diagnosis; and 3) to describe the distribution of
the cost of cancer in Australia during the first
12-months post-diagnosis by population group.
We estimated that the total cost to the Australian
healthcare system was $4.3 billion. Hospital episodes
accounted the majority (77%) of the costs to the health-
care system. This is similar to the AIHW national
Table 4 Total cost of cancer for the first 12-months post-diagnosis, by population groups1




















121,800 3,233,868,900 85,643,100 259,009,200 623,618,600 4,202,139,700 34,500 (41100) 126,913,100 1000 (2000)
Indigenous
Australian
2100 69,064100 2,459,900 4,234,500 8,185,700 83,944,200 40,100 (48100) 760,600 400 (800)
Rurality5
Metropolitan 58,500 1,485,140,700 38,505,200 125,884,200 306,909,000 1,956,439,200 33,500 (38,200) 65,570,600 1100 (1900)
Regional 54,500 1,495,270,400 42,165,900 116,837,100 270,755,900 1,925,029300 35,300 (42300) 52,061400 1000 (1900)




11,300 349,061100 11,248,900 21,232,900 47,295,500 428,838,500 38,000 (43000) 9,226,300 800 (1900)
Q2 5700 160,726,000 3,180,500 11,653,000 28,801,500 204,361,000 35,700 (42300) 4900,200 900 (1800)
Q3 19,900 554,607,600 14,727,500 41,726,900 102,484,100 713,546,100 35,900 (46,800) 17,757,000 1100 (1800)
Q4 56,000 1,469,376,800 42,010,300 128,352,200 288,661,500 1,928,400,700 34,400 (40,400) 59,401,200 1100 (1800)
Q5 (Least
disadvantaged)
30,200 757,934,600 16,309,300 59,474,600 163,267,300 996,985,900 33,000 (38,300) 36,179,100 1200 (2000)
1 Weighted results reported, and rounded to the nearest 100
2 Admitted and non-admitted hospital episodes
3 MBS rebate, excluding items included as non-admitted hospital episodes
4 MBS and PBS patient co-payment
5 Excluding individuals with missing postcodes
6 Index of Relative Socio-Economic Disadvantage
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report, which estimated that hospital admitted patient
services accounted for 79% of the national healthcare
system expenditure in 2008–09 [18]. Likewise, in other
countries, admitted hospital services have been re-
ported as contributing to the greatest proportion of
cancer-related costs [55, 57, 58]. Initially, we described
the total costs to the healthcare system, and the average
costs per person to the healthcare system by cancer
type, and population group. This initial analysis showed
the average costs per person to the healthcare system
were higher for each of our population groups of inter-
est, compared to their reference group – Indigenous
Australians, people living in remote areas, and people
from the most disadvantaged quintile. We found that
the total cost of cancer during the first 12-months
post-diagnosis was significantly different for Indigenous
Australians, people living in remote and very remote
areas, and people living in areas of greater disadvan-
tage. These differences in costs could be due to differ-
ences in health system use, which we will examine in
future studies.
We estimated that the individual patient co-payment
costs were $127 million in the first 12-months follow-
ing diagnosis. The initial analysis found that the aver-
age co-payment costs were lower for Indigenous
Australians, and people from the most disadvantaged
quintile. After adjusting for age, sex, Indigenous
status, rurality, IRSD quintiles, and broad cancer type,
we found that the patient co-payment costs were
lower for Indigenous Australians compared to non-In-
digenous Australians, for people in inner and outer re-
gional areas compared to metropolitan, and patient
co-payment costs were greater for people from IRSD
quintiles 4 and 5. These findings may be due to Aus-
tralia’s universal healthcare system, and policies in
place, such as the Medicare Safety Nets, the PBS
Safety Net, and the CTG PBS Co-payment Programme
to protect vulnerable population groups and people
with higher healthcare co-payments. We will examine
the differences in patient co-payments in more detail
in future studies.
To our knowledge, this is the first study in Australia to
use individual-level data to estimate the cost of cancer for
Indigenous Australians. A previous report by AIHW and
Cancer Australia reported that the average per person
hospital expenditure for Indigenous Australians was half
of that for non-Indigenous Australians [19]. However, this
report used population-level data and only included hospi-
talizations for which cancer was the primary cause [19].
The advantage of using individual-level data allows us to
Table 5 Five generalized linear models of the cost of cancer for the first 12-months1
Hospital episodes2 ED presentations MBS rebate3 PBS rebates Patient co-payment4









































































































* p-value < 0.05
** p-value < 0.01
*** p-value < 0.001
1 Adjusted for age at diagnosis, sex, Indigenous status, rurality, IRSD quintiles, and broad cancer type
2 Admitted and non-admitted hospital episodes
3 MBS rebate, excluding items included as non-admitted hospital episodes
4 MBS and PBS co-payment is the cost to the patient
5 Index of Relative Socio-Economic Disadvantage
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determine if there are differences in health system use,
and cost between Indigenous and non-Indigenous people.
Further studies using CancerCostMod will examine these
differences in more detail.
This is the first model in Australia, which aims to
describe the healthcare system costs and patient
co-payment costs for these population groups experien-
cing inequalities. Previous Australian studies have re-
ported higher OOPE for rural patients with cancer [15,
16]. Recently, Newton et al. (2018) reported that the
highest OOPE was due to surgery (23%), tests (20%),
and accommodation (12%) [16]. Whereas, Gordon et al.
(2009) reported travel costs accounting for the greatest
proportion of patient OOPE (71%), followed by medical
appointments (10%), and PBS co-payments (9%) [15].
Although CancerCostMod only estimates the patient
co-payments for primary health care and prescription
pharmaceuticals, it has the advantage of using adminis-
trative data, and thus is not subject to selection bias
(recruitment and loss-to follow-up), or recall bias in
recalling healthcare expenditure.
A strength of this study is that the base population
includes everyone diagnosed with cancer in Queens-
land, and 3 years of follow-up data were obtained
using linked administrative data. Our data have then
been weighted to the Australian population to allow
us to estimate the healthcare expenditure of cancer to
the Australian healthcare system, and the patient
co-payments for Australians diagnosed with cancer.
A common limitation of Australian health studies, is
the completeness of Indigenous status on health re-
cords. We used multiple imputation to assign Indigen-
ous status to missing records in our original QCR
cohort. As reported, once weighted, our model included
2129 Indigenous Australians. There are currently no re-
liable data on the number of new cancer cases for Indi-
genous Australians for each jurisdiction in Australia.
The most recent national AIHW data reports that in
2012, approximately 1343 new cancer cases were diag-
nosed in Indigenous Australians [59]. However, this es-
timate is based on five (of eight) jurisdictions only, in
which the majority (90%) of Indigenous Australians live
[59]. There is also varying levels of completeness of In-
digenous status for each jurisdiction (from 2% un-
known, to 18% unknown) [59]. Therefore, this national
estimate may be underestimating the true incidence of
cancer in Indigenous Australians [59]. One of the 2015
National Aboriginal and Torres Strait Islander Cancer
Framework priorities is to “strengthen the capacity of
cancer related services and systems to deliver good
quality, integrates services that meet the needs of Abo-
riginal and Torres Strait Islander people” [60], and calls
for improved recording of Indigenous status, and rec-
ommends the use of linked administrative data to look
at patterns of care for Indigenous Australians in order
to meet one of their priorities [60]. CancerCostMod
uses individual-level data, which allows us to evaluate
the service use and to quantify the cost of care for Indi-
genous Australians.
Administrative data have inherent weaknesses, pri-
marily that the data are not collected for the purpose of
research. For example, we were unable to estimate the
cost of cancer by clinical staging, as this is not routinely
collected by the QCR. The QCR does not collect indi-
vidual or household financial information, therefore, we
used aggregated area-level data to classify an individ-
ual’s level of socioeconomic disadvantage. We were also
unable to analyze individual physiological, biological or
clinical factors, which are considered by the treating
specialist and may alter the suitability of different treat-
ment options. The patient co-payment costs will be
limited to costs incurred for MBS and PBS items, which
excludes patient co-payment costs for private or non-
prescription pharmaceuticals, private health insurance
premiums, or hospital excess, or travel/accommodation
costs. Finally, we sought to describe the cost of ED pre-
sentations for people with cancer. The IHPA first used
the ED Classification System in the National Efficient
Price Determination in 2012–13 [45]. The IHPA
NHCDC annual reports include the average cost of
each ED presentation from 2011, however, there have
been several changes to the ED URG classification sys-
tem and we have included the estimation of the costs
of ED presentations separately to the hospital episodes.
Conclusions
These findings are of interest to policy makers and health-
care providers, as they provide an evaluation of the total
cost of cancer. To ensure an equitable healthcare system, it
is first important to determine if there are any inequalities
in relation to healthcare service use and expenditure
amongst population groups whom experience poorer
health outcomes. This paper describes the development of
CancerCostMod, Australia’s first model of health service
use, healthcare expenditure, and patient co-payment ex-
penditure for people with cancer. CancerCostMod can be
used to fill the gap by quantifying the current health system
use, healthcare expenditure and patient co-payment costs
for population groups experiencing poorer health outcomes
- Indigenous people, people living in rural and remote
areas, and socioeconomically disadvantaged persons. We
found significant differences in healthcare expenditure and
patient co-payments for the first 12-months following a
cancer diagnosis for each of these population groups. Can-
cerCostMod can be used to look at the cost from different
perspectives for the first 3 years, with the potential to in-
crease the cohort enrolment period and study period.
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Correction
Following publication of the original article [1], the au-
thors reported errors on their article.
In Tables 3 and 4 of this manuscript, the costs pre-
sented in the “hospital episodes”, “total cost to the health
care system” and “average health care cost per person”
columns were incorrect. Consequently, the numbers in
the “Ratios” and “standard errors” columns related to
the Hospital Episodes section of Table 5 were incorrect.
The corrected Tables are shown below.
Subsequently, the following sentences needed to be
corrected. Corrected content is shown in bold:
Abstract, Results, Discussion
The total initial cost associated with newly diagnosed
cancer for the healthcare system is $4.8 billion. Hospital
episodes accounted for 80% of the healthcare expend-
iture, followed by PBS (13%) and MBS (5%).
Results, subheading “Results of Cost of cancer
during the first 12-months post-diagnosis by
population group”, 2nd paragraph:
Indigenous Australians had significantly higher costs for ED
presentations (23% higher), but significantly lower costs for
MBS rebates (8% lower), PBS rebates (18% lower), and pa-
tient co-payments (61% lower) compared to non-Indigenous
Australians. [The words “for hospital episodes (22%)”
have been removed from the sentence].
The costs for hospital episodes were significantly
higher in the first 12-months post-diagnosis with in-
creasing remoteness, 4% for people living in inner and
outer regional areas, and 10% higher for people living in
remote and very remote areas compared to those living
in metropolitan areas. [these percents were previously
reported as 6% and 15% higher, respectively].
Compared to those living in the most disadvantaged
areas (IRSD Q1), those in quintiles 4–5 had decreasing
costs associated with hospital episodes [quintiles 3–4
were previously reported].
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Table 3 Total cost of cancer during the first 12-months post-diagnosis by cancer type1
COST TO THE AUSTRALIAN HEALTHCARE SYSTEM (AUD) Patient co-payment5 (AUD)
N2 Hospital episodes3 ED presentations MBS rebate4 PBS rebate Total cost to the
healthcare system
Average healthcare
cost per person (SD)
Total Average per
person (SD)
All cancers combined 123,900 3,824,163,400 88,103,100 263,243,600 631,804,300 4,807,314,400 38,800 (42,900) 127,673,700 1000 (2000)
Prostate cancer 20,700 374,172,600 6,416,200 36,828, 600 38,650,600 456,068,000 22,000 (18,700) 16,324,000 800 (1200)
Breast cancer 15,400 377,396,200 6,744,700 36,690, 600 170,956,200 591,787,700 38,300 (31,300) 21,040, 900 1400 (1500)
Colorectal cancer 14,800 643,503,400 11,849,400 30,563,000 71,878,900 757,794,700 51,300 (39,800) 16,979,500 1100 (1800)
Blood and lymphatic system 13,300 616,132,000 13,286,600 40,503,100 176,947,100 846,868,700 63,600 (73,600) 24,655,400 1900 (4100)
Melanoma of the skin 12,300 70,844,800 1,575,700 23,174,800 12,506,700 108,102,000 8800 (13,400) 4,945,100 400 (500)
Tracheal, bronchus and lung cancer 11,100 434,675,600 15,618,400 24,164,600 45,331,000 519,789,700 46,800 (35,700) 10,168,700 900 (1700)
Digestive organs 10,100 433,725,600 12,668,100 20,303,100 31,119,600 497,816,400 49,400 (38,400) 11,273,000 1100 (2000)
Cancers of the urinary tract 6200 202,334,900 5,022,300 10,703,000 17,623,000 235,683,200 38,000 (32,600) 4,816,000 800 (1100)
Gynaecological cancers 5200 159,616,700 3,121,600 10,475,000 16,774,700 189,988,000 36,400 (32,700) 5,171,800 1000 (1600)
Head and neck 4000 141,306,700 2,478,200 10,264,700 9,019,700 163,069,400 40,500 (47,200) 2,374,400 600 (1200)
Other or ill-defined cancers 2700 76,240,900 2,316,900 4,295,300 6,051,400 88,904,500 32,800 (31,500) 2,239,700 800 (1700)
Thyroid and other endocrine glands 2600 55,221,900 799,400 4,195,500 3,631,300 63,848,200 24,600 (35,800) 1,180,600 500 (600)
Eye, brain and CNS 1900 114,903,700 3,113,900 3,324,700 17,342,800 138,685,000 71,800 (73,200) 2,830,000 1500 (2300)
Mesothelioma, Kaposi Sarcoma, and soft tissue 1600 69,741,200 1,882,200 3,245,200 9,187,200 84,055,900 51,500 (47,800) 2,080,100 1300 (2200)
Male genital organs, exc prostate 900 19,635,700 678,900 2,190,200 2,267,400 24,772,300 26,800 (30,900) 643,200 700 (1200)
Other skin cancer 800 15,355,100 283,300 1,749,400 1,456,800 18,844,600 22,700 (30,200) 541,900 700 (1100)
1Weighted results reported, and rounded to the nearest 100
2Excluding broad cancer types with less than 500 individuals (‘bone’, and ‘other thoracic and respiratory organs’)
3Admitted and non-admitted hospital episodes
4MBS rebate, excluding items included as non-admitted hospital episodes














Table 4 Total cost of cancer for the first 12-months post-diagnosis, by population groups1
COST TO THE AUSTRALIAN HEALTHCARE SYSTEM (AUD) Patient co-payment4 (AUD)
n Hospital episodes2 ED presentations MBS rebate3 PBS rebate Total cost to the
healthcare system
Average healthcare
cost per person (SD)
Total Average per
person (SD)
Weighted total 123,900 3,824,163,400 88,103,100 263,243,600 631,804,300 4,807,314,400 38,800 (42,900) 127,673,700 1000 (2000)
Indigenous status
Non-Indigenous Australian 121,800 3,749,654,000 85,643,100 259,009,200 623,618,600 4,717,924,900 38,700 (42,800) 126,913,100 1000 (2000)
Indigenous Australian 2100 74,509,400 2,459,900 4,234,500 8,185,700 89,389,500 42,700 (48,800) 760,600 400 (800)
Rurality5
Metropolitan 58,500 1,738,821,800 38,505,200 125,884,200 306,909,000 2,210,120,300 37,800 (39,900) 65,570,600 1100 (1900)
Regional 54,500 1,721,146,800 42,165,900 116,837,100 270,755,900 2,150,905,700 39,500 (43,800) 52,061,400 1000 (1900)
Remote 10,200 352,165,600 6,805,500 19,718,200 52,844,900 431,534,200 42,200 (53,800) 9,831,600 1000 (2500)
IRSD6 Quintiles5
Q1 (Most disadvantaged) 11,300 387,822,900 11,248,900 21,232,900 47,295,500 467,600,300 41,400 (44,100) 9,226,300 800 (1900)
Q2 5700 183,953,200 3,180,500 11,653,000 28,801,500 227,588,200 39,800 (43,700) 4,900,200 900 (1800)
Q3 19,900 635,646,500 14,727,500 41,726,900 102,484,100 794,585,000 39,900 (48,500) 17,757,000 1100 (1800)
Q4 56,000 1,715,299,900 42,010,300 128,352,200 288,661,500 2,174,323,900 38,800 (42,000) 59,401,200 1100 (1800)
Q5 (Least disadvantaged) 30,200 889,411,700 16,309,300 59,474,600 163,267,300 1,128,462,900 37,300 (40,200) 36,179,100 1200 (2000)
1Weighted results reported, and rounded to the nearest 100
2Admitted and non-admitted hospital episodes
3MBS rebate, excluding items included as non-admitted hospital episodes
4MBS and PBS patient co-payment
5Excluding individuals with missing postcodes














Table 5 Five generalized linear models of the cost of cancer for the first 12-months1
Hospital episodes2 ED presentations MBS rebate3 PBS rebates Patient co-payment4
Ratio Estimate (SE) Ratio Estimate (SE) Ratio Estimate (SE) Ratio Estimate (SE) Ratio Estimate (SE)
Intercept 8.5519 (0.0483) *** – 5.4363 (0.0728) *** – 5.7499 (0.0382) *** – 6.8536 (0.0721) *** – 4.7398 (0.0593) ***
Age 1.01 0.0062 (0.0005) *** 1.01 0.0103 (0.0008) *** 1.00 −0.0021 (0.0004) *** 0.99 −0.0109 (0.0008) *** 1.00 0.0033 (0.0006) ***
Female 0.88 −0.1267 (0.0167) *** 0.95 −0.0537 (0.0262) * 0.95 −0.0551 (0.0129) *** 0.85 −0.1597 (0.0234) *** 0.98 −0.0214 (0.0192)
Indigenous Australians 1.02 0.0220 (0.0525) 1.23 0.2095 (0.0752) ** 0.92 −0.0888 (0.0402) * 0.82 −0.1928 (0.0735) ** 0.39 −0.9315 (0.0619) ***
Inner and outer regional area 1.04 0.0364 (0.0165) * 1.02 0.0196 (0.0275) 0.99 −0.0138 (0.0126) 1.04 0.0366 (0.0231) 0.94 −0.0571 (0.0189) **
Remote and very remote area 1.10 0.0947 (0.0268) *** 1.03 0.0322 (0.0454) 0.90 −0.1092 (0.0207) *** 1.10 0.0912 (0.0381) * 0.98 −0.0219 (0.0311)
IRSD5 Q2 1.02 0.0214 (0.0373) 1.00 0.0004 (0.0626) 1.07 0.0675 (0.0289) * 1.05 0.0474 (0.0519) 1.00 −0.0026 (0.0432)
IRSD5 Q3 0.98 −0.0232 (0.0279) 1.01 0.0097 (0.0420) 1.08 0.0805 (0.0216) *** 1.11 0.1053 (0.0389) ** 1.00 −0.0020 (0.0324)
IRSD5 Q4 0.95 −0.0510 (0.0250) * 0.98 −0.0215 (0.0368) 1.18 0.1642 (0.0193) *** 1.17 0.1582 (0.0348) *** 1.23 0.2033 (0.0289) ***




1Adjusted for age at diagnosis, sex, Indigenous status, rurality, IRSD quintiles, and broad cancer type
2Admitted and non-admitted hospital episodes
3MBS rebate, excluding items included as non-admitted hospital episodes
4MBS and PBS co-payment is the cost to the patient
















The total cost of cancer to the Australian public healthcare system estimated in this study was AU$4.8 
billion for the first twelve months, and the total patient co-payments incurred was $127.7 million. 
The costs to the public healthcare system were presented separately for admitted and non-admitted 
hospital episodes, ED presentations, MBS rebates, and PBS rebates.  
In addition to estimating the total costs, this is the first Australian study where costs have been 
reported separately for those within the population known to experience poorer outcomes following 
a cancer diagnosis (specifically, remoteness, socio-economic status and Indigenous status). After 
adjusting for age, sex, Indigenous status, remoteness, socioeconomic disadvantage, and broad type 
of cancer, there were significant differences for each of the cost categories analysed: 
- Hospital episodes: costs increased with increasing remoteness, costs were significantly lower 
for people living in the least disadvantaged quintiles (Q4-5), but there was no significant 
difference by Indigenous status; 
- ED presentations: costs were significantly greater for Indigenous Australians compared to 
non-Indigenous Australians, but there was no difference by remoteness or socioeconomic 
disadvantage; 
- MBS rebates: costs were significantly lower for Indigenous Australians and people living in 
remote and very remote areas, and costs were significantly higher for people living in IRSD 
Q2-4;  
- PBS rebates: costs were significantly lower for Indigenous Australians, but costs were 
significantly higher for people living in remote and very remote areas, and for people living 
in IRSD Q3-5; and 
- Patient co-payments were significantly lower for Indigenous Australians and for people living 
in regional and remote areas, and significantly higher with decreasing socioeconomic 
disadvantage. 
In addition to the limitations discussed in the published article, another limitation is that the data 
may not capture any changes in treatment and funding policies. The census of all cancer diagnoses in 
Queensland between July 2011 and June 2012, is now up to eight years old. The research team plan 
to build upon this original dataset, and increase the date range for all cancer diagnosis, and the date 
ranges for the data linkage. This will allow the sample size to be increased, and will allow the date 




existing medical conditions, as described in the published protocol,3 we describe that the cost for all 
health service use was included, regardless of whether it is directly attributable to cancer or not. 
Furthermore, the OOP patient co-payments were limited to patient co-payments included in the MBS 
or PBS datasets. As such, it did not include all OOP costs, such as private health insurance, private 
medications, private medical services, travel, accommodation, parking etc. These costs are known to 
be high, particularly travel costs for rural patients and thus the patient co-payments are an 
underestimation of the total patient OOP expenditure.  
This study had several purposes. To describe the development of CancerCostMod, which was the 
primary dataset used in this thesis; to estimate the cost of cancer during the first 12-months post-
diagnosis, and to describe the distribution of these costs by remoteness, Indigenous status, and 
socioeconomic disadvantage. In fulfilling these purposes, the first aim of the thesis was addressed. 
                                                             
3 Callander E, Topp SM, Larkins S, Sabesan S, Bates N. Quantifying Queensland patients with cancer 




Chapter Four: Indirect costs of cancer in Australia 
Introduction 
Many people who are diagnosed with cancer are of working age. Furthermore, due to changes in the 
age of retirement in Australia, it is important to consider the impact cancer will have on the working 
population. In this chapter, the second aim of the thesis is addressed: to quantify the annual indirect 
costs due to changes in labour force participation of people with cancer.  
The aims of this study were to determine the labour force participation characteristics of people with 
cancer, to estimate the indirect costs of cancer due to lost productivity, and to identify any inequality 
in the distribution of labour force absence in Australia. 
This chapter is inserted as published in BMC Public Health: 
Bates N, Callander E, Lindsay D, Watt K. Labour force participation and the cost of lost 
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Labour force participation and the cost of
lost productivity due to cancer in Australia
Nicole Bates1* , Emily Callander2, Daniel Lindsay1,2 and Kerrianne Watt1
Abstract
Background: In Australia, 40% of people diagnosed with cancer will be of working age (25–64 years). A cancer
diagnosis may lead to temporary or permanent changes in a person’s labour force participation, which has an
economic impact on both the individual and the economy. However, little is known about this economic impact of
cancer due to lost productivity in Australia. This paper aims to determine the labour force participation
characteristics of people with cancer, to estimate the indirect cost due to lost productivity, and to identify any
inequality in the distribution of labour force absence in Australia.
Methods: This study used national cross-sectional data from the 2015 Survey of Disability, Ageing and Carers,
conducted by the Australian Bureau of Statistics (ABS). The ABS weighted each component of the survey to
ensure the sample represented the population distribution of Australia. The analysis was limited to people aged
25–64 years. Participants were assigned to one of three health condition groups: ‘no health condition’, ‘cancer’, and
‘any other long-term health condition’. A series of logistic regression models were constructed to determine the
association between health condition and labour force participation.
Results: A total of 34,393 participants surveyed were aged 25–64 years, representing approximately 12,387,800
Australians. Almost half (46%) of people with cancer were not in the labour force, resulting in a reduction of $1.7
billion to the Australian gross domestic product (GDP). Amongst those in the labour force, people with no health
condition were 3.00 times more likely to be employed full-time compared to people with cancer (95% CI 1.96–4.57)
, after adjusting for age, sex, educational attainment and rurality. Amongst those with cancer, people without a
tertiary qualification were 3.73 times more likely to be out of the labour force (95% CI 1.97–7.07).
Conclusions: This paper is the first in Australia to estimate the national labour force participation rates of people
with cancer. People with cancer were less likely to be in the labour force, resulting in a reduction in Australia’s GDP.
Cancer survivors, especially those without a tertiary qualification may benefit from support to return to work after a
diagnosis.
Keywords: Cancer, Oncology, Costs, Health economics, Productivity
Background
Cancer is the leading burden of disease in Australia [1]
and internationally [2]. In 2017, an estimated 134,174
Australians will be diagnosed with cancer, of which 40%
will be of working age (25–64 years) [3]. Using the 2003
Survey of Disability, Ageing and Carers, Schofield et
al. [4] found that half (49%) of older Australians (aged
45–64 years) with cancer were not in the labour force.
In a more recent Australian study of 255 cancer patients,
67% reported changes to their employment [5]. A system-
atic literature review of employment and work-related is-
sues in cancer survivors included 64 international studies
and found that over a six-year period after a cancer diag-
nosis, 26–53% of cancer survivors were out of work (lost
their job or quit) [6]. Similarly, a recent meta-analysis of
international studies found that compared to healthy con-
trol participants, cancer survivors were 1.4 times more
likely to be unemployed [7]. These studies focus on the
individual perspective, and highlight the important finan-
cial distress faced by individual cancer patients and their
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families due to being out of the labour force [5, 8–12].
However, to date there has been minimal focus on the
societal perspective in Australia, and the consideration of
the aggregate costs of these changes in workforce partici-
pation; nor has there been consideration of the distribu-
tion of the costs of labour force absence, looking at the
population groups most likely to be affected. Such infor-
mation could be more useful to policy makers, concerned
with maximising welfare to the whole of society.
Health economic evaluations routinely evaluate the dir-
ect cost of illness; however, the indirect cost of lost prod-
uctivity due to morbidity and premature mortality may
exceed the direct costs of cancer [13–17]. In Europe, the
estimated cost of lost productivity from cancer in 2009 was
42%, a further 18% was attributed to the cost of informal
care, and only 41% of costs were attributed to direct health
care [18]. The National Institute of Health estimated that
in 2010, the cost of lost productivity in the United States
accounted for 61% of the total cost of cancer, compared to
39% for the direct costs [15]. In Korea, the estimated mor-
bidity and premature mortality costs accounted for 55% of
the total cost of cancer, compared to 28% for medical care
in 2009 [17]. In New South Wales, Australia in 2005, lost
productivity accounted for 54% of the total lifetime cost of
cancer, compared to the direct costs which accounted for
29% of the total lifetime costs [13]. However, this report
was from a single state in Australia. Carter, Schofield and
Shrestha [19] recently estimated that approximately 88,000
working years were lost, due to premature deaths from
cancer in 2003 in Australia, which cost $4.2 billion in
present value of lifetime income. Lung and colorectal
cancers accounted for 30% of the total loss of income. This
study provides a national perspective of the cost of cancer
due to premature mortality; however, there is currently
limited work on the productivity cost for people with can-
cer who are out of the labour force.
This paper will contribute to the growing body of re-
search on the indirect costs of cancer. The aims of this
research conducted within an Australian context are to:
1) determine whether people with cancer have different
labour force participation characteristics to people with
no health conditions, or any other long term health
conditions, 2) estimate the cost of cancer due to lost
productivity (limited to the context of paid work) and 3)
identify any inequality in the distribution of labour force
absence amongst those with cancer.
Methods
Data
The primary data source accessed for this data was the
2015 Survey of Disability, Ageing and Carers (SDAC).
This is a national survey conducted every 3 years by the
Australian Bureau of Statistics (ABS). The SDAC sam-
ple was a randomly selected sample of the Australian
population, regardless of health condition or disability
status and included participants from both household and
cared-accommodation, but excluded those residing in
prisons/correctional institutes, religious and/or educational
institutes; very remote areas, and discrete Indigenous com-
munities. The sample frame comprised approximately
25,500 private dwellings, 250 self-care retirement, and a
further 1000 cared-accommodation facilities. To adjust for
any potential bias in survey participants, the ABS weight
the survey data against known population benchmarks.
Briefly, the weight value indicates how many of the popula-
tion unit each sample unit represents. The two compo-
nents were weighted separately, the household component
was benchmarked to the estimated resident population in
each jurisdiction, and the cared accommodation compo-
nent was benchmarked to the census population counts of
this component as described in detail by the ABS [20].
Weighting allows an inference of results to the general
Australian population.
The survey included questions on demographics (such
as age, sex, highest level of education achievement, and
geographical remoteness), labour force participation, and
long-term health conditions (LTHC). LTHC’s were
defined by the SDAC as a condition lasting, or was likely
to last 6 months or more, or symptoms in the previous
12 months for an episodic condition (ie asthma or epi-
lepsy) and coded by the ABS based upon the ICD-10
[20]. Although the original survey included answers for
specific medical conditions, the ABS regrouped some
conditions for data release. For example, the types of can-
cer were grouped by the ABS: skin cancer (ICD C43–44),
breast cancer (ICD C50), prostate cancer (C61), bowel/
colorectal cancers (C18–21) and any other neoplasm
(including benign tumours).
Statistical analysis
Analyses were limited to people aged 25–64 years. Ex-
cluding survey respondents under the age of 25 allowed
those most likely to be participating in higher education
to be excluded; and those over the age of 65 were ex-
cluded, as the traditional retirement in Australia in 2015
was 65 years. Participants were categorised into one of
three health condition groups: ‘no LTHC’ included those
who did not report any LTHC, ‘cancer’ included those
who reported having cancer (skin, breast, prostate,
bowel/colorectal or any other neoplasm) as a LTHC, and
‘any other LTHC’ included those who reported any other
LTHC. Labour force participation (LFP) was recorded as
employed full-time (FT), employed part-time (PT),
unemployed but looking for FT and/or PT work, and
not in the labour force (NILF).1 Educational attainment
was recoded into a dichotomous variable (tertiary vs
non-tertiary education); as was rurality (major cities and
other), and age (25–44 years and 45–64 years).
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Aim 1: Labour force participation of people with cancer
A series of logistic regression models were constructed to
determine the association between cancer and LFP.
Initially, the analysis was limited to include those in the
labour force only. A logistic regression model was con-
structed to estimate the odds of being employed full-time
for people with cancer, LTHC, and no health condition
(respectively), after adjusting for age, sex, educational
attainment and rurality. A second logistic regression
model was constructed to estimate the odds of being out
of the labour force for people with cancer, LTHC, and no
health condition (respectively), after adjusting for age, sex,
educational attainment and rurality.
Aim 2: Cost of labour force absence associated with
cancer
Using the same approach as other Australian studies
[21–25], the financial impact to Australia’s gross domes-
tic product (GDP) due to people with cancer being out
of the labour force was estimated using the Australian
Treasury’s formula [26]:
GDP ¼ GDP=Hð Þ x H=EMPð Þ x EMP=LFð Þ
x LF=Pop15þð Þ x Pop15þ
where GDP = gross domestic product; H = total hours
worked; EMP = total number of persons employed; LF =
total labour force; and Pop15+ = population aged 15 years
and over [26].
This method has been previously used in other studies
[21–25], and differs from the friction cost method,
which argues that people who leave the labour force due
will be replaced by other workers (including those who
were previously unemployed) thus limiting the cost of
workers leaving the labour force [27]. Australia has a
very low unemployment rate (6.3% in July 2015) [28]
and significant labour shortages in some industries
[29], furthermore, the Australian Treasury’s aim to
make Australia’s financial position more sustainable by
promoting productivity, population growth and labour
force participation [30], recognising the signficiant
cost labour force exit has on the Australian economy.
Aim 3: Inequality in the distribution of labour force
absence amongst those with cancer
A concentration index was initially used to determine
whether there was any inequality in the distribution of
labour force absence amongst people with cancer. The
concentration index is normally used as a measure of
health inequality, and assesses the distribution of health
outcomes across socioeconomic groups in a population.
The concentration index reflects the cumulative propor-
tion of health held by the cumulative proportion of the
population, ranked by a measure of socioeconomic
status. The measure of socioeconomic status used was
the highest level of education attainment achieved, as
reported in the survey (7 ordinal categories: Year 8 or
below, Year 10, Year11/12, Certificate, Diploma, Bach-
elor, Post-graduate). The concentration index ranges
from − 1 to 1, with a value of 0 denoting perfect equality
in the distribution of labour force absence, a negative
value denoting a distribution skewed towards people of
lower socioeconomic status, and a positive value denot-
ing a distribution skewed towards people of higher so-
cioeconomic status. The concentration index (CI), and






¼ αþ βRi þ εi
Where σ2R is the variance of Ri (the individual’s rank),
yi is the labour force status of each individual (i = 1, 2,
3….N), α is the intercept, εi is the error terms, and β is
the CI 1. Finally, among only people with cancer, a
multivariate logistic regression model was constructed to
estimate the odds of being not in the labour force, after
accounting for age, sex, educational attainment, and
rurality.
All analyses were undertaken using SAS V9.4 (SAS
Institute Inc., Cary, NC, USA). Weighted estimates are
presented, unless stated otherwise. GDP figures are pre-
sented in 2015 Australian dollars.
Results
Within the 2015 SDAC, a total of 34,393 participants were
of working age (25–64 years), which represented approxi-
mately 12,387,800 people when weighted. Of the partici-
pants in this age group, there were 7,287,100 with no
health conditions, 108,900 people with a type of cancer,
and 4,991,800 with some other LTHC. Table 1 shows the
demographic characteristics for each of the health condi-
tion categories (no LTHC, cancer, and any other LTHC).
Aim 1: Labour force participation of people with cancer
Table 2 shows the employment status for people with no
health condition, people with cancer, and people with
any other LTHC. Almost half (46%) of people with can-
cer were not in the labour force, compared to approxi-
mately a quarter (27%) of people with any other LTHC,
and only 12% of people with no health condition.
Firstly, the analyses were limited to people who were
in the labour force. Of those with cancer who were
employed, 47% were employed full time, compared with
68% of those with any other LTHC, and 74% of those
with no health condition. Amongst those in the labour
force, after adjusting for age, sex, educational attainment
and rurality, those with no health condition had 3.00
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times the odds of being employed full-time than people
with cancer (95% CI 1.96–4.57; p < 0.0001). Similarly,
those with any other LTHC had 2.15 times the odds of
being employed full-time (95% CI 1.41–3.28; p = 0.0004)
than those with cancer.
Secondly, the odds of being out of the labour force
were calculated. Table 3 shows that after adjusting for
age, sex, educational attainment and rurality, those with
no health condition, and those with any other long-term
health condition had lower odds of being out of the
labour force compared to adults with cancer.
Aim 2: Cost of labour force absence associated with
cancer
An estimated 50,100 Australian adults of working age
(25–64 years) with cancer were not in the labour force
in 2015, thereby reducing Australia’s GDP by approxi-
mately $1.7 billion (Table 4).
Table 1 SDAC sample demographic characteristics of Australian
adults of working age, 25–64 years (using weighted totals,









Survey Participants 18,990 355 15,048





















































LTHC long-term health condition



































LTHC long-term health condition, FT full-time, PT part-time, NILF not in the
labour force, have not looked for work in the last 4 weeks, and do not intend
to work or look for work in the future
aThe number and percentage of people who were ‘unemployed’ were not
presented due to low unemployment rate in Australia, and hence the low
sample number of unemployed people
Table 3 Logistic regression model of being not in the labour force
Parameter Estimate Standard Error P-Value
Intercept −2.49 0.16 < 0.001
Male 0.97 0.35 < 0.001
Aged 25–44 0.35 0.03 < 0.001
Tertiary education attainment 0.70 0.04 < 0.001
Lives in major city 0.04 0.04 0.2255
No LTHC −1.68 0.14 < 0.001
Any other LTHC −0.81 0.14 < 0.001
Odds of being out of the labour force
Odds Ratioa 95% CI P-value
Cancer Reference
No LTHC 0.19 0.14–0.25 < 0.001
Any other LTHC 0.45 0.34–0.58 < 0.001
LTHC long-term health condition
aadjusted OR = adjusted for age, sex, educational attainment, and rurality
Table 4 The proportion of people out of the labour force, and














50,100 108,900 46% $1738 million
Sex
Male 19900a 46,600 43% $690 million
Female 30300a 62,300 49% $1051 million
Age
25–44 years 6900 18,500 37% $239 million
45–64 years 43,200 90,400 48% $1499 million
Educational attainment
Non-tertiary 42,100 75,500 56% $1460 million
Tertiary 7500 30,100 25% $260 million
Rurality
Major cities 32,100 74,500 43% $1114 million
Other areas 18,000 34,400 52% $624 million
arounded up
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Aim 3: Inequality in the distribution of labour force
absence amongst those with cancer
The concentration index showing level of inequality in
the distribution of labour force absence amongst people
with cancer was calculated to be − 0.20 (95% CI -0.26 to
− 0.13), which indicates that having cancer and being
not in the labour force is unequally skewed towards
those with a low educational attainment.
Amongst people with cancer, those without a tertiary
qualification were 3.73 times more likely to be out of the
labour force (95% CI 1.97–7.07; p < 0.0001), than people
with tertiary education. Sex, age, and rurality were not
associated with being out of the labour force (p = 0.0818,
p = 0.3723, p = 0.1869 respectively).
Discussion
The results of this paper have shown that in 2015, al-
most half (46%) of adults of working age (25 to 64 years)
with cancer were not in the labour force. Of those in the
labour force, adults with no health conditions had 3
times the odds of being employed full-time than adults
with cancer. Other studies have supported our findings
that following a cancer diagnosis, many patients report a
temporary or permanent change to their labour force
participation, including a reduction in work hours and
stopping work [5, 6, 8, 9, 11, 31–34].
Amongst people with cancer, a greater proportion of
older people (45–64 years) were not in the labour force,
however, this appears to be explained by other demo-
graphic factors. Amongst people with cancer, those with-
out a tertiary qualification had nearly four times the odds
of being out of the labour force; age, sex, and rurality were
not associated with a greater risk. Higher education attain-
ment has been identified as a positive factor in returning
to work [6, 35], which also supports our findings that
labour force absence amongst those with cancer is un-
equally skewed towards those with lower levels of educa-
tion attainment. Other factors which may affect returning
to work include jobs that require manual labour, and those
with less flexible working arrangements [6, 8, 10, 32, 33].
The type of cancer and treatment factors may also nega-
tively impact returning to work [6, 7, 10, 35]. For example,
Clarke et al. [35] found that colorectal and lung cancer
survivors had greater difficulties performing daily activ-
ities, and colorectal, lung, and bladder cancer survivors
were more likely to have functional limitations, which
may impact work ability.
This paper looked at distribution of people being out
of the labour force for any reason, with some people
potentially being out of the labour force directly as a
result of cancer, while others may have chosen early
retirement [11] due to a reassessment of their priorities
following a health shock. In Australia, employees (excluding
casual employees) are entitled to paid sick leave (10 days
each year for full-time employees), and unpaid leave for up
to 3 months [36]. While the Australian retirement age in
2015 was 65 years, at which time individuals may be eligible
to access a government ‘age pension’, individuals may have
access to their superannuation from age 55. However, pre-
vious work has found that despite these sources of financial
support, early retirement due to LTHC has a significant
negative impact on an individual’s income and wealth
[22, 25]. As such cancer survivors may benefit from
additional support by the Government, employers and
medical professionals to facilitate returning to work if
they choose to. Previous studies have shown that many
cancer survivors will return to work after treatment,
from 40% at six-months to 89% at 24-months following
a cancer diagnosis [6].
A key strength of this paper is that it used the 2015
SDAC, which is a national survey weighted to the Austra-
lian population. Participants who identified as having
cancer as a long-term health condition represented 0.9%
of the weighted population. It was estimated that around
1.5% of the Australian population had cancer in 2011–12
[37]. However, we limited our analyses to people of work-
ing age only (25–64 years), which excluded people over
75 years, who had the highest rate of developing cancers
(11.1% for men and 4.4% for women) [37]. Therefore, this
study was representative of the Australian population of
working age.
However, the use of the SDAC also has several limita-
tions. This survey did not include information about the
time since diagnosis, which may be a factor in labour
force participation [8, 9, 12]. Secondly, although the
main types of cancer in Australia (skin, breast, prostate,
and colorectal cancer) are identified in the SDAC, the
number of participants in each type was small, and
therefore, disaggregated analysis by type of cancer was
not possible. Finally, it is possible that some types of
cancers, which may have minimal impacts on returning
to work, may have been over-estimated, particularly if
someone recently had the lesion removed. For example,
non-melanoma skin cancers are the most common type
of cancer in Australia, and in some cases, the cancer is
completely removed with a biopsy, or removed by surgi-
cal excision [38, 39]. We only included LTHC in our
analyses, which was defined in the survey as conditions
lasting or expected to last 6-months [20], which should
exclude cases in which the only treatment received was
complete removal of the lesion.
This paper provides an insight into the economic
burden of cancer due to labour force participation, and
builds upon the growing body of literature. However, we
acknowledge that this is only a small part of the larger
burden of cancer, and are currently conducting a larger
study on the cost of cancer to the healthcare system and
the individual [40]. Future research also should look at
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the distribution of labour force participation rates across
the different types of cancer to ensure equitable access
and allocation of resources.
Conclusion
A large proportion of Australians diagnosed with cancer
are of working age, and in general cancer survival rates
are improving [3]. Furthermore, in light of the increase
of the Australian retirement age, from the current 65 to
67 years by 2023 (increasing by 6 months every 2 years
commencing July 2017 [41]), it is reasonable to expect
that the cost of lost productivity may increase in the
coming years. There is a call for support systems to
facilitate return to work for cancer survivors who want
to work [42]. For some survivors, returning to work after
a cancer diagnosis is an important milestone, both finan-
cially and emotionally [33, 43]. Cancer survivors without a
tertiary qualification may benefit from additional support.
This paper is the first in Australia to estimate the national
labour force participation rates of adults of working age
with cancer, and the indirect cost of cancer due to lost
productivity. This information is valuable when consider-
ing how cancer affects patients and society.
Endnote
1Not in the Labour Force defined as not in the labour
force, and have not looked for work in the last 4 weeks,
and do not intend on working or looking for work in the
future.
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A cancer diagnosis may result in changes in an individual’s labour force participation. At the time of 
the 2015 SDAC, almost half (46%) of people of working age (25 to 64 years) with cancer were not in 
the labour force, resulting in an annual reduction of $1.7 billion to the Australian gross domestic 
product (GDP). After limiting the analysis to people with cancer, people without a tertiary 
qualification were more likely to be out of the labour force. There was no significant differences in 
labour force participation by age, sex, and rurality. Employment policies should support the 
individual’s decision to return to work if they wish to. Amongst those with cancer, some people may 
require additional assistance in returning to the workforce. 
In addition to the limitations discussed in the published article, there are some additional limitations 
relating to the aims of this thesis. Specifically, this thesis aimed to describe the labour force 
participation and indirect costs by Indigenous status, remoteness, and socioeconomic status. Due to 
the limitations of the dataset, it was not possible to analyse the labour force participation and indirect 
costs by Indigenous status or socioeconomic status. In addition to this, due to the sample size in the 
dataset, the remoteness categories were collapsed into ‘major cities Australia, and ‘those living in 
other areas’. Therefore, the analysis was unable to identify any differences in labour force 
participation between metropolitan, regional, and remote.  
Future studies should identify if there are any differences in labour force participation between 
population groups. Due to the limitations of the SDAC as outlined, it may be necessary to recruit 
people diagnosed with cancer and obtain information directly from these participants and their 
families. The information from future studies may then be used to identify people who require 
additional support in returning to the workforce following a cancer diagnosis.   
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PART 3: A CASE STUDY OF THE COST OF FEMALE 
BREAST CANCER IN AUSTRALIA  
In Part 2 of the thesis, the direct and indirect costs of all cancers were estimated, and the distribution 
of these costs by groups known to experience poorer outcomes from cancer were investigated 
(remoteness, Indigenous status, socioeconomic disadvantage). Part 3 of the thesis focuses specifically 
on female breast cancer, and a longer timeframe is included (three years following diagnoses) to 
allow a more detailed examination of relevant costs. The first three years post-diagnosis was chosen 
for several reasons. Logistically, at the time of commencement, data was available until June 2015. 
Each individual had at least three years of follow-up data, unless the individual passed away prior to 
this date. Additionally, previous literature has shown the highest costs are accrued during the first 
12-months following diagnosis, and final 12-months of life; however, there from limited research in 
Australia. Therefore, including the immediate three years post-diagnosis enabled the costs to be 
estimated for both the public healthcare system, and individual to determine how these costs change 
over this time period. Future research will seek to extend both the cohort enrolment dates, and the 
follow-up period. 
Female breast cancer was chosen as it is the most commonly diagnosed cancer in Australia. In 
addition to this, it was selected to overcome a common data limitation in the dataset. All cancer 
diagnoses (excluding non-melanoma skin cancers) are reported to the jurisdiction’s cancer registry. 
However, the stage at diagnosis is not routinely reported. Additional information is collected by the 
Queensland Cancer Registry (QCR), such as tumour size, and evidence of lymph node involvement. 
As described in the following papers, using methods described from previous Queensland studies, 
breast cancer stage was categorised as early, advanced, and unknown. 
Part 3 of the thesis comprises three separate chapters (each a peer-reviewed manuscript ), and 
addresses the third aim of the thesis: to quantify the direct costs to the public healthcare system and 
individual for the first three years following a female breast cancer diagnosis, and to determine the 
distribution of these costs by Indigenous status, remoteness, and socioeconomic disadvantage. 
Chapters Five and Six focus on the cost to the public healthcare system, and Chapter Seven focuses 





Chapter One: Introduction 
Part 1: Introduction and literature review 
Chapter Two: Exploring the cancer survival inequalities in Australia 
Chapter Eight: Discussion and conclusion 
Part 4: Discussion and conclusion 
Chapter Three: Developing CancerCostMod, a linked administrative model 
Bates N, Callander E, Lindsay D, Watt K. CancerCostMod: a model of healthcare 
expenditure, patient resource use, and patient co-payment costs for Australian 
cancer patients. Health Economics Review. 2018; 8:28. doi: 
https://doi.org/10.1186/s13561-018-0212-8 
Bates N, Callander E, Lindsay D, Watt K. Correction to: CancerCostMod: a model of 
healthcare expenditure, patient resource use, and patient co-payment costs for 
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Figure 1: Thesis outline 
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Chapter Five: Hospital costs for women diagnosed with 
breast cancer 
Introduction 
In this chapter, CancerCostMod was used to identify the hospital expenditure associated with female 
breast cancer for the first three-years following diagnosis, and to determine the distribution of these 
costs by Indigenous status, geographical remoteness, and socioeconomic status. CancerCostMod was 
limited to women diagnosed with breast cancer (ICD-O C50). 
At the time of thesis submission, this chapter is under review. It is presented in the thesis in the 
format required by the journal: 
Bates N, Callander E, Lindsay D, Watt K. 2019. Quantifying the hospital costs for women 
diagnosed with breast cancer in Australia, using CancerCostMod – a population-based data 
linkage study. Under Review  
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Abstract 36 
Background: Breast cancer is the most commonly diagnosed cancer in women in Australia. Indigenous women, 37 
women living in rural and remote areas, and socioeconomically disadvantaged women experience poorer 38 
survival following a breast cancer diagnosis. We sought to describe the cost of female breast cancer for hospital 39 
episodes and emergency department presentations in Australia, and whether the distribution of costs varied by 40 
these characteristics.  41 
Methods: We used a linked administrative dataset, CancerCostMod. The base population for this dataset was all 42 
cancer diagnoses in Queensland, Australia between 1JUL2011 and 30JUN2012, as recorded by the Queensland 43 
Cancer Registry. Each record was then linked to Queensland Health Admitted Patient Data Collection, Emergency 44 
Department Information Systems, Medicare Benefits Schedule, and Pharmaceutical Benefits Scheme between 45 
1JUL2011 and 30JUN2015. The dataset was then weighted to be representative of the Australian population. For 46 
this study, CancerCostMod was limited to female breast cancer diagnoses only. The cost of (admitted and non-47 
admitted) hospital episodes and emergency department (ED) presentations were determined. The mean cost 48 
per patient for each six-month time period from diagnosis to three years were then modelled.  49 
Results: Between 1JUL2011 and 30JUN2012, 3,079 Queensland women were diagnosed with breast cancer – 50 
representing 15,335 Australian women once weighted. The total cost of hospital episodes was $558.4 million 51 
during the first three-years, and an additional 12.8 million for ED presentations. The cost of hospital episodes 52 
were consistently greater across the three-year study period for Indigenous women compared to non-Indigenous 53 
women, and for women living in the most socioeconomically disadvantaged quintile, compared to those living in 54 
the least socioeconomically disadvantaged quintile. Some differences in costs of hospital episodes were observed 55 
by remoteness, but these were not consistent. Although there were some differences in the average cost for ED 56 
presentations, there were no consistent differences across the three-year period for the groups of interest. 57 
Conclusions: This is the first study in Australia to quantify the cost of hospital episodes and ED presentations of 58 
Breast Cancer in such detail, and also to describe the distribution of costs by Indigenous status, remoteness, and 59 
socio-economic status. These findings have important policy implications 60 
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Background 61 
Breast cancer is the most commonly diagnosed cancer in women, and is one of the leading causes of cancer 62 
mortality and morbidity in women worldwide.1 In Australia, the incidence of breast cancer is increasing, and was 63 
projected to be the second leading cause of cancer death in females in 2017.2 Despite improved national survival 64 
rates, it is well documented that Aboriginal and/or Torres Strait Islander women (hereafter, respectfully referred 65 
to as Indigenous women), women living in rural and remote areas, and socioeconomically disadvantaged women 66 
experience poorer survival rates.3-5 Similar inequalities by ethnicity, socioeconomic status and remoteness for 67 
female breast cancer survival have been reported within other high income countries.6-8 68 
Reflective of the high burden of breast cancer, the costs of breast cancer in Australia accounted for the highest 69 
total expenditure on cancer for females in 2008-09 (11.4%, AU$235 million), mostly attributable to hospital 70 
services (62%).9 A New South Wales (NSW) report estimated that breast cancer was the third most costly cancer, 71 
accounting for 7% (AU$76.7 million) of the total health system cost of cancer in NSW in 2005.10 These reports 72 
highlight the relative high investment in breast cancer health services within the Australian healthcare system, 73 
but are now nearly a decade old and do not consider other groups with known inequalities. 74 
In 2010-11, the total Australian healthcare expenditure on hospitalizations where the primary diagnosis was 75 
female breast cancer was approximately $162.9 million.11 A report by the Australian Institute of Health and 76 
Welfare in 2013 identified that the average per person hospital expenditure for Indigenous women with breast 77 
cancer was 0.6 times lower than non-Indigenous women.11 To the authors’ best knowledge, this is the only 78 
documented evidence regarding the healthcare expenditure of cancer by Indigenous status; however, only 79 
hospital costs where cancer was the principal diagnosis were included in this report.  80 
Previously published estimates of cancer costs rely on aggregated data, which has several limitations that may 81 
be overcome by individual-level data. For example, individual-level data allows us to identify individual patient 82 
characteristics, such as stage of disease, Indigenous status, remoteness, and socioeconomic status, which may 83 
contribute to differences in costs. In recent years, the use of individual level data in Australian costing studies is 84 
growing. Of the two studies that included breast cancer, one identified costs for patients undergoing 85 
chemotherapy in New South Wales, 12 and one identified the excess costs associated with people over the age 86 
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of 45 diagnosed cancer.13 The first study reported that inpatient hospital care accounted for the highest 87 
proportion of average costs for metastatic breast cancer (44%), and 20% for adjuvant breast cancer.12 The second 88 
study found that for people diagnosed with breast cancer, hospitalizations accounted for the greatest proportion 89 
of costs during both the first 12-months following a diagnosis (44%), and the last 12-months of life (65%).13 90 
The aim of the present study was to identify hospital expenditure for women diagnosed with breast cancer for 91 
the first three years post-diagnosis, and to determine the distribution of this expenditure by Indigenous status, 92 
remoteness, and socioeconomic status, using linked administrative data. It is the first time whole of population 93 
data linkage has been utilized in Australia to estimate costs associated with cancer. This population-based data 94 
linkage study adopted a national health system perspective, in which we looked at the cost to the healthcare 95 
system for hospital episodes (admitted and non-admitted) and emergency department (ED) presentations. 96 
Methods 97 
Study design and study population 98 
The population for this study was nested in a larger dataset, ‘CancerCostMod’.14 The methodology for the 99 
development of ‘CancerCostMod’ is described in detail elsewhere.15 Briefly, the base population for 100 
‘CancerCostMod’ is a census of all cancer diagnoses (excluding non-melanoma skin cancer) in Queensland (1 July 101 
2011 and 30 June 2012), as recorded by the Queensland Cancer Registry (QCR) (N=25,553 patients). Each 102 
individual’s QCR record was linked to their records in: Queensland Health Admitted Patient Data Collection 103 
(QHAPDC); Queensland Health Emergency Department Information Systems (EDIS) by the Queensland Health 104 
Statistical Services Branch; Medicare Benefits Schedule (MBS); and Pharmaceutical Benefits Scheme (PBS) by the 105 
Australian Institute of Health and Welfare (AIHW), from 1 July 2011 and 30 June 2015, so that there were three 106 
full years of data for each individual, post-diagnosis. This dataset was then weighted to the Australian population 107 
with cancer, using a programmed SAS macro called GREGWT (N=123,900).15 For this study, we limited 108 
‘CancerCostMod’ to include records of female breast cancer (ICD-O C50), aged 18 years or greater at the time of 109 
diagnoses.  110 
The QCR database includes sociodemographic determinants at time of diagnosis such as age, sex, Indigenous 111 
status and residential postcode. Postcode was mapped to Index of Relative Socio-Economic Disadvantage (IRSD 112 
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- a summary of the economic and social conditions of an area, and collapsed into quintiles: Q1=most 113 
disadvantaged, Q5=least disadvantaged), and Australian Statistical Geography Standard (ASGS - a measure of 114 
remoteness; categorised into metropolitan, regional (inner and outer), and remote (remote and very remote). 115 
Postcodes were missing records; these were not mapped to IRSD or remoteness. Indigenous status was recorded 116 
for 87% of our original QCR dataset; multiple imputation was used to impute missing Indigenous status, as 117 
described previously.15 118 
The QCR does not routinely collect detailed breast cancer staging, however, it does collect information on the 119 
tumour size and evidence of lymph node involvement. Using methods from previous Queensland studies,4, 16 we 120 
categorized breast cancer stage as:  121 
 ‘Early’, where tumour size was ≤ 20mm, and no evidence of lymph node involvement; 122 
 ‘Advanced’, where tumour size was > 20mm, or if there was any evidence of lymph node involvement 123 
regardless of tumour size, or if the diagnosis was because of metastatic disease; 124 
 ‘Unknown’, where lymph node involvement or tumour size was unknown. 125 
Assigning costs for hospital episodes and ED presentations 126 
Australia has a universal healthcare system, Medicare, which provides free public hospital services, and free or 127 
subsidized primary health care outside of hospitals. Private health insurance is optional. Funding of Australian 128 
hospitals are a mixture of the Australian Government, State/Territory Government, individual out-of-pocket 129 
payments, Department of Veteran’s Affairs (DVA), Private Health Insurance and other. In 2011-12, approximately 130 
89% of funding for public hospitals were from the Australian and State Governments, compared to 32% for 131 
private hospitals. Private hospitals received 44% of their funding from PHI, and 11% from individuals.17 The 132 
QHAPDC and EDIS datasets contained all separations and ED presentations at a Queensland hospital, which 133 
included both public and private hospitals.The methods used to assign cost are described in detail elsewhere.15  134 
In brief, the cost of each public hospital admitted episode of care was attributed to the Australian Refined 135 
Diagnostic-Related Group (AR-DRG) using the cost as reported by the National Hospital Data Collection (NHCDC) 136 
report (available online)18 for the AR-DRG for the relevant year. To reflect possible variations in costs of delivering 137 
healthcare to some participants, we included an adjustment for certain patient demographics.19 The cost 138 
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attributed to each AR-DRG for private hospital separations was assigned for the relevant year using the average 139 
charge per separation reported by the Private Hospital Data Bureau (PHDB) Annual Reports (available online) for 140 
each AR-DRG.20 141 
In Australia, some oncology patients may receive treatment at a hospital as a non-admitted (out-) patient, and 142 
are therefore not captured in the QHAPDC dataset, however these services are often funded under the MBS and 143 
so are captured on the MBS claims records. In order to include these costs, we identified hospital items from the 144 
MBS dataset.15 The benefit paid under the MBS was used to assign a cost to each service. Hereafter, admitted 145 
and non-admitted hospital episodes will be referred to as ‘hospital episodes’. 146 
Each Emergency Department (ED) presentation was coded to the ED classification system Urgency Related Group 147 
(URG) using the triage category, discharge destination and the primary reason for attending the ED (ICD-10-AM). 148 
The cost attributed to each URG for each ED presentation was assigned using the average cost per presentation 149 
as reported by the NHCDC Report (available online)18 for the relevant year.  150 
We analyzed and presented the results of hospital episodes and ED presentations separately, as the ED 151 
classification system is relatively new. It was first used in costing information from the NHCDC Round 14 (2009-152 
2010) and in the national price determination from 2012-13.21  153 
The cost of hospital episodes and ED presentations were calculated for each month for each individual from the 154 
date of diagnosis (t=0) to 36 months post-diagnosis. If an individual had no health services for the month, the 155 
cost was recorded as $0. If an individual passed away during the study period, there was no cost recorded for 156 
subsequent months following death. All costs are reported in Australian dollars (AUD), and adjusted to the 2016-157 
17 financial year, using the Reserve Bank of Australia inflation calculator.22 158 
Statistical analysis 159 
Descriptive analysis was undertaken to identify the demographic characteristics of the weighted sample. The 160 
costs were then aggregated into six-month time periods to quantify the total cost within each 6-month time 161 
period of hospital episodes and ED presentations for all participants, and then separately by age group (18-44 162 
years, 45-64 years, and 65 years and older), breast cancer stage, Indigenous status, remoteness, and 163 
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socioeconomic status. As there were a large number of records with no health service utilized during each period, 164 
the dataset was limited to those who had at least one hospital episode or ED presentation before calculating the 165 
average number and average cost of health services during each time period. 166 
Finally, the mean costs per patient for each six-month time period following diagnosis were modelled with 167 
generalized linear models using a gamma distribution, and a log link function. This included the number of 168 
months the patient survived as an offset to the model. Independent variables included in the analysis were 169 
Indigenous status (reference group=non-Indigenous women), age group (reference group=18-44 years), 170 
remoteness (reference group=metropolitan), socioeconomic disadvantage (reference group=IRSD Q5 (least 171 
disadvantaged)), breast cancer stage (reference=early), number of services during the time period analysed, and 172 
death during the time period (binary).  173 
All analyses were undertaken using SAS V9.4 (SAS Institute Inc., Cary, NC, USA). Human Research Ethics approval 174 
was obtained from the Townsville Hospital and Health Service Human Research Ethics Committee (HREC) 175 
(HREC/16/QTHS/11), AIHW HREC (EO2017/1/343) and James Cook University HREC (H6678). Permission to waive 176 
consent was approved from Queensland Health under the Public Health Act 2005. No identifiable information 177 
was provided to the authors. 178 
Results 179 
Between 1 July 2011 and 30 June 2012, 3,079 women over the age of 18 were diagnosed with breast cancer in 180 
Queensland. Once weighted for the Australian population, this represented 15,335 women. Demographic 181 
characteristics at diagnosis of women diagnosed with breast cancer are shown in Table 1. The mean age at 182 
diagnosis was 61 years (SD: 14 years). 183 
  184 
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Table 1: Demographic characteristics at diagnosis of Australian female breast cancer patients, diagnosed 185 
between 1 July 2011 and 30 June 2012 (weighted) 186 
 N 
N 3,079 
N (weighted) 15,335 
Age group  
18-44 years (%) 1,848 (12.1) 
45-64 years (%) 7,536 (49.1) 
65 years and above (%) 5,951 (38.8) 
12-month mortality 646 (4.2) 
Indigenous status  
Indigenous women (%) 248 (1.6) 
Non-Indigenous women (%) 15,087 (98.4) 
Remoteness *  
Metropolitan (%) 7,712 (50.6) 
Regional (%) 6,359 (41.7) 
Remote (%) 1,180 (7.7) 
Index of Relative Socio-Economic Disadvantage *  
Quintile 1 (most disadvantaged) (%) 1,095 (7.2) 
Quintile 2 (%) 767 (5.0) 
Quintile 3 (%) 2,483 (16.3) 
Quintile 4 (%) 6,669 (43.7) 
Quintile 5 (least disadvantaged) (%) 4,236 (27.8) 
Breast cancer stage  
Early (%) 6,695 (43.6) 
Advanced (%) 7,174 (46.8) 
Unknown (%) 1,466 (9.6) 
* Those with missing postcode data at diagnosis were excluded (weighted n=85) 187 
 188 
The total cost of admitted and non-admitted hospital episodes over the three years post-diagnosis was AU$558.4 189 
million (Table 2). The first six-months following diagnosis contributed to around half (50.1%) of the total costs 190 
for hospital episodes in this cohort (AU$279.5 million), with a total of 758,594 hospital episodes. The average 191 
cost of hospital episodes during the first three years post diagnosis was $36,675 per person (SD 36,488). The 192 
average number of hospital episodes over the three-year study period was 124 (SD 109). The first six-months 193 
following diagnosis also had the highest average number of hospitalizations per patient (50 episodes), and 194 
highest average cost per patient ($18,377). In all but the first six-months, the standard deviation was larger than 195 
the mean, indicating a wide dispersion of both the average number of hospital episodes and average costs 196 
between individuals.  197 
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Table 2: Costs to the health system for hospital episodes of female breast cancer in Australia, for women 198 
diagnosed between 1 July 2011 and 30 June 2012 (weighted) 199 
 Number of 
patients 














0-6 months 15,211      758,594   279,524,527  50 (39) 18,377 (15,896) 
7-12 months 14,520      431,607     95,526,937  30 (33) 6,579 (11,589) 
13-18 months 14,240      195,401     46,225,336  14 (20) 3,246 (8,046) 
19-24 months 13,916      170,698     44,299,437  12 (24) 3,183 (8,306) 
25-30 months  13,715      169,598     49,751,793  12 (29) 3,628 (13,196) 
31-36 months 13,345      154,685     43,072,866  12 (26) 3,228 (9,477) 
 200 
Table 3 shows the cost of ED presentations for female breast cancer patients in Australia for women diagnosed 201 
between 1 July 2011 and 30 June 2012. The total cost for ED presentations was $12.8 million, and there were 202 
17,403 ED presentations across the three years. The first six-months following diagnosis contributed $4.9 million 203 
(38.4%) of the total costs. The average cost of ED presentations during the first three years per person was $2,077 204 
(SD: 2,360) and the average number of ED presentations was 3 (SD: 3). The average cost per patient was also 205 
highest in the first six-months following diagnosis ($1,429). During each of the six-month periods, the standard 206 
deviation shows less variance from the mean than hospital episodes for both the average number of ED 207 
presentations and the average total cost of ED presentations.  208 
Table 3: Costs to the health system for ED presentations of female breast cancer in Australia, for women 209 




All ED presentations for cohort 
(15,335 individuals) 
Average per patient who had an ED 
presentation 
Time since diagnosis  Number of ED 
presentations 
Cost Number of ED 
presentations 
(SD) 
Cost of ED 
presentations ($) 
(SD) 
0-6 months 3,445 6,594      4,922,775  2 (1) 1,429 (1,122) 
7-12 months 1,566 2,377      1,794,763  2 (1)         1,146 (897)  
13-18 months 1,394 2,250      1,565,506  2 (2)         1,123 (870)  
19-24 months 1,269 1,942      1,409,814  2 (2)         1,111 (987)  
25-30 months  1,324 2,123      1,577,551  2 (2)         1,191 (1,032)  
31-36 months 1,366 2,117      1,551,278  2 (1) 1,136 (1,027) 
 211 
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Figure 1 shows the average cost per patient for hospital episodes and ED presentations by age group (A and B), 212 
breast cancer stage (C and D), Indigenous status (E and F), remoteness (G and H), and socioeconomic 213 
disadvantage (I and J) by six-month time periods. There are some small differences in the average cost per patient 214 
by age group for both hospital episodes and ED presentations. The average cost per patient for hospital episodes 215 
(C) was greater for women diagnosed with advanced stage disease during the first six-months, and 7-to-12 216 
months following diagnosis; however, women diagnosed with unknown stage disease had greater average ED 217 
presentations during these time periods. The average cost per patient was higher for Indigenous women than 218 
non-Indigenous women for both hospital episodes (E) and ED presentations (F) across all time points for the 219 
three-year study period. In terms of remoteness, there was little difference in the average cost per patient for 220 
hospital episodes (G); but some cost differences were observed for ED presentations (H) – specifically, women 221 
living in remote areas had slightly higher costs compared to women living in metropolitan or regional areas, and 222 
there was an increase in the average cost of ED presentations for women living in remote areas during months 223 
12-to-18. The average cost per patient for hospital episodes was similar by IRSD quintiles (I); and there were 224 
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Figure 1: Average cost per patient for Hospital Episodes and ED Presentations by age group, breast cancer 227 
stage, Indigenous status, remoteness, and socioeconomic disadvantage. Average costs per patient were 228 
calculated for each six-month period from diagnosis to 3-years. The figures on the left present the unadjusted 229 
average costs for admitted and not-admitted hospital episodes, and on the right present the unadjusted 230 
average cost for ED presentations by characteristics of interest. 231 
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 232 
Table 4 shows the parameter estimates produced by the six generalised linear models, estimating the mean 233 
admitted and non-admitted hospital episode cost per patient for each six-month time period for hospital 234 
episodes, adjusting for Indigenous status, remoteness, socioeconomic status, age group at diagnosis, stage of 235 
disease at diagnosis, number of hospital episodes during time period being analysed, and death during time 236 
period being analysed. Costs were significantly greater for Indigenous than non-Indigenous women in all but one 237 
of the time periods analysed (13-to-18 months). There were some differences in the mean cost per patient by 238 
remoteness, but this was not consistent across all time periods. Compared to women living in the least 239 
disadvantaged area (Q5), costs were significantly greater for women from the most disadvantaged area (Q1) for 240 
all but the final six-month period, and for women living in the second most disadvantaged area (Q2) during 25-241 
to-30 months and 31-to-36 months. 242 
Finally, we examined the mean cost per patient for each six-month time period for ED presentations, adjusting 243 
for Indigenous status, remoteness, socioeconomic status, age group at diagnosis, stage of disease at diagnosis, 244 
number of ED presentations during time period being analysed and death during time period being analysed 245 
(Table 5). Compared to non-Indigenous women, costs for Indigenous women were 1.41 times greater during 25-246 
to-30 months post-diagnosis. Women living in remote areas had significantly lower costs during 13-to-18 months, 247 
25-to-30 months, and 31-to-36 months compared to women living in metropolitan areas. There were no 248 
significant differences across the socioeconomic quintiles. 249 
  250 
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Table 4: Parameter estimates of independent variables in generalised linear regression model of the costs for hospital episodes for women diagnosed with breast cancer 251 
between 1 July 2011 and 30 June 2012, Australia (Weighted data)  252 




















Intercept   8.3246 (0.0662) ***   
5.8759 
(0.1223) ***   
5.0887 
(0.1322) ***   
4.9019 
(0.1450) ***   
4.7931 
(0.1467) ***   
4.0776 
(0.1569) *** 
Indigenous women 1.47 0.3857 (0.1011) *** 1.59 
0.4645 
(0.1844) * 1.29 
0.2509 
(0.1884)  1.93 
0.6580 
(0.2187) ** 2.51 
0.9198 
(0.2328) *** 2.50 
0.9163 
(0.2351) *** 















(0.0979) * 1.29 
0.2543 





IRSD Q1 1.17 0.1609 (0.0573) ** 1.36 
0.3097 
(0.1027) ** 1.76 
0.5660 
(0.1108) *** 1.72 
0.5421 
(0.1192) *** 1.64 
0.4917 
(0.1287) *** 1.26 
0.2327 
(0.1300) 








(0.1416) *** 1.39 
0.3294 
(0.1455) * 




(0.0788) * 0.78 
-0.2493 
(0.0857) ** 0.96 
-0.0393 
(0.0915)  0.87 
-0.1390 
(0.0920) 
IRSD Q4 1.04 0.0386 (0.0318) 1.27 
0.2389 
(0.0568) *** 1.00 
-0.0035 
(0.0632)  0.86 
-0.1535 





Age 45-64 years 1.00 -0.0049 (0.0388) 0.73 
-0.3093 
(0.0692) *** 0.68 
-0.3876 
(0.0749) *** 0.61 
-0.4862 
(0.0814) *** 0.54 
-0.6138 
(0.0862) *** 0.80 
-0.2277 
(0.0854) ** 




(0.0777) *** 0.75 
-0.2866 
(0.0846) *** 0.61 
-0.4950 
(0.0900) *** 1.04 
0.0422 
(0.0884) 
Advanced stage 1.27 0.2354 (0.0253) *** 1.45 
0.3690 
(0.0469) *** 1.23 
0.2049 
(0.0497) *** 1.19 
0.1749 
(0.0533) *** 1.23 
0.2083 
(0.0565) *** 1.46 
0.3753 
(0.0566) *** 
Unknown stage 0.84 -0.1725 (0.0501) *** 1.30 
0.2653 









Number of hospital 
episodes during 
period analysed 
1.01 0.0053 (0.0003) *** 1.03 
0.0306 
(0.0010) *** 1.07 
0.0654 
(0.0024) *** 1.07 
0.0647 
(0.0029) *** 1.06 
0.0590 
(0.0029) *** 1.06 
0.0599 
(0.0029) *** 
Death during period 
analysed 0.48 
-0.7279 
(0.0456) *** 0.34 
-1.0740 
(0.0903) *** 0.33 
-0.1226 
(0.0993) *** 0.36 
-1.0221 
(0.1103) *** 0.38 
-0.9773 
(0.1077) *** 0.37 
-0.9914 
(0.1174) *** 
*   p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001 253 
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Table 5: Parameter estimates of independent variables in generalised linear regression model of the costs for ED presentations for women diagnosed with breast cancer 254 
between 1 July 2011 and 30 June 2012, Australia (weighted data). 255 
  0-6 months  7-12 months  13-18 months  19-24 months  25-30 months  31-36 months 












Intercept   4.9887 (0.1672) ***   
3.6519 
(0.2344) ***   
3.5262 
(0.1462) ***   
3.5033 
(0.1427) ***   
3.0024 














(0.1448) * 1.10 
0.0926 
(0.1341) 








(0.0711)  0.85 
-0.1602 
(0.0704) * 








(0.1113) * 0.70 
-0.3627 
(0.1059) *** 































































(0.0939) * 1.18 
0.1618 
(0.0959) 


























1.47 0.3847 (0.0290) *** 1.65 
0.4991 
(0.0566) *** 1.36 
0.3061 
(0.0278) *** 1.39 
0.3320 
(0.0317) *** 1.39 
0.3315 




period analysed 0.62 
-0.4840 
(0.0931) *** 0.75 
-0.2813 
(0.0957) ** 0.79 
-0.2334 
(0.0602) *** 0.77 
-0.2633 
(0.0666) *** 0.83 
-0.1832 
(0.0566) ** 0.86 
-0.1487  
(0.0538) ** 
*   p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001 256 
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Discussion 257 
This is the first Australian study to use whole of population linked administrative data to estimate the cost of 258 
admitted and non-admitted hospital episodes and ED presentations for women diagnosed with breast cancer. 259 
The total cost of hospital episodes was $558.4 million, and the total cost of ED presentations was $12.8 million 260 
for the first 36-months following diagnosis. The first six-months post-diagnosis accounted for the highest 261 
proportion of the costs for hospital episodes (50%) and ED presentations (38%). 262 
The AIHW estimated that the cost of hospital admissions for female breast cancer was $146.33 million in 2008-263 
09.9 More recently, the AIHW and Cancer Australia estimated that the total expenditure for hospital admissions 264 
for female breast cancer was $162.9 million in 2010-11.11 However, both reports only include admitted hospital 265 
episodes where the principal diagnosis was female breast cancer. These reports also exclude non-admitted 266 
patient services. It is difficult to directly compare our results to these reports, as we sought to estimate the cost 267 
for admitted and non-admitted hospital episodes. We also estimated the total cost of all hospital episodes, 268 
irrespective of primary diagnosis for women diagnosed with breast cancer between 1 July 2011 and 30 June 269 
2012.  270 
A key aim of this study was to look at the distribution of costs amongst groups who are known to experience 271 
poorer health outcomes. After adjusting for age, remoteness, socioeconomic status, stage of disease, number of 272 
hospital episodes, and death during period analyzed, we found that the mean cost per patient for hospital 273 
episodes was significantly greater for Indigenous women compared to non-Indigenous women throughout 274 
almost all of the first three years post-diagnosis. This could be due to Indigenous women potentially having more 275 
comorbidities,23, 24 which may add to the complexity of treatment, thereby increasing hospital costs. Although 276 
we found some differences in costs when comparing remoteness, this was not consistent. We found consistently 277 
higher costs for women living in the most disadvantaged area compared to those living in the least disadvantaged 278 
area. 279 
Previous Australian studies have identified differences in treatment following a breast cancer diagnosis.23, 25-28 280 
For example, there is evidence that women living in outer regional and remote areas have lower rates of breast 281 
conserving surgery, and higher rates of mastectomy compared to cities.25, 26 Higher rates of mastectomy have 282 
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also been observed in women from more disadvantaged areas,26 those who lived further away from a radiation 283 
facility,26 and Indigenous women.23 These differences in treatment may explain some of the differences in costs 284 
that we observed in our study. Further analysis is required to determine if these differences are driving the 285 
differences in cost in this cohort. 286 
We found no significant differences by remoteness, socio-economic status or Indigenous status in the average 287 
cost per patient for ED presentations during the first 12-months post-diagnosis. Women living in remote areas 288 
had significantly lower costs during 13-to-18 months, and 25-to-30 months post-diagnosis. Women living in 289 
regional or remote areas had lower costs during 31-to-36 months post-diagnosis. We found no significant 290 
differences in any time period when comparing socioeconomic disadvantage. Future work should focus on 291 
determining if there are differences in the reasons for ED presentations in this cohort. 292 
The key strength of this study is the use of population-based data linkage to estimate total costs and costs by 293 
patient characteristics. The use of individual level administrative data overcomes potential measurement bias 294 
(recall, self-report, interviewer, etc), and is advantageous over using population-level data or aggregated data. 295 
However, the use of administrative data also has inherent weaknesses. Notably, the QCR does not routinely 296 
collect stage of disease at diagnosis, therefore we identified the stage as ‘early’, ‘advanced’, and ‘unknown’. We 297 
used aggregated area-level data to classify an individual’s level of socioeconomic disadvantage, as individual or 298 
household financial information is not routinely collected by the QCR. 299 
We quantified the cost to the Australian healthcare system for hospital admissions and ED presentations for 300 
women diagnosed with breast cancer. We identified that the mean hospital episode cost and ED presentation 301 
cost differs for the population groups of interest. This paper is the first in Australia to identify the inequalities in 302 
healthcare expenditure by remoteness, Indigenous status and socio-economic status. This has important 303 
implications for health policy and health service planning in relation to breast cancer prevention, such as 304 
improving participation in the national screening program for these population groups. Planned future studies 305 
will look at service use and drivers of costs for hospital episodes and ED presentations amongst these sub-306 
populations whom experience poorer health outcomes. 307 
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Table 1: Additional descriptive costs to the health system for hospital episodes and ED presentations, for women diagnosed between 1 July 2011 and 30 June 
2012 (weighted) 
 Hospital episodes ED presentations 
Time since 
diagnosis (months) 
Mean ±SD Median IQR Max Mean ±SD Median IQR Max 
0-6  183,767 ± 15,896 15,891 11,054 314,875 1,429 ± 1,122 1,146 1,303 6,724 
7-12 6,579 ± 11,589 2,608 8,626 274,412 1,146 ± 897 979 809 6,286 
13-18 3,246 ± 8,046  505 2,710 171,443 1,123 ± 870 975 609 6,611 
19-24 3,183 ± 8,306  392 1,766 125,954 1,111 ± 987 955 608 10,650 
25-30 3,628 ± 13,196  377 1,854 418,178 1,191 ± 1,032 987 780 8,401 
31-36 3,228 ± 9,477 366 1,616 209,459 1,136 ± 1,027  982 767 8,300 




This study estimated the direct costs to the public healthcare system for admitted and non-admitted 
hospital episodes and ED presentations during the first three-years following a breast cancer 
diagnosis. For women diagnosed with breast cancer, Indigenous status and socioeconomic 
disadvantage were associated with significantly higher costs for admitted and non-admitted hospital 
episodes, after adjusting for relevant confounders (remoteness, age, stage, number of hospital 
episodes, death). Specifically, costs were significantly higher in Indigenous women and women living 
in the most disadvantaged quintile for admitted and non-admitted hospital episodes. There were no 
consistent differences in the costs for ED presentations.  
The findings of this study should be considered in the context of several unavoidable limitations 
inherent to the administrative data used. Firstly, the QCR does not include stage of disease at 
diagnosis, therefore, stage was categorised into early, advanced, and unknown. Secondly, 
remoteness and socioeconomic status were categorised using aggregated area-level data. Thirdly, 
non-admitted hospital services were not captured in the QHAPDC dataset. As described, hospital-
related MBS items were included in the hospital analysis, which may have over-estimated hospital 
services. Finally, co-morbidities were not included in the dataset, and the analysis did not include the 
impact of co-morbidities on the cost. 
This study addressed part of the third aim of the thesis: to quantify the direct costs to the public 
healthcare system and individual for the first three years following a female breast cancer diagnosis, 
and to determine the distribution of these costs by Indigenous status, remoteness, and 
socioeconomic disadvantage. Future studies should consider 1) the drivers of the costs to the hospital 
system and the distribution of these costs, 2) the impact of co-morbidities on the costs, and 3) extend 




Chapter Six: Out-of-hospital costs for women diagnosed 
with breast cancer 
Introduction 
In the previous chapter, the direct costs to the public healthcare system for admitted and non-
admitted hospital episodes and ED presentations during the first three-years following a breast 
cancer diagnosis in women were presented. In this chapter (Chapter Six), the focus remains on costs 
to the public healthcare system, but the emphasis is now on the total cost of MBS services and PBS 
prescriptions for these women.  
At the time of thesis submission, this chapter is under review. It is presented in the thesis in the 
format required by the journal: 
Bates N, Callander E, Lindsay D, Watt K. 2019. Estimating the out-of-hospital costs for 
Australian women diagnosed with breast cancer – using CancerCostMod, a linked 
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Introduction: Breast cancer is the most commonly diagnosed cancer in women in Australia. Although 
survival has improved, there are variations in outcomes by Indigenous status, remoteness, and 
socioeconomic status. This study estimate the cost to the Australian Government for out-of-hospital 
medical services and prescription pharmaceuticals for women diagnosed with breast cancer during the 
first 36-months post-diagnosis; and to determine the distribution of these costs by Indigenous status, 
remoteness, and socioeconomic status. 
Methods: We identified women diagnosed with breast cancer from a larger study, CancerCostMod. 
The base population of CancerCostMod included all cancer diagnoses (01JUL2011-30JUN2012), which 
was then linked to administrative health records (01JUL2011-30JUN2015), and weighted to be 
representative of the Australian population. Our analysis was limited to include costs of out-of-hospital 
medical services identified through the Medicare Benefits Schedule (MBS), and prescription 
pharmaceuticals (Pharmaceutical Benefits Scheme (PBS)). We calculated these costs for MBS and PBS 
for each 6-month period post-diagnosis, and then modelled the mean cost per patient for each period.  
Results: 3,079 women were diagnosed with breast cancer, representing 15,335 Australian women 
after weighting. The total cost for MBS services during the first three years post-diagnosis was $73.7 
million, and an addition $239.2 million for PBS prescriptions. We found no consistent difference in the 
average cost for MBS services by remoteness, Indigenous status or socio-economic status. There were 
consistent differences in the average cost of PBS prescriptions by these characteristics. 
Conclusions: This unique study quantified the total healthcare expenditure for out-of-hospital medical 





Breast cancer is the most commonly diagnosed cancer in women in Australia.1 In 2017, an estimated 
17,586 women were diagnosed with breast cancer,1 and the incidence is expected to rise.2 Survival 
rates for female breast cancer have improved, and are currently at 90%.1 However, there are some 
women who experience poorer survival, including Aboriginal and Torres Strait Islander women 
(hereafter respectfully referred to as Indigenous women), women living outside of metropolitan areas, 
and socioeconomically disadvantaged women.  
Treatment options for female breast cancer include surgery, radiotherapy, chemotherapy, and 
hormonal therapy; or a combination of these. There are many factors to consider when deciding on 
the best treatment, including the type and stage of cancer, hormone status, lymph node status, patient 
history, and the woman’s preference.3 While initially, many of the treatment options may be in a 
hospital setting, women may also need to access some medical services outside of the hospital setting, 
such as General Practitioner (GP) visits, pathology and imaging services, allied health services, and 
pharmacy. Amongst the treatment options is also the choice to be treated within either the private or 
the public healthcare system.  
Australia has a mixed payment system, where the individual may choose to be treated in the private 
and/or public health system. Australia’s universal health insurance scheme, Medicare, provides free 
treatment at a public hospital. If an individual chooses to be treated at a private hospital, Medicare 
may cover a proportion of fees.4 Medicare also contributes a rebate (proportion of the fee) for services 
listed on the Medicare Benefits Schedule (MBS) for services conducted outside of hospitals.4 The MBS 
includes GP visits, some allied health services, pathology, imaging and optometry. For MBS services, if 
the fee charged is greater than the Medicare rebate, than the patient pays a co-payment. If the fee 




The Pharmaceuticals Benefits Scheme (PBS) provides rebates for listed prescription drugs, with the 
patient paying a co-payment, and the Federal government paying the remainder of the charge.4  
To date, there are limited recent studies quantifying the out-of-hospital costs to the Australian 
healthcare system for women diagnosed with breast cancer. Goldsbury et al.5 estimated the excess 
cost of cancer (including breast cancer) in Australia for people aged 45 years and older, compared to 
matched cancer-free controls. Another study estimated the average cost of cancer (including breast) 
for people undergoing chemotherapy in New South Wales.6 However, to the authors’ best knowledge, 
no Australian study has identified the distribution of costs for out-of-hospital medical services and 
prescription, by remoteness, Indigenous status or socio-economic status.  
The most recent Government expenditure report estimated that female breast cancer accounted for 
the greatest healthcare expenditure in females, approximately $235million, however this was for 
2008-09. Out-of-hospital services accounted for approximately $29million, and an additional 
$60million for prescription pharmaceuticals.7 This national report used aggregated data related only 
to specific cancer services, which may underestimate the total costs, and does not allow estimates to 
be stratified for different population groups. The use of individual-level administrative data may 
overcome these limitations. Furthermore, this report is now potentially out-of-date due to increased 
incidence of breast cancer, changes to treatment protocols, and any new additions to the PBS. For 
example, between 2000 and 2012, 23 new anticancer drugs were added to the PBS, including three for 
the treatment of breast cancer.8 The expenditure for anticancer drugs listed on the PBS rose from 
$64.8 in 1999-2000 to $466.3 million in 2011-12.8 
This study used CancerCostMod, a model developed to estimate the healthcare expenditure of people 
diagnosed with cancer using linked administrative data.9,10 We adopted a national healthcare system 




with breast cancer during the first three years following diagnosis; and 2) determine the distribution 
of these costs by Indigenous status, remoteness, and socioeconomic status. 
Methods 
Study population 
The population for this study was sourced from a larger study, ‘CancerCostMod’, described in detail 
elsewhere.9,10 Briefly, the base population was a census of all cancer diagnoses (excluding non-
melanoma skin cancer) recorded by the Queensland Cancer Registry (QCR), Australia between 
1JUL2011 and 30JUN2012 (n=25,553 patients). All new cases of cancer in Australia, except for non-
melanoma skin cancer, are required to be reported to the jurisdiction’s cancer registry.1,11 The QCR 
records were then linked to Queensland Health Admitted Patient Data Collection (QHAPDC) and 
Queensland Health Emergency Department Information Systems (EDIS) by the Queensland Health 
Statistical Services Branch before being linked to MBS and Pharmaceutical Benefits Scheme (PBS) 
records by the Australian Institute of Health and Welfare (AIHW) from 1JUL2011 to 30JUN2015. The 
authors then weighted this base population to the Australian population with cancer, using GREGWT, 
a programmed SAS macro (weighted N=123,900). For this paper, we limited ‘CancerCostMod’ to 
include records of female breast cancer (ICD-O C50). 
Demographics 
Sociodemographic characteristics at the time of diagnosis, such as age, sex, Indigenous status, and 
residential postcode were included in the QCR dataset. The authors mapped the patient postcode at 
diagnosis to the Index of Relative Socio-Economic Disadvantage (IRSD), which is a summary of the 
economic and social conditions of an area, and is a measure of relative socioeconomic disadvantage.12 
IRSD was collapsed into quintiles (Q1=most disadvantaged, and Q5=least disadvantaged). Postcode 




then categorised into ‘metropolitan’, ‘regional’ (inner and outer), and ‘remote (remote and very 
remote’). Records with missing postcodes were unable to be mapped to IRSD or remoteness. As 
described previously,9 Indigenous status was recorded for 87% of our original QCR dataset. We used 
multiple imputation to impute missing Indigenous status.9 
Breast cancer staging 
The stage at diagnosis is not routinely collected by the QCR, however, using methods published in 
previous Queensland studies,14,15 breast cancer stage was categorised as:   
 ‘Early’: tumour size ≤ 20mm, and no evidence of lymph node involvement; 
 ‘Advanced’: tumour size > 20mm, or any evidence of lymph node involvement regardless of 
tumour size, or if the diagnosis was because of metastatic disease; 
 ‘Unknown’: lymph node involvement or tumour size unknown. 
Assigning costs to MBS services and PBS prescriptions 
For this study, we limited CancerCostMod to out-of-hospital MBS services (i.e., excluding item codes 
included in the hospital, which have been described previously9), and PBS prescriptions. The variables 
related to MBS services included information on the date of service/prescription, patient postcode, 
provider postcode, item code, full charge, Government rebate, and patient co-payment. This dataset 
excluded any services or items not covered by MBS or PBS; items claimed through the Department of 
Veteran Affairs; and prescriptions distributed under alternative arrangements.  
Monthly rebate amounts were calculated separately for MBS services and PBS prescriptions for each 
individual from the date of diagnosis (time=0), to 36-months following diagnosis. The rebate amount 
is the amount paid by the Federal Government per service. From hereafter this will be referred to as 




recorded for subsequent months. All costs are reported in Australian dollars (AUD), adjusted to the 
2016-17 financial year using the Reserve Bank of Australia inflation calculator.16 
Statistical analysis 
Descriptive analyses were undertaken to ascertain the demographic characteristics of women 
diagnosed with breast cancer. We aggregated the costs into six-month time periods from date of 
diagnosis (t=0) to 36 months post-diagnosis for MBS services and PBS prescriptions. The dataset was 
limited to those who had at least one MBS service or PBS prescription at each time period to calculate 
the average number and average cost during each of these time periods. 
Finally, we used generalized linear models with a gamma distribution and a log link function to model 
the mean costs per patient for each six-month time period. This included the number of months the 
patient survived as an offset to the model. Independent variables were: Indigenous identification 
(reference group=non-Indigenous women), age group (reference group=18-44 years), remoteness 
(reference group=metropolitan), socioeconomic disadvantage (reference group=IRSD Q5 (least 
disadvantaged)), breast cancer stage (reference=early), number of MBS services or PBS prescriptions 
during the time period being modelled (continuous), and death during the time period being modelled.  
All analyses were undertaken using SAS V9.4 (SAS Institute Inc., Cary, NC, USA). Human Research Ethics 
approval was obtained from the Townsville Hospital and Health Service Human Research Ethics 
Committee (HREC) (HREC/16/QTHS/11), AIHW HREC (EO2017/1/343) and James Cook University HREC 
(H6678). Permission to waive consent was approved from Queensland Health under the Public Health 
Act 2005. No identifiable information was provided to the authors. 
Results 
In Queensland, 3,079 women were diagnosed with breast cancer between 01JUL2011 and 30JUN2012, 




at diagnosis of women diagnosed with breast cancer. The average age at diagnosis was 61 years (SD: 
14 years). 




N (weighted) 15,335 
Age group (years)  
18-44 (%) 1,848 (12.1) 
45-64 (%) 7,536 (49.1) 
≥65 (%) 5,951 (38.8) 
12-month mortality 646 (4.2) 
Indigenous status  
Indigenous women (%) 248 (1.6) 
Non-Indigenous women (%) 15,087 (98.4) 
Remoteness*  
Metropolitan (%) 7,712 (50.6) 
Regional (%) 6,359 (41.7) 
Remote (%) 1,180 (7.7) 
Index of Relative Socio-Economic Disadvantage*  
Q1 (most disadvantaged) (%) 1,095 (7.2) 
Q2 (%) 767 (5.0) 
Q3 (%) 2,483 (16.3) 
Q4 (%) 6,669 (43.7) 
Q5 (least disadvantaged) (%) 4,236 (27.8) 
Breast cancer stage  
Early (%) 6,695 (43.6) 
Advanced (%) 7,174 (46.8) 
Unknown (%) 1,466 (9.6) 
*Those with missing postcode data at diagnosis were excluded (weighted n=85) 
During the first three years after diagnosis, the total MBS costs were $73.7 million (Table 2). The first 
six-months following diagnosis incurred the greatest total number of MBS services (429,278), and the 
greatest total MBS costs of approximately $25 million. The average total cost per person during the 



















Costs (AU$) (SD) 
0-6  14,884      429,278  25,001,241  29 (21) 1,680 (1,200) 
7-12  14,022      271,654  11,437,954  19 (16) 816 (874) 
13-18  13,991      248,924  11,099,762  18 (15) 793 (776) 
19-24  13,488      223,412  8,748,235  17 (15) 649 (707) 
25-30  13,499      226,000  9,222,178  17 (14) 683 (646) 
31-36  12,947      209,753  8,199,681  16 (14) 633 (622) 
 
The total number of PBS prescriptions for women diagnosed with breast cancer was 1,447,350 
prescriptions, which totalled approximately $239.2 million (Table 3). The average cost of PBS 
prescriptions during the first three-years following diagnosis was $16,404 (SD: 21,761) and the average 
number of PBS prescriptions was 99 (SD: 90).  















Cost (AU$) (SD) 
0-6  14,034 355,884   105,927,632  25 (19) 7,548 (9,921) 
7-12  13,421 246,277      63,063,993  18 (17)  4,699 (9,299) 
13-18  12,852 223,778      33,743,789  17 (17) 2,626 (5,985) 
19-24  12,360 211,787      13,817,867  17 (17)  1,118 (2,353) 
25-30  11,918 208,215      12,273,637  17 (17)  1,030 (2,697) 
31-36  11,515 201,408      10,383,381  17 (17)  902 (2,057) 
Figure 1 shows the average cost for MBS and PBS by age group (A and B), stage of disease (C and D), 
Indigenous status (E and F), remoteness (G and H), and socioeconomic disadvantage (I and J). The first 
six-months accounted for a greater average cost per person for each of the characteristics presented 
in Figure 1. Interestingly, there was little variation in average costs per person in each of the six-month 




some differences in average cost per person by age-group; costs were higher in younger women for 
both MBS services and PBS prescriptions than women aged 45-64 years, and 65 years and older. There 
were also differences in the average cost per person for MBS services and PBS prescriptions by cancer 
stage. MBS rebates in the first 6-months were greater in women diagnosed with advanced stage 
disease, and PBS prescriptions were also higher in this group in both the first 6-months, and 7-to-12 
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Figure 1: Average cost per patient for MBS services and PBS prescriptions by age group, breast cancer 
stage, Indigenous status, remoteness, and socioeconomic disadvantage. Average costs per patient 
were calculated for each six-month period from diagnosis to 3-years. The figures on the left present 
the unadjusted average costs for MBS services, and on the right present the unadjusted average cost 




Table 4 shows the parameter estimates produced by the six generalised linear models, estimating the 
mean costs for MBS services per patient for each six-month time period, adjusting for Indigenous 
status, remoteness, IRSD quintile, age group at diagnosis, stage of disease at diagnosis, and death 
during time period being analysed. There was no significant difference in the average MBS costs by 
Indigenous status across each of the time periods. Costs were 10% higher among women living in 
regional areas than those living in metropolitan areas during the 19-to-24 month period. Compared to 
women in the least disadvantaged quintile (Q5), costs were 10% higher in women living in Q4 during 
the first six-months post-diagnosis, and 15% lower for women living in Q2 (2nd most disadvantaged) 
during the period of 13-to-18 months. Compared to women in the age group 18 to 44 years, costs were 
consistently lower among women in the older two age groups for each of the six-month periods 
analysed. Women diagnosed with advanced stage disease had significantly higher costs during the first 
three six-month periods analysed, and for the 31-to-36 months period; however, there was no 





Table 4: Parameter estimates of independent variables in generalised linear regression model of the MBS costs for women diagnosed with breast cancer (weighted data).  






































































































































































Death during period 











The ratio presented are relative to the reference group: Indigenous status (reference=non-Indigenous women), age group (reference=18-44 years), remoteness 
(reference=metropolitan), socioeconomic disadvantage (reference=IRSD Q5 (least disadvantaged)), breast cancer stage (reference=early), number of services accessed during 
the period analysed, and death during the time period being modelled. 





Finally, we examined the cost per patient for each six-month time period for PBS prescriptions, 
adjusting for Indigenous status, remoteness, IRSD quintile, age group at diagnosis, stage of disease at 
diagnosis, and death during time period being analysed (Table 5). Costs were significantly lower among 
Indigenous for PBS items during 7-to-12 months (65% less), and 13-to-18 months (63% less) compared 
to their non-Indigenous counterparts. Compared to women living in metropolitan areas, women living 
in regional areas had 12% higher costs in the first six-months, and 24% higher costs during months 7-
to-12. Compared to women living in the least disadvantaged quintile (Q5), women living in the first, 
third, and fourth quintiles had significantly lower costs for PBS prescriptions during the first 12 months, 






Table 5: Parameter estimates of independent variables in generalised linear regression model of the costs for PBS prescriptions for women diagnosed with breast cancer. 
Weighted data presented. 
  0-6 months  7-12 months  13-18 months  19-24 months  25-30 months  31-36 months 

































































































































































Death during period 











The ratio presented are relative to the reference group: Indigenous status (reference=non-Indigenous women), age group (reference=18-44 years), remoteness 
(reference=metropolitan), socioeconomic disadvantage (reference=IRSD Q5 (least disadvantaged)), breast cancer stage (reference=early), number of services accessed during 
the period analysed, and death during the time period being modelled. 





This novel study is the first in Australia to use individual-level linked administrative data to quantify 
the out-of-hospital healthcare costs to the Federal Government for women diagnosed with breast 
cancer. We estimate that the total costs to Medicare for MBS services during three years post-
diagnosis was $73.7 million, and $239.2 million for PBS prescriptions. The average cost per patient over 
the study period was $4,911 for MBS services, and $16,404 for PBS prescriptions. 
We estimated that the first six-months accounted for the highest costs during the study period 
following a female breast cancer diagnosis. This is similar to other studies which analyzed the cost of 
breast cancer by phase of care that have reported that the initial phase (defined by authors as the first 
3-months, 6-months, or 12-months) and the terminal phase (last 12-months of life) have the highest 
costs.5,17-19 At this time, we were unable to estimate the cost of breast cancer by phase of care, due to 
the relatively short study period. This may be possible in future studies, if the study period for 
CancerCostMod is expanded. 
Our study found that during the first year post-diagnosis, MBS services accounted for approximately 
$36 million, and PBS prescriptions accounted for approximately $169 million. These findings are 
greater than that reported in the AIHW report, which estimated the cost of breast cancer to be $29 
million for out-of-hospital, and $60 million for prescription pharmaceuticals in 2008-09.7 Our study 
found a large increase in pharmaceuticals compared to the 2008-09 report, and there may be several 
possible reasons, including the listing of new anticancer medications on the PBS. In Australia, the 
Pharmaceutical Benefits Advisory Committee reviews all submissions for new medications or changes 
to current medications to be listed on the PBS. Karikios et al.8 reported three new breast cancer 
medications listed on the PBS between 2000 and 2012 (Trastuzumab 2007, Lapatinib 2008, and nab-
Paclitaxel 2009). Our findings seem to confirm that the cost of cancer to the PBS has increased for 




Previous studies have identified differences in clinical management of female breast cancer for the 
population groups covered in this study.20-23 However, the majority of these other studies focused on 
surgical and radiotherapy treatment following diagnosis, which would be accessed through a hospital 
setting, and thus excluded from the analysis in this study. Our study found no significant difference in 
the average cost of MBS services between Indigenous and non-Indigenous women diagnosed with 
breast cancer. Although there were some six-month periods with significant differences in the average 
cost of MBS services by remoteness, or socioeconomic status, we did not observe a consistent 
difference.  
These findings are interesting, as it is well documented that there are many barriers in accessing 
primary health care for Indigenous Australians, people living in remote areas, and socioeconomically 
disadvantaged persons.11,24-26 Barriers include reduced physical access to health services outside of 
urban areas,24 and availability of culturally appropriate services.25 The out-of-pocket (OOP) costs are 
also a potential barrier to accessing services, which may be more acutely felt by these population 
groups.11,25,26 The Medicare Safety Net is a policy to reduce high OOP costs, in which once an individual 
or family group reach a threshold, they will receive a higher proportion of rebate paid by Medicare, 
reducing their co-payment.4 The lack of differences in average cost of rebates paid, may mean that 
these policies are supporting equitable access to services, but this study did not compare the number 
or type of services accessed by this cohort. It is possible that there were differences in the type of MBS 
services accessed, and the number of times these services were accessed. Due to potential OOP fees 
associated with medical services, it is possible that some individuals may choose to access services 
which incur little or no OOP fee (ie bulk-billed services, or free public hospital treatment). For example, 
GP bulk-billing rates have been increasing in Australia, and in 2016-17, 86% of GP attendances were 
bulk-billed.11 This may be of particular interest for population groups who may be at greater risk of 
financial hardship. Future studies should examine if there are any differences in the number and type 




In contrast to the findings for MBS services, we did find significant differences in the average cost of 
PBS prescriptions by Indigenous status, remoteness, and socioeconomic disadvantage. Costs were 
significantly lower among Indigenous women diagnosed with breast cancer during months 7-to-12 and 
13-to-18. Compared to women living in the least disadvantaged quintile (Q5), women living in Q1 and 
Q3-4 had significantly lower costs during the 0-to-6 months, and 7-to-12 months post-diagnosis. 
Whereas, women from regional areas had greater costs than their metropolitan counterparts during 
the first 6-months and 7-to-12 months. Future research should investigate if there are differences in 
prescribing and uptake of recommended treatment in this cohort.  
This main strength of this paper is that the base population was a census of all women diagnosed with 
breast cancer in Queensland, which we then weighted to be representative of the Australian 
population. The use of administrative data allowed us to include all out-of-hospital MBS services, and 
PBS prescriptions that were reimbursed by the Australian Government. There are also weaknesses 
associated with administrative data. For example, the stage of disease at diagnosis is not routinely 
collected in Australia, therefore we categorized the stage of disease as ‘early’, ‘advanced’, and 
‘unknown’. Our dataset did not contain individual or household income, and we therefore used the 
ABS area-level data to map postcode to socioeconomic disadvantage. The use of area-based 
socioeconomic measures may not reflect a person’s actual socioeconomic position as it is an area-
based measure. Another limitation of our study was that our dataset excluded any services or items 
not covered by MBS or PBS, as outlined in the methods. 
For the first time in Australia, this study identified the total healthcare expenditure for MBS services 
and PBS prescriptions adjusting for patient demographics. In the future, we plan to expand the 
population of CancerCostMod to include cancer diagnoses past the end of our current range, and to 
increase the years of linked administrative data. As this will increase both our sample size and study 
period, this will allow us to identify the costs by phase of disease (initial, continuing, and terminal 




listed PBS medications. Future studies should also determine if there are any differences in the access 
of MBS services and PBS prescriptions.  
The cost to Medicare for MBS services and PBS rebates for women diagnosed with breast cancer is 
substantial. This is the first of its kind in Australia to used linked administrative to estimate these costs 
for population groups experiencing poorer health outcomes following a breast cancer diagnosis. 
Although we found some differences in the cost for MBS services, there was not a consistent pattern 
across the first three-years following diagnosis. We did find more significant differences in the average 
cost for PBS prescriptions by Indigenous status, remoteness and socio-economic status.  
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Table 2: Additional descriptive costs to the health system for MBS services and PBS prescriptions, for women diagnosed between 1 July 2011 and 30 June 
2012 (weighted) 
MBS services PBS prescriptions 
Time since 
diagnosis (months) 
Mean ±SD Median IQR Max Mean ±SD Median IQR Max 
0-6 16,80 ± 1,200 1,472 1,633 9,105 7,548 ± 9,921 2,026 11,480 62,048 
7-12 816 ± 874 545 800 6,054 4,699 ± 9,299 1,082 2,700 51,641 
13-18 793 ± 776 548 745 8,730 2,626 ± 5,985 750 1,282 62,553 
19-24 649 ± 707 428 659 8,686 1,118 ± 2,353 616 984 31,327 
25-30 683 ± 646 488 649 6,341 1,030 ± 2,697 529 897 45,801 
31-36 633 ± 622 445 675 5,643 902 ± 2,057 468 778 29,221 
TOTAL 4,911 ± 3,199 4,266 3,733 26,340 16,404 ± 21,761 8,756 16,240 139,168 
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Summary 
This study found a large increase in the rebates paid for both PBS prescriptions and MBS services 
compared to the 2008-09 national expenditure report for cancers and other neoplasms, confirming 
the rising costs in both of these areas. After adjusting for relevant confounders (age group, stage, 
number of services, and death), there were no consistent differences in the MBS rebates paid as a 
function of Indigenous status, remoteness, or socio-economic disadvantage. However, there were 
differences in the PBS rebates paid by the Australian Government on these characteristics. 
Specifically, costs were significantly higher in Indigenous women during months 7-to-12 and 13-to-
18, women living in regional areas during the first 12-months, and women living in most 
disadvantaged quintile (Q1), Q3-4 during the first 12-months. 
The same dataset was used in chapter 6 as in chapter 5, hence the limitations inherent to the dataset 
are the same. These limitations included limited data on stage of disease at diagnosis, using 
aggregated area-level data for socioeconomic status and remoteness, and that the impact of co-
morbidities were not included in the analysis. Furthermore, the PBS dataset did not include items 
dispensed to public patients in public hospitals, or medications dispensed under alternative funding 
schemes. As such, not all chemotherapy medications would be included in the dataset, and would 
underestimate the expenditure associated with pharmaceutical use. 
This study addressed part of the third aim of the thesis: to quantify the direct costs to the public 
healthcare system and individual for the first three years following a female breast cancer diagnosis, 
and to determine the distribution of these costs by Indigenous status, remoteness, and 
socioeconomic disadvantage. This study did find differences in costs for Indigenous women during 
months 7-to-12 and 13-to-18, however, it was outside the scope of the study to conduct an in-depth 
exploration of these differences in relation to treatment options and pathways. Future studies are 
planned to consider 1) the drivers of out-of-hospital costs, specifically in relation to treatment options 
and pathways for Indigenous breast cancer patients and Indigenous patients with any type of cancer, 
2) the impact of co-morbidities on the costs, and 3) extend the timeframes to provide a continuous
analysis of the costs and changes of costs across time. 
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Chapter Seven: Patient co-payments for women 
diagnosed with breast cancer 
Introduction 
Chapters Five and Six of this thesis presented the health service costs associated with breast cancer 
among women in the three years following diagnosis, using CancerCostMod. In this chapter, the focus 
is on costs to the individual. Specifically, CancerCostMod is used to estimate the total patient co-
payments for MBS services and PBS prescriptions, and to determine the distribution of these co-
payment costs by Indigenous status, remoteness, and socioeconomic status. 
This chapter is inserted as published in the Supportive Care in Cancer: 
- Bates N, Callander E, Lindsay D, Watt K. Patient co-payments for women diagnosed with
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Abstract
Purpose Among Australian women, breast cancer is the most commonly diagnosed cancer. The out-of-pocket cost to the patient
is substantial. This study estimates the total patient co-payments for Medicare Benefits Schedule (MBS) and Pharmaceutical
Benefits Scheme (PBS) for women diagnosed with breast cancer and determined the distribution of these costs by Indigenous
status, remoteness, and socioeconomic status.
Methods Data on women diagnosed with breast cancer in Queensland between 01 July 2011 and 30 June 2012 were obtained
from the Queensland Cancer Registry and linked with hospital and Emergency Department Admissions, and MBS and PBS
records for the 3 years post-diagnosis. The data were then weighted to be representative of the Australian population. The co-
payment charged for MBS services and PBS prescriptions was summed. We modelled the mean co-payment per patient during
each 6-month time period for MBS services and PBS prescriptions.
Results A total of 3079 women were diagnosed with breast cancer in Queensland during the 12-month study period, representing
15,335 Australian women after weighting. In the first 3 years post-diagnosis, the median co-payment for MBS services was AU$
748 (IQR, AU$87–2121; maximum AU$32,249), and for PBS prescriptions was AU$ 835 (IQR, AU$480–1289; maximum
AU$5390). There were significant differences in the co-payments for MBS services and PBS prescriptions by Indigenous status
and socioeconomic disadvantage, but none for remoteness.
Conclusions Women incur high patient co-payments in the first 3 years post-diagnosis. These costs vary greatly by patient.
Potential costs should be discussed with women throughout their treatment, to allow women greater choice in the most appro-
priate care for their situation.
Keywords Breast cancer . Patient co-payment . Financial toxicity . Australia
Introduction
In 2018, it was anticipated that an estimated 18,087 women
would be diagnosed with breast cancer, which is the most
commonly diagnosed cancer in women within Australia [1].
Most recent estimates suggest that 5-year survival for women
diagnosed with breast cancer in Australia is 90% [1].
However, improvements in treatment and survival come at a
cost to both the healthcare system and the patient. Recent
Australian studies have highlighted that women diagnosed
with breast cancer will face significant out-of-pocket (OOP)
costs [2–4]. These high OOP costs may result in people diag-
nosed with cancer delaying or forgoing healthcare [5–7]. This
financial burden placed on individuals and their families due
to a cancer diagnosis is known as ‘financial toxicity’ [8].
Australia has a universal healthcare system, Medicare,
which has three parts: hospital, medical, and prescription
pharmaceutical. Individuals receive free treatment at public
hospitals and free or subsidized medical services outside of
public hospitals. The Medicare Benefits Schedule (MBS) in-
cludes medical services such as attendances by medical doc-
tors, tests and scans, most procedures performed by doctors,
optometrists, and some allied health services. For items listed
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on the MBS, Medicare pays a rebate (proportion of the fee) to
the service provider. If the fee charged is equal to the rebate,
the patient incurs no co-payment (the service is ‘bulk-billed’);
however, if the fee charged by the service provider is greater
than the rebate, the patient will be charged an OOP co-
payment [9]. Medical service providers in Australia may set
their own fees, resulting in unregulated OOP fees for patient
[10].
The Pharmaceutical Benefits Scheme (PBS) is a list of
approved prescription pharmaceuticals, for which the patient
is charged a co-payment, and the Australian Government
funds the remainder of the fee [9]. There are also a number
of policies in place to protect individuals and family groups
from spending a high amount on patient co-payments during
the year. Individuals and families with a concession card or
health care card may be eligible to obtain medications and
health services at a lower cost. In addition to this, the respec-
tive Medicare and PBS Safety Nets have a number of thresh-
olds which depend on the individual or family group circum-
stances, such as concessional cardholders. Once an individual
or family group reach the threshold, they will have a higher
proportion of their service/prescription subsidized for the re-
mainder of the year [9]. In 2010, the Closing the Gap (CTG)
PBS prescriptions were introduced, which allowed
Indigenous Australians to have access to PBS medicines at a
lower cost or for free [11].
There is growing concern regarding the high OOP expen-
diture associated with a breast cancer diagnosis. A recent re-
port commissioned by the Breast Cancer Network Australia
indicated that the median OOP for women was $4809 in the
first 5 years post-diagnosis (interquartile range (IQR), $1510
and $17,200) [4]. Although similar OOP costs for women
living in urban and non-urban areas were reported, women
living in non-urban areas were found to access fewer services.
Women living in non-urban areas were also reported to spend
more on accommodation costs compared with women from
urban areas [4]. In a recent Queensland study using adminis-
trative data to estimate the OOP costs of major cancers, the
median co-payment for women diagnosed with breast cancer
was $4192 (IQR, 1165–7459) during the first 2 years follow-
ing diagnosis [3]. However, the sample was relatively small
(84 women diagnosed with breast cancer), and the study did
not compare costs by sub-populations such as Indigenous sta-
tus, remoteness, or socioeconomic status. A longitudinal study
of 287 Queensland women diagnosed with breast cancer
found that the greatest total costs (direct and indirect) were
during the first 6 months post-diagnosis, followed by a grad-
ual decline over the next 18 months [2]. Costs were higher for
women diagnosed with positive lymph nodes and for younger
women (≤ 50 years) [2]. In a study of people diagnosed with
cancer and being treated at The Townsville Hospital
(Queensland), travel expenses accounted for the greatest
OOP costs (71%), followed by medical services (10%) and
medications (9%) [12]. Costs were highest for people living
further away from the hospital and for people receiving radio-
therapy [12]. The two latter studies relied on self-reported
costs, which have some limitations associated with recall.
The use of linked administrative data may overcome this
shortcoming.
A linked administrative data model (CancerCostMod) was
used in the present study to estimate the patient co-payments
for women diagnosed with breast cancer. For this study, we
adopted an individual perspective to (1) estimate the total
patient co-payments for MBS services and PBS prescriptions
for women diagnosed with breast cancer during the first
3 years following diagnosis and (2) determine the distribution




The methodology for ‘CancerCostMod’ has been previously
described [13]. Briefly, this dataset comprises all cancer diag-
noses (excluding non-melanoma skin cancer) in the
Queensland Cancer Registry (QCR) between 01 July 2011
and 30 June 2012 (N = 25,553 patients), which were then
linked with data on hospital admissions (Queensland Health
Admitted Patient Data Collection (QHAPDC)) ED presenta-
tions (Emergency Department Information Systems (EDIS)),
MBS, and PBS from 01 July 2011 and 30 June 2015. The
Queensland Health Statistical Services Branch completed the
linkage of QCR, QHAPDC, and EDIS, and then the
Australian Institute of Health andWelfare (AIHW) linked this
dataset to MBS and PBS. The base population was weighted
by the authors to the Australian population to be representa-
tive of the Australian population. The authors used a pro-
grammed SAS macro, GREGWT (weighted N = 123,900)
[13]. The 2012 Australian Cancer Database was used as the
benchmark for the weighting [14]. For this study, we extracted
from ‘CancerCostMod’ records of female breast cancer (ICD-
O C50) in those aged 18 years or greater at the time of
diagnosis.
Sociodemographic characteristics
Sociodemographic variables obtained in the QCR dataset at
the time of diagnosis were age, sex, Indigenous status, and
residential postcode. Postcode was mapped to the Index of
Relative Socio-Economic Disadvantage (IRSD) and collapsed
into quintiles (Q1 =most disadvantaged, and Q5 = least disad-
vantaged). The IRSD is a summary of the economic and social
conditions of an area and is a measure of relative socioeco-
nomic disadvantage [15]. Postcode was also mapped to the
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Australian Statistical Geography Standard [16] to obtain a
measure of remoteness: metropolitan, regional (inner and out-
er), and remote (remote and very remote). The original QCR
dataset had 151 records with missing postcodes were unable
to be mapped to IRSD or remoteness. Indigenous status was
recorded for 87% of the sample obtained from the QCR. The
authors imputed records with missing Indigenous status.
Briefly, records of patients with missing Indigenous status
who lived in a local government area where ≥ 75% of the
population were Indigenous Australian were assigned to be
‘Indigenous.’ We then used multiple imputation to impute
the remaining records with missing Indigenous status. These
methods have been described in more detail previously [13].
Breast cancer staging
The stage at diagnosis is not routinely collected by jurisdic-
tional cancer registries in Australia. As such, we categorized
stages into ‘early’ (tumour size ≤ 20 mm with no evidence of
lymph node involvement), ‘advanced’ (tumour size > 20 mm,
or if any lymph node involvement regardless of size, or if there
was metastatic disease), and ‘unknown’ (tumour size or lymph
node involvement was unknown) using similar methods pub-
lished in previous Queensland studies [17, 18].
Assigning patient co-payments to MBS services
and PBS prescriptions
The MBS and PBS datasets used in developing
CancerCostMod included information on the date of service/
prescription, patient postcode, provider postcode, item code,
full charge, Government rebate, and patient co-payment. The
patient co-payment was summed monthly for MBS services
and PBS prescriptions from the date of diagnosis (time = 0)
for 36 months following diagnosis. If an individual died dur-
ing the first 3 years following diagnosis, no costs were record-
ed for subsequent months following death. All co-payments
were adjusted to the 2016–2017 financial year using the
Reserve Bank of Australia inflation calculator [19]. All costs
are reported in Australian dollars (AUD).
The MBS and PBS datasets include all MBS services and
PBS prescriptions, which includes oncology and non-
oncology medical services and prescriptions. This study ex-
cluded any costs associated with treatment that was not cov-
ered by Medicare, such as some medical services, over-the-
counter, or private prescriptions. Other OOP costs such as
private health insurance, hospital excess or charges, travel,
accommodation, food, or indirect costs due to changes in la-
bour force participation for the patient (and their caregiver/s)
were also excluded. Patient comorbidities were also excluded
from the dataset and, therefore, not adjusted for in the analysis.
Statistical analysis
Descriptive analyses were conducted to determine the charac-
teristics of women diagnosed with breast cancer. To describe
the total co-payment costs for this sample, we aggregated the
co-payments for MBS and PBS separately into 6-month time
periods from the date of diagnosis (t = 0) to 36 months post-
diagnosis. We report the total and average patient co-payment
separately for MBS services and PBS prescriptions during
each of the time periods analysed (limited to those who
accessed at least one health event).
Finally, we modelled the mean patient co-payment during
each 6-month time period using generalized linear models,
using a negative binomial regression, and a log link function.
There were six separate models (one for each 6-month period)
for MBS co-payments and 6 separate models for PBS co-pay-
ments. Covariates included in these analyses were Indigenous
status (reference = non-Indigenous women), age group (refer-
ence = 18–44 years), remoteness (reference = metropolitan),
socioeconomic disadvantage (reference = IRSD Q5 (least dis-
advantaged)), breast cancer stage (reference = early), number
of medical services accessed during the period analysed, and
death during the time period being modelled. These are vari-
ables that may have influenced treatment and therefore costs
associated with treatment. The models also included the num-
ber of months the individual survived as an offset to the mod-
el. All analyses were undertaken using SAS V9.4 (SAS
Institute Inc., Cary, NC, USA).
Human Research Ethics approval was obtained from the
Townsville Hospital and Health Service Human Research
Ethics Committee (HREC) (HREC/16/QTHS/11), AIHW
HREC (EO2017/1/343), and James Cook University HREC
(H6678). Permission to waive consent was approved from
Queensland Health under the Public Health Act 2005. No
identifiable information was provided to the authors.
Results
Between 1 July 2011 and 30 June 2012, 3079 women were
diagnosed with breast cancer in Queensland. This represents
15,335 Australian women once weighted. Demographic char-
acteristics at diagnosis are shown in Table 1. The mean age for
this cohort was 61 years (SD, 14 years). Demographic char-
acteristics were similar for the weighted and unweighted
sample.
During the first 12 months following diagnosis, 646 wom-
en passed away. Of this, 44% lived in metropolitan areas, 36%
lived in regional areas, and 11% lived in remote areas (please
note that due to missing postcode data, this does not add to
100%). Of those who passed away during the first 12 months
following diagnosis, 7% lived in the most disadvantaged areas
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(IRSD Q1), 3% lived in Q2, 16% lived in Q3, 46% lived in
Q4, and 20% lived in Q5 (least disadvantaged). Table 2
describes the stages of disease at diagnosis for Australian
women diagnosed with breast cancer by Indigenous status,
remoteness, and socioeconomic status.
Table 3 describes the number of MBS services and PBS
prescriptions accessed by women diagnosed with breast can-
cer during the first 3 years post-diagnosis. On average, each
woman accessed 233 services MBS services (SD, 144) during
the first 3 years following a breast cancer diagnosis and an
average of 99 PBS prescriptions (SD, 90).
A summary of the patient co-payments for MBS services
and PBS prescriptions over the first 3 years following diagno-
sis is reported in Table 4. During the first 3 years post-diag-
nosis, the average co-payments for MBS services was
AU$1440 (SD, $1946). For MBS patient co-payments, the
standard deviation was larger than the mean in each of the 6-
month periods, indicating a wide dispersion in the average
patient co-payment between individuals. This was not ob-
served for PBS prescriptions. During the first 3 years post-
diagnosis, the average co-payments for PBS prescriptions
was AU$974 (SD, $707).
The average patient co-payments for MBS services and
PBS prescriptions are shown in Fig. 1 by age group (panels
a and b), stage of disease (panels c and d), Indigenous status
(panels e and f), remoteness (panels g and h), and socioeco-
nomic disadvantage (panels i and j). In most of the panels, the
first 6 months following diagnosis accounted for a higher
proportion of patient co-payments. There is some variation
in the average co-payment for MBS services during the 0–6
and 7–12 months post-diagnosis by age group and stage of
disease, but after 12 months, there is little to no variation.
There is some variation in the average co-payment for PBS
prescriptions over the first 6 months by age group and stage
of disease. Indigenous women have lower average patient
co-payments for both MBS services and PBS prescriptions
across all time periods. There was some variation observed
in the average patient co-payment for MBS services when
Table 1 Demographic characteristics at diagnosis of Australian women






18–44 years (%) 1848 (12.1)
45–64 years (%) 7536 (49.1)
≥ 64 years (%) 5951 (38.8)
12-month mortality 646 (4.2)
Indigenous status
Indigenous women (%) 248 (1.6)
Non-Indigenous women (%) 15,087 (98.4)
Remoteness*
Metropolitan (%) 7712 (50.6)
Regional (%) 6359 (41.7)
Remote (%) 1180 (7.7)
Index of Relative Socio-Economic Disadvantage*
Quintile 1 (most disadvantaged) (%) 1095 (7.2)
Quintile 2 (%) 767 (5.0)
Quintile 3 (%) 2483 (16.3)
Quintile 4 (%) 6669 (43.7)
Quintile 5 (least disadvantaged) (%) 4236 (27.8)
Breast cancer stage
Early (%) 6695 (43.6)
Advanced (%) 7174 (46.8)
Unknown (%) 1466 (9.6)
*Those with missing postcode data at diagnosis were excluded (weighted
n = 85)
Table 2 Stages of disease at
diagnosis of Australian women
diagnosed with breast cancer
between 1 July 2011 and 30
June 2012 (weighted)
Early Advanced Unknown
Indigenous Australian (%) 75 (30) 123 (50) 50 (20)
Non-Indigenous Australian women (%) 6620 (44) 7052 (47) 1415 (9)
Remoteness**
Major city (%) 3424 (44) 3567 (46) 721 (9)
Regional (%) 2757 (43) 3066 (48) 536 (8)
Remote (%) 514 (44) 537 (46) 129 (11)
Index of Relative Socio-Economic Disadvantage**
Quintile 1 (most disadvantaged) (%) 439 (40) 557 (51) 99 (9)
Quintile 2 (%) 368 (48) 351 (46) 49 (6)
Quintile 3 (%) 1085 (44) 1188 (48) 210 (9)
Quintile 4 (%) 3018 (45) 3078 (46) 573 (9)
Quintile 5 (least disadvantaged) (%) 1786 (42) 1995 (47) 455 (11)
**Those with missing postcode data at diagnosis were excluded (weighted n = 85)
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comparing by remoteness and socioeconomic disadvantage.
Women living in metropolitan areas appear to have slightly
higher co-payments for MBS services throughout the first
3 years compared with women living in regional and remote
areas. Women living in the least disadvantaged quintiles (Q4
and Q5) had higher patient co-payments for MBS services
compared with those living in quintiles 1–3. There was very
little variation in the patient co-payment for PBS prescriptions
by remoteness or socioeconomic disadvantage.
Table 5 shows the parameter estimates produced by the six
generalized linear models, estimating the mean patient co-
payment per patient for each 6-month time period for MBS
services, adjusting for Indigenous status, remoteness, socio-
economic status, age group at diagnosis, stage of disease at
diagnosis, number of MBS services during period analysed,
and death during time period being analysed. For MBS ser-
vices, co-payments were 82% lower in Indigenous women
during 0–6 months and 79% lower during the 7–12 months
post-diagnosis compared with those in non-Indigenous wom-
en. There were no consistent differences between areas of
remoteness. Compared with women living in the least disad-
vantaged area (Q5), women living in Q1, Q2, and Q3 had
significantly lower costs for 0–6 months and 7–12 months.
Finally, we examined the mean co-payment per patient for
each 6-month time period for PBS services, adjusting for
indigenous status, remoteness, socioeconomic status, age
group at diagnosis, stage of disease at diagnosis, number of
PBS services during the period analysed, and death during
the time period being analysed (Table 6). Co-payments were
significantly lower for Indigenous women during each of the 6-
month periods analysed compared with those for non-
Indigenous women (ranging from 41% less during months 7–
12, to 30% less during 19–24 months). There were no signif-
icant differences by remoteness in any of the 6-month periods
analysed. Compared with women living in the least disadvan-
taged quintile (Q5), patient co-payments reduced with increas-
ing disadvantage in the first 6 months post-diagnosis (Q1, 21%
fewer; Q4, 13% fewer). Women from the most disadvantaged
quintile also had 18% fewer costs during 13–18 months, 15%
fewer costs during 19–24 months, 19% fewer costs during 25–
30 months, and 16% fewer costs during 31–36 months.
Discussion
The total patient co-payments for the first 3 years for women
diagnosed with breast cancer was approximately $21.7 mil-
lion for MBS services and $14.2 million for PBS prescrip-
tions. The average patient co-payment for MBS services dur-
ing the first 3 years was $1440, with some women paying a
maximum of $32,249. In addition, the average co-payments
paid per patient for PBS prescriptions during the first 3 years
post-diagnosis was $974, with a maximum of $5390.
We presented the costs for patient co-payments for MBS
services and PBS prescriptions. A recent Queensland study
estimated the median patient co-payments for all services and
prescriptions billed through Medicare during the first 2 years
post-diagnosis was $4192 [3]. These results are also compara-
ble to other reports of high OOP costs in Australia following
a breast cancer diagnosis [2, 4]. Both of these other studies
include direct and indirect costs following a breast cancer
diagnosis. Our data set did not include costs which did not
incur a rebate paid by Medicare. However, our study is unique
Table 3 Number of MBS services and PBS prescriptions for women
diagnosed with breast cancer in Australia (weighted)
Time since diagnosis
(months)
MBS services PBS prescriptions
Mean ± SD Mean ± SD
0–6 75 ± 45 25 ± 19
7–12 47 ± 39 18 ± 17
13–18 30 ± 27 17 ± 17
19–24 28 ± 31 17 ± 17
25–30 28 ± 34 17 ± 17
31–36 26 ± 31 17 ± 17
Table 4 Patient co-payments of MBS services and PBS prescriptions for women diagnosed with breast cancer in Australia (weighted)
Time since diagnosis
(months)

















0–6 649 ± 845 229 1–1121 6620 326 ± 322 205 105–451 2137
7–12 294 ± 605 61 0–253 9404 175 ± 148 141 77–222 1759
13–18 145 ± 314 54 0–164 5901 156 ± 131 121 72–216 1282
19–24 140 ± 390 49 0–149 10,193 153 ± 127 115 73–219 1192
25–30 140 ± 423 54 0–145 9899 145 ± 124 112 61–193 1536
31–36 133 ± 407 44 0–138 10,745 143 ± 118 116 61–192 1203





in that it describes the distribution of patient co-payments by
Indigenous status, remoteness, and socioeconomic status.
We found that Indigenous women and women living in
areas of socioeconomic disadvantage had significantly lower
patient co-payments for MBS services during the 12 months
following diagnosis, even after adjusting for the number of
services used during this time. These findings may indicate
that the policies in place to protect individuals and family
groups from spending a high amount on patient co-payments
during the year are working. These policies include lower
payments for eligible Concession Card holders, as well as
the Medicare and Extended Medicare Safety Nets. Once an
individual or family group patient reaches the threshold set for
that calendar year, then they may receive a greater proportion
of Medicare rebate for out-of-hospital services [9].
In Australia, the rebate paid by Medicare is set in the
Schedule (a listing of all Medicare services subsidized by
the Government); however, health practitioners are able to
set the fee charged for the service provided, resulting in un-
regulated patient co-payments. Some MBS service providers
may also choose to bulk-bill patients, resulting in no patient
co-payment. Some un-referred services may be eligible for
bulk-bill incentives from the government [20]. In 2015,
OOP expenditure in Australia was 20%, which was equal to
the Organisation for Economic Cooperation and Development
average (20%), but higher than the average paid in the UK
(15%), New Zealand (13%), and Canada (15%) [21]. This is
of concern, as it is known that people may delay or forgo
healthcare due to costs [5, 7]. Previous work by some of the
authors found that 21% of Australian adults with cancer
skipped care due to the costs [5]. In a survey of people with
cancer, 10.9% indicated that the cost of treatment influenced
their decision about cancer treatment [7]. A recent study using
CancerCostMod identified that on average, Indigenous
Australians with cancer had lower patient co-payments for
MBS services and PBS prescriptions combined compared
with non-Indigenous Australians with cancer. There were also
differences in the number and type of MBS services accessed
between Indigenous Australians and non-Indigenous
Australians [22]. Future studies should identify if there are
differences in the type and number of MBS services and
PBS prescriptions for women diagnosed with breast cancer.
In relation to PBS prescriptions, we found that after
adjusting for the number of prescriptions, patient co-
payments were significantly lower in Indigenous women
and in women living in areas of socioeconomic disadvantage
(Q1–4). Again, these findings may indicate that the prescrip-
tions dispensed under the CTG scheme for Indigenous
Australians, lower co-payments for people with eligible
Concession Cards, and the PBS Safety Net may be protecting
individuals and family groups from paying excessive patient
co-payments for their prescriptions. In contrast to unregulated
patient co-payments for MBS services, patients will pay up to
the patient co-payment for approved PBS medications (2018
general patient, $39.50; and concession card holder $6.40)
[23]. However, previous studies have found that cost is a bar-
rier in obtaining the prescription [6, 24]. In a survey of people
with cancer, 11% indicated that medications prescribed for
their cancer treatment caused financial burden. Those who
had a reduced income following their diagnosis reported
greater financial burden due to prescribed cancer medications.
Almost 12% of participants indicated that they used an alter-
native (over-the-counter, medication already at home, medi-
cines from someone else) to their prescribed cancer-related
medications [6].
Our study found no consistent difference in the patient co-
payments paid for MBS services or PBS prescriptions by re-
moteness. In comparison, previous studies have reported
higher patient OOP expenditure for people living outside of
urban areas. A recent Western Australia study reported that of
people diagnosed with one of the four most common cancers,
total OOP expenditure was higher in participants residing out-
side of the South West region, who had private health insur-
ance and were under the age of 65 years. This study included
direct and indirect costs. The categories which accounted for
the greatest proportion of expenditure were surgery, tests, ac-
commodation, and fuel [25]. These results were similar to a
Queensland study, which reported travel expenses accounting
for the greatest proportion (71%) of total costs for cancer
patients [12]. OOP costs were greatest for people living more
than 100 km from the hospital in which they received care,
compared with those who lived within 100 km from this hos-
pital [12]. Our study was unable to estimate indirect costs, as
these were not covered by Medicare.
This study has several strengths, primarily due to the use of
population-based linked administrative data. We included the
patient co-payment costs of all MBS services and PBS pre-
scriptions from date of diagnosis to 36 months post-diagnosis
for women diagnosed with breast cancer. The data was
weighted to be representative of the Australian population.
We have previously calculated that the age-standardized inci-
dence rate of women diagnosed with breast cancer for
CancerCostMod was 120.56 per 100,000, compared with
the national age-standardized incidence rate of 120.42 per
100,000 for women diagnosed with breast cancer in 2012
[13]. Administrative data also overcomes potential measure-
ment bias (poor recall, self-report, interviewer, etc.). However,
administrative data also has several weaknesses. For example,
Fig. 1 Average patient co-payments for MBS services and PBS prescrip-
tions by age group (a, b), breast cancer stage (c, d), Indigenous status
(e, f), remoteness (g, h), and socioeconomic disadvantage (i, j). Average
costs per patient were calculated for each 6-month period from diagnosis
to 3 years. The figures on the left present the unadjusted average patient
co-payments for MBS services, and on the right present the unadjusted




Table 5 Parameter estimates of independent variables in generalized linear regression model of the co-payments for MBS services for women diagnosed with breast cancer between 1 July 2011 and 30
June 2012, Australia (weighted data presented)
0–6 months 7–12 months 13–18 months 19–24 months 25–30 months 31–36 months
Ratio Coefficient (SE) Ratio Coefficient (SE) Ratio Coefficient (SE) Ratio Coefficient (SE) Ratio Coefficient (SE) Ratio Coefficient (SE)
Intercept 3.2038 (0.1917)*** 1.8748 (0.2348)*** 2.0679 (0.1605)*** 1.9362 (0.1263)*** 1.7002 (0.1209)*** 1.3809 (0.1364)***
Indigenous women 0.18 − 1.7388 (0.2791)*** 0.21 − 1.5685 (0.3202)*** 0.99 − 0.0139 (0.2673) 0.82 − 0.1972 (0.2623) 0.65 − 0.4288 (0.2730) 1.06 0.0556 (0.3063)
Regional 1.05 0.0443 (0.0835) 1.02 0.0226 (0.0968) 0.99 − 0.0083 (0.0484) 0.95 − 0.0557 (0.0472) 1.09 0.0896 (0.0454)* 0.99 − 0.0136 (0.0501)
Remote 1.27 0.2370 (0.1440) 1.04 0.0360 (0.1671) 1.01 0.0079 (0.0839) 0.91 − 0.0926 (0.0780) 1.03 0.0264 (0.0781) 0.92 − 0.0816 (0.0853)
IRSD Q1 0.59 − 0.5337 (0.1591)*** 0.62 − 0.4783 (0.1860)* 0.74 − 0.3064 (0.0957)** 0.97 − 0.0350 (0.0933) 0.72 − 0.3236 (0.0921)*** 0.76 − 0.2694 (0.0985)**
IRSD Q2 0.64 − 0.4427 (0.1797)* 0.49 − 0.7087 (0.2095)*** 0.72 − 0.3322 (0.1062)** 0.90 − 0.1021 (0.1021) 0.73 − 0.3095 (0.0978)** 0.83 −0.1923 (0.1070)
IRSD Q3 0.58 − 0.5499 (0.1176)*** 0.59 − 0.5270 (0.1348)*** 0.86 − 0.1470 (0.0692) 0.94 − 0.0594 (0.0677) 0.78 − 0.2450 (0.0648)*** 1.01 0.0079 (0.0714)
IRSD Q4 0.89 − 0.1129 (0.0879) 0.90 − 0.1107 (0.1025) 0.84 − 0.1773 (0.0502)*** 0.92 − 0.0799 (0.0478) 0.81 − 0.2084 (0.0468)*** 0.88 − 0.1256 (0.0513)*
Age 45–64 years 1.06 0.0604 (0.1090) 1.02 0.0168 (0.1268) 0.92 − 0.0869 (0.0623) 0.98 − 0.0215 (0.0582) 0.95 − 0.0506 (0.0584) 1.10 0.0909 (0.0626)
Age ≥ 65 years 0.71 − 0.3448 (0.1129)** 0.60 − 0.5067 (0.1318)*** 0.63 − 0.4545 (0.0662)*** 0.73 − 0.3089 (0.0622)*** 0.73 − 0.3120 (0.0626)*** 0.89 − 0.1214 (0.0677)
Advanced stage 0.73 − 0.3197 (0.0718)*** 1.08 0.0801 (0.0876) 1.02 0.0168 (0.0409) 1.03 0.0276 (0.0387) 0.98 − 0.0169 (0.0383) 0.96 − 0.0405 (0.0417)
Unknown stage 0.58 − 0.5402 (0.1365)*** 0.63 − 0.4689 (0.1672)** 0.95 − 0.0472 (0.0948) 1.07 0.0655 (0.1003) 1.09 0.0896 (0.1022) 0.81 − 0.2159 (0.1149)
Number of MBS services
during period analysed
1.03 0.0260 (0.0011)*** 1.03 0.0261 (0.0014)*** 1.02 0.0207 (0.0009)*** 1.02 0.0188 (0.0007)*** 1.02 0.0182 (0.0007)*** 1.02 0.0200 (0.0009)***
Death during period analysed 0.62 − 0.4778 (0.1269)*** 0.92 − 0.0790 (0.1768) 0.87 − 0.1349 (0.1419) 0.65 − 0.4251 (0.1035)*** 0.71 − 0.3416 (0.1000)*** 0.72 − 0.3334 (0.1155)**
The ratios presented are relative to the reference group: Indigenous status (reference = non-Indigenous women), age group (reference = 18–44 years), remoteness (reference =metropolitan), socioeconomic
disadvantage (reference = IRSD Q5 (least disadvantaged)), breast cancer stage (reference = early), number of medical services accessed during the period analysed, and death during the time period being
modelled




Table 6 Parameter estimates of independent variables in generalized linear regression model of the co-payments for PBS prescriptions for women diagnosed with breast cancer between 1 July 2011 and
30 June 2012, Australia (weighted data presented)
0–6 months 7–12 months 13–18 months 19–24 months 25–30 months 31–36 months
Ratio Coefficient (SE) Ratio Coefficient (SE) Ratio Coefficient (SE) Ratio Coefficient (SE) Ratio Coefficient (SE) Ratio Coefficient (SE)
Intercept 3.9211 (0.0765)*** 2.3079 (0.0779)*** 2.0292 (0.0844)*** 1.7807 (0.0829)*** 1.3308 (0.0802)*** 0.9763 (0.0892)***
Indigenous women 0.61 − 0.4926 (0.1191)*** 0.59 − 0.5234 (0.1125)*** 0.61 − 0.4973 (0.1206)*** 0.70 − 0.3632 (0.1345)** 0.63 − 0.4557 (0.1299)*** 0.68 − 0.3855 (0.1419)**
Regional 1.01 0.0059 (0.0347) 0.96 − 0.0382 (0.0338) 1.02 0.0174 (0.0356) 1.01 0.0105 (0.0354) 1.08 0.0742 (0.0364) 1.07 0.0648 (0.0386)
Remote 1.09 0.0816 (0.0583) 0.99 − 0.0081 (0.0574) 1.10 0.0935 (0.0609) 1.06 0.0536 (0.0603) 0.99 − 0.0088 (0.0619) 1.09 0.0826 (0.0658)
IRSD Q1 0.79 − 0.2370 (0.0672)*** 0.91 − 0.0971 (0.0654) 0.82 − 0.1955 (0.0681)** 0.85 − 0.1580 (0.0674)* 0.81 − 0.2156 (0.0701)** 0.84 − 0.1776 (0.0735)*
IRSD Q2 0.75 − 0.2850 (0.0742)*** 0.83 − 0.1845 (0.0732)* 0.84 − 0.1718 (0.0762)* 0.87 − 0.1394 (0.0756) 0.78 − 0.2486 (0.0770)** 0.83 − 0.1923 (0.0819)*
IRSD Q3 0.83 − 0.1870 (0.0479)*** 0.93 − 0.0748 (0.0468) 0.92 − 0.0798 (0.0492) 0.96 − 0.0459 (0.0492) 0.90 − 0.1085 (0.0505)* 0.95 − 0.0533 (0.0535)
IRSD Q4 0.87 − 0.1405 (0.0372)*** 0.95 − 0.0527 (0.0361) 0.93 − 0.0707 (0.0381) 0.96 − 0.0388 (0.0380) 0.90 − 0.1102 (0.0389)** 0.96 − 0.0422 (0.0414)
Age 45–64 years 0.87 − 0.1406 (0.0456)** 1.19 0.1725 (0.0446)*** 1.08 0.0784 (0.0477) 1.11 0.1065 (0.0481)* 1.18 0.1633 (0.0498)*** 1.18 0.1631 (0.0529)**
Age ≥ 65 years 0.37 − 0.9955 (0.0477)*** 0.70 − 0.3612 (0.0487)*** 0.66 − 0.4123 (0.0518)*** 0.68 − 0.3875 (0.0525)*** 0.77 − 0.2604 (0.0539)*** 0.80 − 0.2206 (0.0572)***
Advanced stage 1.35 0.2996 (0.0309)*** 1.03 0.0253 (0.0288) 1.02 0.0214 (0.0300) 1.04 0.0417 (0.0299) 1.08 0.0746 (0.0308)* 1.05 0.0468 (0.0323)
Unknown stage 1.09 0.0821 (0.0589) 1.07 0.0685 (0.0583) 1.13 0.1234 (0.0613)* 1.21 0.1887 (0.0620)** 1.17 0.1556 (0.0667)* 1.51 0.4111 (0.0735)***
Number of PBS services
during period analysed
1.03 0.0251 (0.0010)*** 1.02 0.0207 (0.0011)*** 1.02 0.0179 (0.0011)*** 1.02 0.0186 (0.0011)*** 1.02 0.0181 (0.0011)*** 1.02 0.0173 (0.0012)***
Death during period analysed 0.74 − 0.3063 (0.0536)*** 1.07 0.0696 (0.0574) 0.96 − 0.0411 (0.0650) 0.85 − 0.1670 (0.0630)** 0.95 − 0.0537 (0.0607) 1.07 0.0719 (0.0648)
The ratios presented are relative to the reference group: Indigenous status (reference = non-Indigenous women), age group (reference = 18–44 years), remoteness (reference =metropolitan), socioeconomic
disadvantage (reference = IRSD Q5 (least disadvantaged)), breast cancer stage (reference = early), number of PBS services accessed during the period analysed, and death during the time period being
modelled




the QCR does not routinely collect stage of disease at diagno-
sis, or breast cancer type, or socioeconomic status of individ-
uals. Therefore, we identified the stage as ‘early’, ‘advanced’,
and ‘unknown’ and used aggregated area-level data to identify
socioeconomic disadvantage and remoteness. We were unable
to estimate patient OOP costs which were not covered by
Medicare, such as some medical services, over-the-counter
medications, private prescriptions, private health insurance
(including premiums and excess), travel, accommodation,
food, or indirect costs due to changes in labour force partici-
pation for the patient (and their caregiver/s). These indirect
costs are known to account for a high proportion of the costs
to the patient [2, 12, 25]. Patient comorbidities were also ex-
cluded from the dataset and, therefore, not adjusted for in the
analysis.
The sample of women diagnosed with breast cancer that
was used in this manuscript was obtained from a larger
dataset, CancerCostMod. The original data included had in-
digenous status recorded for 87% of the records [13]. In the
development of this dataset, Indigenous status was imputed
for records with missing or unknown Indigenous status.
Missing Indigenous status is a common data limitation in
Australian health studies [26]. Previously, Australian national
cancer statistics have included data from five (of eight) juris-
dictions only, as these jurisdictions are considered to have
sufficient completeness of Indigenous status for reporting
[1]. It is possible that the national statistics underestimate the
true incidence of cancer in Indigenous Australians [27]; it is
also possible that we have overestimated the number of new
cases of cancer for Indigenous Australians.
Conclusion
This study supports previous findings of high OOP co-
payments following a breast cancer diagnosis. We also found
significant differences in the patient co-payments for women
diagnosed with breast cancer in Australia by Indigenous status
and socioeconomic disadvantage. Although it may be difficult
to predict all of the patient co-payments throughout their can-
cer journey, there is a call for greater transparency for patient
co-payments. As costs are a potential barrier to accessing
treatment, health professionals should be aware of potential
co-payments which may be incurred and discuss these with
the patient throughout their cancer journey.
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This chapter represents the final chapter of Part 3, which focused on the costs associated with women 
diagnosed with breast cancer for the three years following diagnoses. Chapters Five and Six presented 
costs to the health care system, but this chapter specifically focused on the costs to the individual. 
This study found that Indigenous women paid significantly lower patient co-payments than their non-
Indigenous counterparts for MBS services and PBS prescriptions during the first year post-diagnosis. 
Patient co-payments for MBS services were significantly lower during the first 12-months post 
diagnosis in women living in the most disadvantaged areas (Q1-3), compared to women living in the 
least socioeconomically disadvantaged areas (Q5), and patient co-payments for PBS prescriptions 
were significantly lower in the first six-months following diagnosis. MBS and PBS co-payments were 
consistently lower in women living in the more disadvantaged quintiles throughout the three-year 
follow-up period. There were no differences in co-payments for MBS or PBS services by remoteness.  
The same dataset was used in this study as for the previous two chapters, thus there are the same 
limitations inherent to the dataset. In addition to these limitations, the patient OOP costs included in 
this study are limited to patient co-payments only. It was not possible to include costs that were not 
captured in the MBS and PBS datasets, as such, costs for travel, accommodation, parking, child care, 
private health insurance, private prescriptions/health services etc were not included in the analysis. 
This study addressed part of the third aim of the thesis: to quantify the direct costs to the public 
healthcare system and individual for the first three years following a female breast cancer diagnosis, 
and to determine the distribution of these costs by Indigenous status, remoteness, and 
socioeconomic disadvantage. Future studies should consider 1) the drivers of high OOP co-payments 
and the distribution of these costs, 2) the impact of co-morbidities on the costs, and 3) extend the 
timeframes to provide a continuous analysis of the costs and changes of costs across time. Finally, 
future studies should consider other types of OOP costs that were not captured in this chapter, and 
the distribution of these costs by population group. 
In Part 4 of the thesis, the findings presented in Chapters Three to Seven are synthesised in the 
context of relevant literature, strengths and limitations. Finally, recommendations and conclusions 
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Chapter Eight: Discussion and Conclusion 
Cancer is the leading burden of disease in Australia,1 and imparts a significant economic burden on 
the public healthcare system, society, and the individual. The overall objective of this thesis was to 
describe the cost of cancer in Australia, with a particular focus on identifying the distribution of this 
cost by those groups within the population known to experience poorer outcomes following 
diagnosis. Indigenous Australians, people living in remote areas, and socioeconomically 
disadvantaged people experience inequalities in cancer survival. In this final chapter of the thesis, the 
results presented in Chapters Three to Seven are summarised and synthesised to better understand 
the cost of cancer in Australia, and the distribution of these costs by the mentioned characteristics 
(Indigenous status, remoteness, socioeconomic disadvantage). Policy and practice implications, as 
well as strengths and limitations of the overall programme of research are discussed, and areas for 
future research are highlighted. The findings of this thesis need to be considered in the context of the 
Australian policy at the time of data collection, and publication of findings. 
Summary of the key findings 
This thesis is comprised of four Parts. Part 1 of this thesis contained the introduction and literature 
review, which contextualised this body of work. Part 2 comprised two chapters, which described the 
direct and indirect costs for all cancers in a 12-month time period (Chapters Three and Four 
respectively). Chapter Three described the development of CancerCostMod, a model based on linked 
administrative data that was used for the majority of the thesis. Also identified in Chapter Three was 
the cost of cancer in Australia for the first 12-months post-diagnosis – this was an estimated $4.8 
billion to the public healthcare system, and an additional $127.7 million to the individual.  
Results from this study showed that during the first 12-months following a cancer diagnosis, there 
were significant differences in the costs to the public healthcare system and individual by Indigenous 
status, remoteness and socioeconomic disadvantage. The costs to the public healthcare system were 
categorised as: admitted and non-admitted hospital episodes, ED presentations, MBS rebates, and 
PBS rebates. For admitted and non-admitted hospital episodes, compared to people living in 
metropolitan areas, costs were 4% higher for people living in inner/outer regional areas, and 10% 
higher for people living in remote/very remote areas. Costs were significantly lower for people living 
areas of lower disadvantage (Q4 = 5% lower, and Q5 = 7% lower) compared to people living in the 
most disadvantaged area (Q1). There was no significant difference in the costs for hospital episodes 
between Indigenous and non-Indigenous people diagnosed with cancer. For ED presentations, costs 
were 23% higher among Indigenous Australians compared to non-Indigenous Australians. No 
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differences in cost for ED presentations were observed by remoteness or socioeconomic 
disadvantage.  
The cost for out-of-hospital medical services were calculated using MBS rebates paid by Medicare. 
During the first 12-months following a cancer diagnosis, rebates paid were 8% lower in Indigenous 
Australians compared to non-Indigenous Australians. Using people living in metropolitan areas as the 
reference, rebates paid for the healthcare of people living in remote and very remote areas were 10% 
lower, but there was no difference for people living in regional areas. Compared to people living in 
the most disadvantaged area (Q1), the rebates paid for the healthcare of people living in areas of 
lower disadvantage (Q2-Q4) were significantly higher (Q2=7%, Q3=8%, and Q4=18%).  
The cost to the public healthcare system for PBS prescriptions was captured using the rebates paid 
for PBS approved prescriptions. During the first 12-months, the PBS rebates paid were 18% lower for 
Indigenous Australians compared to non-Indigenous Australians. People living in remote/very remote 
areas had 10% greater rebates paid for PBS prescriptions compared to people living in metropolitan 
areas, and compared to those living in the most disadvantaged quintile, people living in Q3-Q5 had 
significantly higher PBS rebates (Q3=11%, Q4=17%, and Q5=19%). 
The patient co-payments for MBS services and PBS prescriptions were combined to provide the total 
co-payments paid during the first 12-months. Patient co-payments were 61% lower in Indigenous 
Australians compared to non-Indigenous Australians. Compared to people living in metropolitan 
areas, patient co-payments were 6% lower for people living in inner/outer regional areas. Higher co-
payments were observed in people living in the two least disadvantaged quintiles compared to people 
living in the most disadvantaged quintile (Q4=23% and Q5=32%). 
In Chapter Four, the annual indirect cost associated with labour force absence for all cancer types in 
Australia was examined, using the 2015 Survey of Disability, Ageing and Carers (SDAC). This study 
identified that at the time of the 2015 SDAC, 46% of people of working age with cancer (aged 25-64 
years) were not in the labour force, resulting in $1.7 billion reduction in Australia’s GDP. Of people 
with cancer, those without a tertiary qualification (which was used as a proxy measure of 
socioeconomic status) were more likely to be out of the labour force. However, there were no 
differences between people living in major cities and those living outside of major cities in terms of 
labour force participation. Indigenous status was not available in the dataset, and was thus not 
included in the analysis. 
Part 3 of the thesis focused on female breast cancer, but a longer timeframe was examined (three 




female breast cancer to the public healthcare system (Chapters Five and Six), and the individual 
(Chapter Seven) during the first three years following diagnosis were presented in these three 
chapters. Female breast cancer was chosen as a case study in this thesis, as it is the most commonly 
diagnosed cancer in Australia.2  
Chapter Five identified the hospital costs for women diagnosed with breast cancer and Chapter Six 
quantified the rebates paid by the Australian government for MBS services and PBS prescriptions. 
Results presented in Chapter Five indicate that the average cost per person for admitted and non-
admitted hospital episodes was higher for Indigenous women compared to non-Indigenous women, 
and women living in the most disadvantaged quintile compared to women living in the least 
disadvantaged area. There were little to no differences in the average cost of ED presentations during 
the first two-years, but in the third year post-diagnosis, costs were lower in women living in remote 
areas than those living in metropolitan areas.  
In Chapter Six, little to no consistent differences were identified in the average rebates paid by 
Medicare for MBS services by remoteness, Indigenous status or socio-economic disadvantage. 
However, there were differences in the average rebate paid by Medicare for PBS prescriptions 
throughout the three-year study period for Indigenous women (lower costs during months 7-to-12 
and 13-to-18) compared to non-Indigenous women, regional (higher costs during the first 12 months) 
compared to metropolitan, and for women living outside of the least disadvantaged quintile (lower 
costs during the first 12-months). 
Chapter Seven identified the high patient co-payments for MBS services and PBS prescriptions 
incurred by women following a breast cancer diagnosis. These findings support previous Australian 
studies which have identified high out-of-pocket (OOP) costs borne by women diagnosed with breast 
cancer.3-5 The cost of healthcare is a known barrier for people accessing cancer treatment.6, 7 
Significant differences were observed in the co-payments paid by Indigenous status, remoteness, and 
socioeconomic status. Specifically, for MBS services, Indigenous women incurred 82% lower co-
payments during the first 6-months, and 79% lower co-payments during months 7-to-12 compared 
to non-Indigenous women. Socioeconomic disadvantage was a strong predictor for patient co-
payments paid for MBS services across the three year study period. Compared to women living in the 
least socioeconomically disadvantaged quintile (Q5), co-payments were significantly lower in women 
living in the most socioeconomically disadvantaged quintile (Q1) for all but one 6-month time period 
during the first three-years post diagnosis. Co-payments were significantly lower among women living 




A similar trend was seen for patient co-payments incurred for PBS prescriptions. Compared with non-
Indigenous women, Indigenous women diagnosed with breast cancer had significantly lower patient 
co-payments throughout the three-year study period. Socioeconomic disadvantage was associated 
with PBS co-payments incurred by individuals. Costs were significantly lower for women living in the 
two most disadvantaged quintiles (Q1 and Q2) compared to women living in the least disadvantaged 
quintile (Q5), for all but one of the six time periods analysed.  
Implications for practice and policy 
Direct costs and service delivery 
In Chapter Three, differences were identified in the direct cost to the public healthcare system and 
the individual for adults diagnosed with cancer. These differences may be due to several factors, 
including differences in stage of disease at diagnosis; differences in accessing care, either due to 
barriers or personal choice; and differences in treatment, as reported in Australian studies.8-21 Stage 
of disease is not routinely collected by the QCR, therefore it was not possible to adjust for stage of 
disease in the analyses. However, in Chapters Five to Seven, breast cancer stage was categorised by 
the author using information on breast tumour size, and evidence of lymph node involvement 
(categorised as early, advanced, or unknown). While the findings presented in Chapters Five to Seven 
relate specifically to breast cancer, the findings from these chapters support the findings from 
Chapter Three. The differences in the direct costs remain for women diagnosed with breast cancer 
even after adjusting for stage of disease at diagnosis.  
Cancer staging is important, as this gives an indication of the extent or spread of the cancer. This 
information may be used to estimate chances of survival, and to determine the appropriate 
treatment options available. The most commonly used staging system is the Tumour, Node, 
Metastasis (TNM) staging system, which contains information on the size and extent of the main 
tumour, lymph nodes, and if the cancer has metastasized.22, 23 The limited information on cancer stage 
at diagnosis is a recognised limitation of cancer data in Australia.2, 24 Cancer Australia is currently 
working on projects to improve national data on the stage of disease at diagnosis for the five most 
commonly diagnosed cancers.24 The AIHW Cancer in Australia 201925 report included a chapter 
regarding cancer stage at diagnosis for the five most commonly diagnosed cancers in Australia. The 
availability of staging information in the future will enable stage of disease to be considered in future 
analyses. 
In this thesis, differences were found in the cost of admitted and non-admitted hospital episodes by 
remoteness, socioeconomic disadvantage and Indigenous status. Although no significant difference 




differences were found in Chapter Five. Indigenous women diagnosed with breast cancer had higher 
costs for hospital episodes, even after adjusting for stage of disease, and number of hospital episodes. 
The higher costs for hospital episodes found in the breast cancer case study could be due to 
differences in the type of treatment following diagnosis. Previous studies have identified that 
compared to non-Indigenous women, Indigenous women have higher rates of mastectomy and lower 
rates of breast conserving therapy.8, 10, 26 The differences identified in the hospital costs between 
Indigenous and non-Indigenous women may partially be due to possible differences in treatment. 
The study presented in this thesis aimed to identify the hospital expenditure for women diagnosed 
with breast cancer, and to determine the distribution of costs by patient characteristics. Future 
studies could consider the costs for different clinical treatment pathways in more detail.  
Improving cancer outcomes for Indigenous Australians remains a national concern. Providing 
“culturally safe services and a culturally competent workforce”27(p 15) have been identified as one of 
several recommendations in the National Aboriginal and Torres Strait Islander Cancer Framework to 
improve cancer outcomes for Indigenous Australians.27 Cancer care involves a multi-disciplinary team 
which includes doctors, nurses, and allied health staff. All staff should receive ongoing cultural safety 
training to ensure care are provided with culturally appropriate care. A recent study of cancer services 
found that having Indigenous staff members and specific Indigenous staff roles were beneficial to 
engage with Indigenous people with cancer.28 Culturally appropriate services and workforce must be 
a priority for all aspects of cancer and healthcare, and must commence at prevention and screening. 
Although prevention and screening were not the focus of this thesis, any changes in health policy 
must consider funding for prevention and not just treating the disease. Providing culturally 
appropriate services has been identified as a fundamental component to improve cancer outcomes 
for Indigenous Australians.27 
In Chapter Three, higher costs were identified for hospital episodes for people living outside of 
metropolitan areas (4% higher for people living in regional areas, and 10% higher for people living in 
remote areas). In contrast, no consistent trends were observed by remoteness in the female breast 
cancer study. The differences identified in Chapter Three could be due to differences in accessing 
services by area of remoteness. Differences in clinical management by remoteness have been 
reported in Australia; however, the majority of evidence is for breast and prostate cancers.13-19 A 
recent systematic review reported limited evidence regarding differences in clinical management by 
remoteness.29 Physical access to oncology services reduces with increasing remoteness.30 Thereby, 
some patients may need to travel or relocate to receive care.31, 32 Eligible patients may be able to 
apply for assistance in their state if they are required to travel. Queensland Health offers the Patient 
Travel Subsidy Scheme (PTSS) to assist patients who are referred for specialist medical services not 
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offered at their local public facility.33 Patients will still incur out-of-pocket costs, as the PTSS is not 
intended to cover all costs associated with travel or accommodation.34 The costs associated with 
travel and accommodation are substantial for people diagnosed with cancer who live outside 
metropolitan or major regional centres,4, 21, 35-39 and thus may be a barrier in accessing treatment.  
One strategy to help overcome the geographical distance in Australia has been the introduction of 
tele-oncology. The tele-oncology model of care enables patients to receive chemotherapy at rural 
hospitals.40, 41 However, this may not be appropriate for all patients or for all cancer types, as some 
patients will still be required to travel to receive care. The Townsville Cancer Centre has used this 
model of care since 2007 to provide medical oncology services in North Queensland.40, 41 The model 
of care has been shown to safely deliver chemotherapy,42 improve timely access to medical oncology 
services,43 and has been found to be acceptable for patients and health workers.44, 45 There has also 
been one study which evaluated the cost-savings of this model of care compared to the usual model 
of care in North Queensland (Townsville Cancer Centre and six rural sites). The study reported savings 
due to a reduction in travel costs to the healthcare system.46 To date, this is the only study to evaluate 
the costs of tele-oncology in Australia. Future studies should evaluate the cost-savings of tele-
oncology to the Australian healthcare system on a wider scale in Australia, as well as the potential 
cost-savings to the patient due to a reduction in travel and accommodation costs.  
In regards to ED presentations, Chapter Three found higher costs for Indigenous Australians, 
however, there was no difference by remoteness or socioeconomic disadvantage. In contrast, the 
findings from Chapter Five (breast cancer study) showed that, after adjusting for Indigenous status, 
socioeconomic disadvantage, remoteness, age, stage, number of ED presentations, and death there 
was little difference in the costs for ED presentations for female breast cancer patients. A recent 
commissioned review found that disease-related factors, treatment-related factors (e.g., adverse 
drug reactions and complications), and patient related factors (e.g., demographics, comorbidities, 
and Indigenous status) increased ED presentations in New South Wales for cancer patients.47 Adverse 
reactions following chemotherapy account for a large proportion of unplanned hospitalisations.48-50 
ED presentations are not only costly to the healthcare system,51 but also a cause of distress for the 
patient and their family, therefore, any interventions to reduce potentially avoidable ED 
presentations would be beneficial to the patient and the healthcare system. Future studies should 
identify if there are a difference in the number of ED presentations in this cohort, and if these 
presentations are potentially avoidable. This information may be used to develop targeted 
interventions to educate and manage symptoms if possible for patients, their families, and their 
primary health care provider. For example McKenzie et al.48 proposed the need for coordinated multi-




The differences observed in the rebates paid by Medicare for MBS services and PBS prescriptions 
(Chapter Six) may in part be linked to the patient co-payments incurred. The MBS contains a list of 
approved items, which Medicare will pay a rebate to the service provider. However, medical service 
providers may set their own fees, resulting in unregulated OOP fees for patients.52 Some service 
providers may choose to charge the amount equal to the rebate, and thereby ‘bulk-bill’ the patient, 
resulting in no patient co-payment. The findings from Chapter Three may partially be described by 
differences in the number of MBS services accessed, or PBS prescriptions dispensed. The findings 
from Part 4 (Chapters Five to Seven, the female breast cancer case study) found that there was no 
trend in the differences rebates paid for MBS services by remoteness, Indigenous status, or 
socioeconomic disadvantage after adjusting for number of MBS services in each time period. 
However, there were differences identified in the rebates paid for PBS services by these 
characteristics despite adjusting for number of PBS prescriptions dispensed. 
The OOP fees have been reported to be high for cancer patients. The financial toxicity associated with 
high OOP costs of cancer is a growing concern.4, 35, 37, 53 The Medicare Safety Net and PBS Safety Net 
are two policies which are designed to protect individuals and/or family groups from high patient co-
payments throughout the calendar year. Once an individual and/or family group reach the threshold 
for the safety net they are eligible to have their medical services or prescriptions subsidised at a 
higher rate for the remainder of the year.54 In addition to this, Indigenous Australians are able to 
access eligible prescription pharmaceuticals at a lower cost, or free under the Closing the Gap (CTG) 
PBS prescription program.55 The CTG Prescription programme excludes hospital prescriptions.55 This 
is of particular importance for cancer treatment, where most of the oncology services are offered 
through the hospital as either an admitted patient or non-admitted patient. It is not uncommon for 
hospital prescriptions to be dispensed outside of the hospital (in other words, dispensed at a 
community pharmacy). There are many reasons, including, but not limited to the medication not 
being stocked at the hospital pharmacy, discharge medications, repeats or ongoing medication, and 
patient choice. Therefore, if these prescriptions are dispensed at a community pharmacy, the 
prescription is not eligible to be dispensed under the CTG programme. The Society of Hospital 
Pharmacists of Australia reported that hospital staff are facilitating access to medication by liaising 
with the GPs, which was administratively burdensome.56 The exclusion of hospital prescriptions from 
the programme should be re-considered for Indigenous Australians receiving care, which is primarily 
in a hospital setting. 
The findings from Chapter Three and Seven indicate that these policies are working, as even after 
adjusting for co-variates, co-payments were lower for people living in the most disadvantaged areas 
and Indigenous Australians compared to their comparison groups. In Chapter Three, MBS and PBS 
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patient co-payments were combined, whereas, patient co-payment for MBS and PBS were analysed 
separately in Chapter Seven. Chapter Three identified some differences in total patient co-payments 
by remoteness, but there was no significant difference by remoteness in the female breast cancer 
study for patient co-payments for MBS services or PBS prescriptions (Chapter Seven). 
In Chapter Seven, large variation was observed in the mean patient co-payments paid by women with 
breast cancer for MBS services during each of the six-month periods. In contrast, there was little 
variation in the mean PBS co-payments paid. This may be because the patient pays up to the patient 
co-payment for PBS prescriptions, and although there may be variation in the amount paid if the item 
is under the patient co-payment, this is ‘minimal’ compared to the possible variation in MBS services.  
As a result of the variation in fees charged for MBS services, it may be possible that some patients 
may choose to visit a medical provider who bulk-bills over a specialist with an unknown, but 
potentially greater OOP co-payment. A recent study using CancerCostMod found that Indigenous 
Australians had a greater ratio of MBS services for non-referred attendances for enhanced primary 
care, other, and practice nurse items; but had less than half the number of specialist attendances.57 
The proportion of bulk-billed GP services has increased, and was 86% in 2016-17.58 Medicare have 
incentive payments for bulk-billing on eligible un-referred services.59 It is possible that there are 
differences in the type of MBS services accessed due to cost.  
There is a growing call for medical professionals to discuss the potential patient OOP costs with the 
patient.60-62 This may allow potential costs to be considered when choosing the best treatment 
pathway. The high OOP costs in Australia have received attention in recent years, and in 2018 and 
2019, a number of published reports have made recommendations for addressing these high OOP 
costs. A common theme in these reports was increased fee transparency, by having published fees 
on websites.60-62 The Consumers Health Forum of Australia and the University of Melbourne also 
recommend improving informed financial consent for consumers.62 The report identified the 
responsibility of improving informed financial consent falls on all health professionals.62  Although 
the report identified that GPs may be the gatekeeper for referrals to specialists, there were many 
challenges to GPs providing accurate information on fees for specialists or other health 
practitioners.62 Therefore, all health professionals should be responsible for openly discussing out-of-
pocket fees with individuals.  
In addition to these recommendations, all patients and their families should be offered individualised 
support to help navigate possible schemes and policies available to them. Although there is 
information about the Safety Nets, and PTSS available online or on request, this may be confusing, or 




example, information on the PBS Safety Net is available online, or through the pharmacy on request. 
However, if patients (and their family) use different pharmacies, they must keep track of their 
expenditure on a Prescription Record Form (available on request from the pharmacy). As a 
pharmacist, I would discuss the safety net with patients where possible and recommend that 
individuals and families keep a Prescription Record Form throughout the year. As discussed 
previously, eligible patients may apply for travel assistance; however, patients must apply for this 
before travelling. Therefore, medical professionals should be aware of and discuss the state’s relevant 
travel assistance scheme when referring patients to hospitals for specialist services.  
Labour force participation and indirect costs 
Workforce participation changes are not uncommon following a cancer diagnosis.63-66 A systematic 
review reported that an average of 62% of cancer survivors returned to work at 12-months, and an 
average of 89% of individuals returned to work within 24 months post- diagnosis.63 In Australia, full-
time employees are entitled to 10 days of paid sick leave, and up to three months of unpaid leave.67 
However, in some cases, people may need to take more time off, which must be negotiated with their 
employers. Although there was no evidence from Chapter Four in this thesis that labour force 
participation was associated with remoteness for people with cancer, people living in areas of 
increasing remoteness may have additional difficulties in balancing work, as they may be required to 
travel, or relocate to access cancer treatment.31, 32 In a recent Queensland qualitative study, 45 
patients diagnosed with haematological cancers were interviewed. The study identified that farmers 
and rural property owners reported additional responsibilities of maintaining their property during 
their treatment.32 
Changes in workforce participation following a cancer diagnosis can also contribute to financial 
hardship for an individual and their family.64, 68-71 This is also a concern for carers, who may be 
required to take extended leave to assist their loved one. Changes in workforce participation, which 
may result in a reduction of household income may contribute to increased financial hardship.7, 72 The 
financial hardship is a concern, as the OOP cost of cancer is known to be high,4, 35, 37, 53 and is a potential 
barrier in accessing care.6, 64, 73 These changes in workforce, and the resulting changes in income 
should be considered by health professionals when discussing the potential OOP costs with 
individuals. For many survivors, returning to work is an important milestone.68, 69 Survivors wishing to 
return to work should discuss this with their health professional team and their employers. Some 
individuals may require additional assistance to enable their return to work.  
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Strengths and limitations 
This thesis used two main datasets: 1) CancerCostMod, a model based on linked administrative data, 
and 2) the 2015 Survey of Disability, Ageing, and Carers (SDAC). The strengths and limitations of the 
use of these two datasets in this thesis will be described separately. 
CancerCostMod 
CancerCostMod was developed using individual-level administrative data from multiple sources. 
There are many strengths in using a dataset such as the one developed for the thesis. The base 
population for CancerCostMod was a census of all individuals diagnosed with cancer in Queensland 
between 1 July 2011 to 30 June 2012. In Australia, cancer is a notifiable disease, and all diagnoses 
(excluding non-melanoma skin cancer) are reported to the jurisdiction’s cancer registry. A census 
from the Queensland Cancer Registry ensured that all cancer diagnoses in Queensland were included 
in the base population, and minimised potential selection bias. Using weighted data, this thesis was 
able to estimate the costs for the Australian population. The use of individual level administrative 
data ensures that the dataset was not subject to measurement bias (including but not limited to 
memory, self-report, interviewer, etc.), and allows analysis to be conducted at an individual level.  
Both the 2015 National Aboriginal and Torres Strait Islander Cancer Framework27 and the current 
Cancer Australia’s Strategic Plan call for action to ensure equitable health service delivery of cancer 
services for all Australians.74 The individual level analysis enabled the distribution of costs by patient 
characteristics to be analysed. Therefore, the findings from this thesis may be of interest to policy 
makers to strengthen cancer related services for all Australians. The use of linked administrative data 
allowed data from several sources (QCR, Queensland Health Admitted Patient Data Collection, 
Queensland Health Emergency Department Information System, MBS, and PBS) to be consolidated 
into a single dataset. As such, the data used in this thesis met recommendations from the Productivity 
Commission and the AIHW.58, 75 
However, there are inherent limitations of using administrative data. For example, the QCR does not 
collect information on the stage of disease at diagnosis, individual or household income, or other 
comorbidities. The individual’s postcode at diagnosis was used to map to the Australian Bureau of 
Statistics’ Index of Relative Socio-Economic Disadvantage (IRSD). This is a measure of the economic 
and social conditions of an area.76 IRSD is an aggregated area-level measure of socioeconomic 
disadvantage, and therefore may not accurately represent all individuals living in the area.  
The original QCR dataset recorded Indigenous status for 87% of the individuals. Indigenous status was 




Indigenous status to those with missing records. These have been discussed in Chapter Three. The 
first step assigned Indigenous status if individuals resided in a Local Government Area that had 
greater than or equal to 75% of the population identified as Indigenous. The ABS define a Discrete 
Indigenous Community as a community in which half of the individuals identify as Indigenous 
Australian.77 The 75% used in developing CancerCostMod was chosen as a conservative cut-off. For 
those remaining records, multiple imputation was used to assign Indigenous status. The multiple 
imputation methods used in CancerCostMod were similar to those used in a previous New South 
Wales cancer study.78 There are potential limitations to this approach: firstly, it was assumed that 
Indigenous status was correctly recorded in the original QCR dataset; secondly, the steps taken to 
assign Indigenous status for those with missing records may have incorrectly assigned Indigenous 
status.  
The base population was weighted to be representative of the Australian population, however, this 
has some inherent limitations. The Queensland cancer cohort was benchmarked to the Australian 
cancer incidence by cancer type, age, and sex. It was not possible to weight for additional 
characteristics (Indigenous status, remoteness and socioeconomic status), as such, there may be 
inherent variations which could not be captured in the CancerCostMod dataset. This means that if 
Queensland is different to other states in regards to Indigeneity, remoteness, and socioeconomic 
status, then it is not possible to be perfectly representative to the Australian population, as the base 
population is still Queensland.Cancer stage at diagnosis is not routinely collected by QCR. Therefore, 
cancer stage was not adjusted in the analysis in Chapter Three. For Part 3, the female breast cancer 
case study, the stage was categorised into early, advanced, or unknown stage. The methods used in 
categorising these stages were identified from previous Queensland studies79, 80 and have been 
described in each of the studies in Part 3 (Chapters Five to Seven).  
Non-admitted hospital services were not captured in QHAPDC, however, in Australia, some oncology 
patients may receive treatment as a day patient, or as a non-admitted patient. As described in 
Chapter Three, the MBS dataset was used to capture these out-patient hospital services. The PBS 
dataset did not include items dispensed to public patients in public hospitals, or medications 
dispensed under alternative funding schemes, thus the cost of PBS items to the public healthcare 
system would be an underestimation of the true costs. In regards to patient OOP costs, the MBS and 
PBS datasets did not capture private medical services, over-the counter medications, or private 
prescription pharmaceuticals, and thus these OOP costs were unable to be estimated. Furthermore, 
other OOP costs incurred by patients and their families which were not captured in the administrative 
data included private health insurance, accommodation, travel, childcare, lost wages, etc. OOP costs 
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incurred for travel and accommodation are known to be high for cancer patients and their families.4, 
21, 35-39 
2015 SDAC 
There were many strengths in using the 2015 SDAC to address the indirect cost of cancer due to lost 
productivity from morbidity. The 2015 survey was the eighth (and most recent) SDAC conducted by 
the Australian Bureau of Statistics (ABS).81 This survey was chosen for the thesis because it provided 
a national cross-section of labour force participation for people with long-term health conditions, 
including cancer. The ABS weights the survey, which allows the results to be generalised to the 
Australian population.81 This study was also the first in Australia to quantify the cost of lost 
productivity due to cancer for adults of working age.  
However, the use of an existing survey does have several limitations. These include that the SDAC 
was a cross-section only, therefore selection bias is unavoidable. The SDAC did not include 
information on the time since diagnosis. Due to a small sample size (of people with cancer), it was 
not possible to provide analysis by the main type of cancer.82 The SDAC categorised remoteness as 
‘Major cities Australia’, ‘inner regional Australia’, and ‘other areas’ using the Accessibility and 
Remoteness Index of Australia (ARIA).81 In the thesis, due to sample size, ‘inner regional Australia’ 
and ‘other areas’ were collapsed into one category. Therefore, this study was only able to identify if 
there was any difference in labour force participation between people living in major cities and those 
living in other areas. 
In addition to these limitations, there were additional limitations in using the 2015 SDAC in identifying 
any differences in labour force participation or indirect costs by the characteristics of interest in this 
thesis. Specifically, it was not possible for this study to identify differences in the distribution of labour 
force participation by Indigenous status or socioeconomic disadvantage. To the author’s best 
knowledge, no study has identified if there are differences in employment following a cancer 
diagnosis for Indigenous Australians. The findings from Chapter Four show that of those with cancer, 
people without a tertiary qualification were significantly more likely to be out of the labour force. The 
proportion of Indigenous Australians attending tertiary education are lower than that of non-
Indigenous Australians.83 Therefore, Indigenous Australians diagnosed with cancer who do not have 
a tertiary qualification may also be more likely to be out of the workforce.  
Directions for future research 
The cost of cancer is increasing, and will continue to increase.84-86 In order to allocate finite resources 




Australia, and described the costs by characteristics known to result in poorer outcomes (Indigenous 
status, remoteness, socioeconomic disadvantage). The development of CancerCostMod, a model 
based on linked administrative data which uses individual-level data, confers many possibilities for 
future research. 
Future research should build upon the initial results from the first study in this thesis (Chapter Three), 
which quantified the cost of cancer during the first 12-months post-diagnosis, and found that there 
are differences in costs to the public healthcare system and the individual by remoteness, Indigenous 
status, and socioeconomic disadvantage. The use of individual level data may be used to model the 
costs for different treatment pathways. This could be used to identify areas which may benefit from 
additional funding. The use of administrative data may also allow determine if there are any 
differences in the clinical treatment pathways by patient characteristics, and to quantify the costs 
associated with these differences. Previous literature in Australia has identified that there are 
differences in uptake of treatment options,8-21 but administrative data could be used to monitor these 
differences.  
Female breast cancer was chosen as the case study in this thesis, as it is the most commonly 
diagnosed cancer. Future research using CancerCostMod will consider other cancer sites. Increasing 
the cohort population past July 2012, would increase the sample size, thus allowing the costs to be 
examined for less common cancer types. This will also allow analysis of cancer types, which have 
known inequalities for population groups, such as lung cancer, or cervical cancer. This may help 
allocation of resources, or funding to particular types of cancer for prevention, treatment, or research 
for treatment.  
Another direction for future research would be to increase the cohort of CancerCostMod by including 
diagnoses past June 2012, and by increasing the follow-up period. If CancerCostMod is expanded, it 
may be possible to include the costs of cancer in Australia for the maintenance phase, and terminal 
phase (last 12-months of life). A number of international studies have used linked administrative data 
to identify the cost of cancer by phase (initial, maintenance, and terminal).87-92 These studies have 
identified that the initial and terminal phases have higher costs.87-91 However, no study has evaluated 
the distribution of these costs by characteristics known to result in poorer outcomes such as those 
examined in this thesis (Indigenous status, remoteness, socioeconomic disadvantage). The inclusion 
of these phases by these characteristics may highlight distinct phases which have greater disparity 
between costs, and thus benefit from a more in-depth examination. 
In addition to this, future studies should focus on the distribution of other areas of OOP costs to the 
individual and their family, such as travel, accommodation, parking, and private medical expenses. In 
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order to obtain OOP costs not captured in this thesis, direct patient data collection will be required. 
Administrative data can be used in combination with patient surveys to confirm the costs to the 
patient. No identifiable patient information was provided to the authors, therefore, the dataset used 
in this thesis will not be able to identify other areas of OOP costs.  
Conclusion 
This thesis represents a novel body of work which determined the distribution of cost of cancer in 
Australia to both the public healthcare system and individual by Indigenous status, remoteness, and 
socioeconomic disadvantage. During the first 12 months following diagnosis, this was an estimated 
$4.8 billion to the public healthcare system, and an additional $127.7 million to the individual. The 
findings confirm that there are differences in costs to the public healthcare system and the individual 
by these characteristics. The lower patient co-payments paid by Indigenous Australians and those 
living outside of the least disadvantaged areas indicates that the policies protecting individuals from 
high co-payments appear to be working.  
These results are of particular importance for policy makers to ensure equitable allocation of 
healthcare resources throughout Australia. Future studies should identify if there are any differences 
in service use and access for these population groups which are driving these differences in costs. 
Linked administrative data has many advantages, primarily that selection and measurement bias are 
limited. Importantly for this thesis, the use of linked individual-level data enabled the analysis of the 
costs by characteristics of interest (Indigenous status, remoteness, and socioeconomic disadvantage). 
Health service research and cost-of-illness studies are of particular importance and may contribute 
to reducing the survival inequalities identified for Indigenous Australians, people living in remote and 
very remote areas, and socioeconomically disadvantaged persons. Continuous monitoring and 
evaluation of these survival inequalities are required to ensure that all Australians have equitable 
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